

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 7/48	A2	(11) International Publication Number: WO 96/40048 (43) International Publication Date: 19 December 1996 (19.12.96)
(21) International Application Number: PCT/US96/09975 (22) International Filing Date: 7 June 1996 (07.06.96) (30) Priority Data: 08/481,698 7 June 1995 (07.06.95) US (60) Parent Application or Grant (63) Related by Continuation US 08/481,698 (CIP) Filed on 7 June 1995 (07.06.95) (71) Applicant (for all designated States except US): KARO BIO AB [SE/SE]; Novum, S-141 57 Huddinge (SE). (72) Inventors; and (75) Inventors/Applicants (for US only): LAVIN, Thomas, N. [US/US]; 10 Canterbury Lane, Watchung, NJ 07060 (US). VAHLQUIST, Anders, B. [SE/SE]; Institutionen for Dermatologi, Linköpings Universitetsjukhus, S-581 85 Linköping (SE). (74) Agents: HOSCHEIT, Dale, H. et al.; Banner & Allegretti, Ltd., Suite 1100, 1001 G Street, N.W., Washington, DC 20001 (US).		(81) Designated States: AU, CA, JP, KP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: NOVEL USES FOR THYROID HORMONES OR THYROID HORMONE-LIKE COMPOUNDS (57) Abstract This invention relates to the use of topically applied thyroid hormones and thyroid hormone-like compounds which are receptor binding ligands, either agonists or antagonists, to improve the appearance of the skin and underlying subcutaneous fat and improve certain medical conditions when applied topically. These compounds can be used to treat skin conditions such as stria, cellulite, roughened skin, actinic skin damage, intrinsically aged skin, photodamaged skin, lichen planus, ichthyosis, acne, psoriasis, wrinkled skin, and to diminish the size and improve the appearance of skin scarring from surgical or naturally occurring wounds, and to reduce the incidence of hyperkeratotic scarring. These hormones or hormone analogs will also increase the rate of epithelialization and collagen production. The thyroid agonists and antagonists may also promote differentiation and amelioration of dedifferentiated skin in premalignant lesions. The thyroid agonists and antagonists can be active in all organisms which contain the thyroid hormone receptors, notably amphibians, birds and subjects. Combination with Vitamin D analogs glucocorticoid and retinoids will potentiate and modify the effects of the thyroid hormones for increased benefit. Side effects of thyroid hormones which occur when the hormone is given orally and prevent usefulness for the above conditions are prevented when the hormone is topically applied.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

NOVEL USES FOR THYROID HORMONES OR THYROID HORMONE-LIKE COMPOUNDS

TECHNICAL FIELD

5 This invention relates to skin care preparations containing thyroid hormones, thyroid hormone metabolites, derivatives of those compounds and other thyroid hormone receptor binding chemical entities and to the use of such compositions including to correct skin abnormalities, to improve the appearance of the skin, and to control subcutaneous fat deposition when applied to the skin.

10

BACKGROUND

A wide variety of skin care preparations are currently available. There are currently available several preparations for the treatment of cellulite, a dimpling of the skin over excess superficial fat deposits, but these are believed to have doubtful efficacy. A wide
15 variety of medically useful skin preparations are also currently available, comprising primarily glucocorticoids and retinoid topical medicaments, both of which have varying side-effects and usefulness. There is a considerable number of skin conditions and diseases such as stria, cellulite, roughened skin, actinic skin damage, intrinsically aged skin, photodamaged skin, lichen planus, ichthyosis, acne, psoriasis, wrinkled skin, eczema,
20 seborrhoeic dermatitis, scleroderma, hyperkeratinizing disorders, keloids and skin scarring.

Eczema (dermatitis) is an itchy inflammation of the superficial skin layers caused by an outside agent or by endogenous factors. The terms dermatitis and eczema are used interchangeably.

The obvious treatment of eczema is to try to avoid precipitating factors.

5

Additionally, eczema is usually treated with topical steroids such as hydrocortisone, clobetasone butyrate, betamethasone and clobetasol propionate. The side effects of steroid use, particularly in the long term are well known and consist of skin atrophy, risk for systemic absorption of the drug and rebound phenomena when the drug is withdrawn.

10

There is a need for improved or alternate compositions for the treatment of dermatitis skin conditions such as psoriasis and eczema. New principles for treating eczema in particular should aim at reducing the reactivity of cutaneous cells, inhibiting cytokine release and improving the epidermal barrier recovery.

15

The structurally similar thyroid hormones triiodothyronine (T_3) and thyroxine (T_4) have a very wide range of effects. In adult mammals they influence nearly all organs, the metabolism of nutrients, basal metabolic rate and oxygen consumption. In humans, the deficiency or excess of circulating thyroid hormones results in the well characterised syndromes, hypo- and hyperthyroidism. Small concentrations of thyroid hormone metabolites which are also endocrinologically active exist. Among these compounds are tri-iodothyroacetic acid ("Triac") and tri-iodopropionic acid ("Tri-prop").

20

Thyroid hormones exert many of their actions by binding to a family of receptor proteins termed the *C-erb-A* family. In humans, this receptor protein family is now known to comprise several members, notably the human thyroid receptor alpha-1, the human thyroid receptor alpha -2 which binds the hormone poorly or not at all, the human thyroid receptor B-1, and the human thyroid receptor B-2. These proteins are part of a larger superfamily of steroid hormone receptors which comprises the glucocorticoid receptors, the retinoic acid receptors, the vitamin D receptors, and the insect moulting receptors - the receptors for ecdysone and the insect juvenile hormones. Receptors for thyroid hormones are found in human skin, human fibroblasts and keratinocytes and they are also found in all other tissues within the human body (1).

In addition to the naturally occurring thyroid hormones, a large number of chemical compounds which bind to the thyroid hormone receptor and which produce thyroid hormone-like effects have been synthesized see for example US5401772.

Thyroid hormones, in many cases, act indirectly by influencing the effects of other hormones and tissues (1). For example in the rat, thyroid administration increases pituitary growth hormone production which in turn affects hepatic protein production including that of alpha-2 euglobulin. Functionally, in the rat, growth hormone may act as a second message for thyroid hormone(1). The biology of thyroid hormones has been extensively studied after oral administration, which makes the relationship between a direct effect of thyroid hormones and an indirect effect mediated by thyroid hormone

modulation of other autocrine, paracrine or endocrine factors difficult to ascertain.

Orally administered thyroid hormones influence the connective tissue biology of the skin.

When given orally, thyroid hormones induce an increase in neutral salt and acid soluble collagen, but decrease insoluble collagen in the skin of guinea pigs (2). Fibronectin

5 production is decreased in human fibroblasts and fibroblast glycosaminoglycans are either decreased or unchanged depending on the experimental conditions used (3,4,5,7,7a).

Keratin gene expression for both the basal cell keratin K5 and K14 genes and the differentiation specific K10 gene is negatively regulated by thyroid hormones (9,8) in keratinocyte culture. These effects are mirrored by similar cell culture responses to retinoic
10 acid (9) or the retinoid Tretinoin (19).

Histological studies of skin from individuals who have an excess of thyroid hormone show an increased number of cell layers in the skin, reflected by mean epidermal cell number, increased protein turnover with increased proline incorporation and generalized increases
15 in epidermal proliferation compared to normal skin (11). In individuals who have a lack of thyroid hormone, the skin is atrophic with thinning of the epidermis and a decrease in cellularity. In human clinical biology, thyroid hormone excess leads to a general smoothing of the skin and the loss of wrinkles especially over the olecranon (elbow) surface.

20 Thyroid hormones also accelerate fat synthesis and lipolysis (breakdown). In rats which have an excess of thyroid hormone either chemically or by natural means, fat stores are in

general decreased (12,13), although in humans clinical observation of thyroid hormone excess discloses either an increase or decrease in weight. The synthesis of fats may be increased (14,15) or decreased (12,13,16,21). Attempts to utilize the effects of excess oral thyroid hormone for weight loss in humans have in general failed because of severe adverse side effects (25,26).

5

Orally given thyroid hormone compound or thyroid hormone-like compounds in excess of normal bodily requirements or medical conditions which are associated with excess thyroid hormone such as Grave's disease or toxic nodular goitre produce an acceleration of heart beat with associated heart failure, cardiac arrhythmias, osteoporosis, increased intestinal motility leading to diarrhoea, psychiatric abnormalities, and an increase in the basal metabolic rate. Attempts to use oral thyroid hormones for diminishing lipid levels in man resulted in increased cardiac deaths (17).

10

RO76691 and 76692 respectively disclose an anti-wrinkle cream comprising a crude preparation from animal endocrine glands, including the thyroid gland, and a method of obtaining lipoid extracts from animal byproducts respectively. No data on the efficacy of the anti-wrinkle cream is provided nor is the thyroid hormone content of the cream provided or even mentioned. In particular, there is no suggestion in those patents of the efficacy of the compositions, methods, and uses of the present invention.

15

20

The use of Triac and its salts for a reduction of cellulite is disclosed in FR 2.153.202 (7134447). FR2197577 (72.30781) discloses various derivatives of Triac, including para

hydroxy esters thereof, as having utility for the same indication. EP060776 discloses activity of an isopropyl derivative of Triac for the same indication. CH642851 (1168/80) discloses the utility of a liposome formulation of Triac together with glycosoaminoglycans for reducing cellulite. GB1354263 also discloses the use of Triac itself for reducing fat deposits. GB1400851 relates to the synthesis of ethyl esters and alkyl carboxy acids derivatives of Triac and their use in reducing cellulite in combination with leeches, hyaluronidase, proteases, and lipase.

None of the above publications disclose or suggest the usefulness of compounds selected from those that bind the thyroid hormone receptor. The relationship between Triac and thyroid hormones is not made in any of these patents and no data is presented to show the relationship of the above mentioned compounds to the thyroid hormone dependent endocrine system via an effect mediated through the human thyroid receptor. In fact, FR2354101 discloses the use of Triac as an inhibitor of phosphodiesterase and its effect to increase cyclic AMP. This effect occurs only at dose ranges of approximately 10^{-4} M in *in vitro* experiments using isolated adipocytes. In concert with this mode of activity, the prior art literature makes claims for effective concentrations of chemical entity for anti-cellulite effects as greater than 50 mg of Triac or Triac derivative per 100 ml of vehicle and usually between 100 and 200 mg / 100 gms of excipient.

FR96.171 discloses the topical cellular growth accelerating activity and mitogenic of thyroxine (0.001-0.008 mg. %) in a propylene glycol diethyl ether vehicle in rat skin. No mention is made of other compounds which have thyroid hormone receptor binding

activity such as Triac or Tri-iodothyronine, or other thyromimetic compounds known at the time (Journal of Medicinal Chemistry, 6, p 554-563, 1963). No teaching concerning the effects of thyroid hormone receptor binding entities on epidermal differentiation, gene expression or keratinization is made. GB782,745 and 859,546 describe the topical usefulness of compounds of a class which partially overlap with chemical entities which bind to the thyroid hormone receptor, but includes compounds including L-T-1 with no thyroid hormone receptor binding activity, and only a small subset of compounds which do recognize the receptor. In these patents, no claims are made for chemical entities characterized by binding to the thyroid hormone receptor or having thyroid hormone like activity. US3198702 discloses a method of treating burns comprising the topical application of certain thyroxin analogues which are a subset of the same class of compounds claimed to have activity in GB 782745 and 859546.

No prior art document discloses the skin differentiating and collagen promoting effects of thyroid hormone or its analogues.

SUMMARY OF THE INVENTION

According to one aspect of the invention there is provided a composition for topical application, the composition comprising at least one thyroid hormone compound or thyroid hormone-like compound together with a pharmacologically acceptable base.

The topically-applied thyroid hormones, or thyroid hormone-like compounds used in the

compositions and methods of the present invention are advantageous in that they enable the use of these chemical compounds to control subcutaneous or dermal fat stores to improve the appearance of the skin, or normalize the physiology of the skin under pathophysiologic conditions without causing the undue adverse effects of orally administered thyroid hormone in a direct thyroid hormone dependent manner avoiding renal and hepatic metabolism of the thyroid hormone receptor binding chemical entity. In particular, the method of delivery of the thyroid hormone and thyroid hormone-like compounds avoids liver and kidney metabolism of the hormones, blood circulation of the hormones to other tissues and binding to blood carrier proteins which can alter efficacy.

For the purposes of this invention a "thyroid hormone" or "thyroid hormone-like compound", which terms are used interchangeably herein, is any chemical entity, including peptides, which at least partially binds to thyroid hormone receptor TR- α or β with a chemical affinity constant, K_d , lower than $1\mu\text{M}$ when tested in receptor binding assay, described by Lavin (27) using pure or substantially pure natural or recombinant thyroid hormone α or β receptor containing the ligand binding domain or thyroid hormone receptor containing preparations such as rat nuclei. Such ligands may be considered hormones when they have similar agonistic effects as the natural hormone or may be considered antagonists when the compounds antagonize the effects of the natural hormones. Partial agonist/antagonists also may exist. (Suitable ligands may be agonists or antagonists).

The topically-applied thyroid hormones, or thyroid hormone-like compounds used in the

compositions and methods of the present invention are advantageous in that they enable the use of these chemical compounds to control subcutaneous or dermal fat stores, to improve the appearance of the skin, or normalize the physiology of the skin under pathophysiologic conditions without causing the undue adverse effects of orally administered thyroid hormone. In particular, the method of delivery of the thyroid hormone and thyroid hormone-like compounds avoids liver and kidney metabolism of the hormones, blood circulation of the hormones to other tissues and binding to blood carrier proteins which can alter efficacy.

The thyroid hormone or thyroid hormone-like compound is preferably in pure form, i.e. not contaminated with other similar compounds.

The said at least one thyroid hormone compound or thyroid hormone-like compound may be selected from, for example, one of the following illustrative list of compounds:

Triiodothyronine (T_3); L and D tetraiodothyronine - thyroxine (T_4); 3,3',5' triiodothyronine (reverse T_3) ; 3,3'-diiodothyronine ; T_3 T_4 analogues such as 3,5,3'-Triiodothyroacetic acid ; 3,5,3'-Tetraiodothyroacetic acid ; 3,5,3'-Triiodo-L-thyronine ; 3,5,3'-Triiodo-L-thyronine methyl ester ; 3,5,3'-Triiodo-L-thyronine hydrochloride ; L-thyroxine ; L-thyroxine hydrochloride ; L- T_3 , T_4 Fo ; Tetrac ; Triac ; Tetraprop ; Triprop ; T_4 Bu ; T_3 Bu ; Thyroxamine ; Triiodothyronamine ; L-3'- T_1 ; L-3'- T_1 ; L-3,5'- T_2 ; L-3,3'- T_2 ; L-3,3',5'- T_3 ; DL- Br_2 I ; L- Br_2 iPr ; L- Me_2 I ; L- Me_3 ; L- Me_4 ; L- Me_2 iPr ; DL-IMeI ; 1-3,5-Dimethyl-3'-isopropylthyronine (DIMIT) ; DL-BPT $_4$; B-triac ; BP- tetrac ; DL-SBT $_3$; DL-

SBT₄ ; DL-MBT₃ ; MB-tetrac ; T₂ ; T₂F ; T₂Cl ; T₂Br ; T₃ ; T₂Me ; T₂Et ; T₂iPr ; T₂nPr ;
 T₂sBu ; T₂tBu ; T₂iBu ; T₂Phe ; T₂OH ; T₂NO₂ ; T₂F₂ ; T₂Cl₂ ; T₄ ; T₂Me₂ ; 3,5,3',5'-
 tetraiodo-D-thyronine ; 3,5,3'-Triiodo-D-thyronine ; 3,5- Diiodo-4-

hydroxyphenylpropionic acid (DIHPA) ; Aryloxamic acids ; (arylamino) acetic acids ;
 arylpropionic acids ; arylthioacetic acids ; (aryloxy)acetic acid ; 3,3'-T₂ ; 3,5-T₂ ; 3'-5'-T₂ ;

5 (5-Benzyloxy-2-methoxyphenyl)-(2-methoxypyrimidin-5-yl)-methanol ; Benzyloxy-2-
 methoxyphenyl)-(6-methylpyridin-3-yl)methanol ; (5-Benzyloxy-2- methoxyphenyl)-(5-
 bromo-2-methoxypyridin-4-yl)methanol ; (5-benzyloxy-2- methoxyphenyl)-(2,6-
 difluoropyridin-3-yl)methanol ; (5-Benzyloxy-2-methoxyphenyl)- (2-methoxypyridin-4-
 yl)methanol ; 4-Methoxy-3-[(2-methoxypyrimidin-5- yl)methyl]phenol ; 4-Methoxy-3-[(6-

10 methylpyrid-3-yl)methyl]phenol ; 5-Benzyloxy-2- methoxybenzyl Bromide ; (5-
 Benzyloxy-2-methoxyphenyl)-(6-chloropyridazin-3-yl)- acetonitrile ; 4-Benzyloxy-2-[2-
 methoxythiazol-5-yl)methyl]anisole ; 6-[(5-Hydroxy-2- methoxyphenyl)methyl]thiazol-2-
 (3H) ; 3'-Heteroarylmethyl-4'-)-methyl-3,5-dinitro-N- trifluoro-acetyl-L-thyronine Ethyl
 Esters ; 3'-heteroarylmethyl-3,5-di-iodo-4'-)-methyl-N- trifluoro-acetyl-L-thyronine Ethyl

15 Esters ; 3'-heteroarylmethyl analogues of 3,3',5-tri- iodo-L-thyronine (T₃) ; 3'-substituted
 derivatives of the thyroid hormone 3,3',5-triiodo- L-thyronine (T₃) ; L-3'-T₁ ; L-3,5'-T₂ ; L-
 3,3'-T₂ ; L-3,3',5'-T₃ ; DL-Br₂I ; L-Br₂iPr ; L-Me₃I ; L-Me₃ ; L-Me₄ ; L-Me₂iPr ; DL-IMeI ;
 L-3,5-Dimethyl-3'-isopropylthyronine (DIMIT) ; DL-BPT₁ ; B-triac ; BP-tetrac ; DL-SBT₃
 ; DL-SBT₄ ; DL-MBT₃ ; MB-tetrac ; T₂ ; T₂F ; T₂Cl ; T₂Br ; T₃ ; T₂Me ; T₂Et ; T₂iPr ;

20 T₂nPr ; T₂sBu ; T₂tBu ; T₂iBu ; T₂Phe ; T₂OH ; T₂NO₂ ; T₂F₂ ; T₂Cl₂ ; T₄ ; T₂Me₂ ; 3,5,3',5'-
 tetraiodo-D-thyronine ; 3,5,3'-Triiodo-D-thyronine ; 3,5-Diiodo-4-hydroxyphenylpropionic
 acid (DIHPA) ; Aryloxamic acids ; (arylamino)acetic acids ; arylpropionic acids ;

arylthioacetic acids ; (aryloxy)acetic acid ; 3,3'-T₂ ; 3,5-T₂ ; 3'-5'-T₂ ; α -methyl-3,5,3'-
triiodothyroacetic acid, α -methyl-3,5,3'-triiodothyropropionic acid, and α -methyl-3,5,3',5'-
tetraiodothyropropionic acid ; methylene- and carbonyl-bridged analogs of iodinated
thyronines thyroacetic acids ; Iodinated benzofurans ; 3,5-diiodo-4-(2-N,N-
diethylaminoethoxy)phenyl-(2-butylbenzofur-3-yl)methanol hydrochloride ; 2-methyl-3-
5 (3,5-diiodo-4-(2-N,N-diethylamino- ; ethoxy)-benzoyl)benzofuran hydrochloride ; 2-n-
butyl-3-(3,5-diiodo-4-carboxymethoxy-benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4-
hydroxy-benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4-carboxymethoxy-
benzyl)benzofuran ; [4'-hydroxy-3'-iodo-3,5 diiodo-4-(2-N,N-dimethylamino- ;
ethoxy)benzophenon hydrochloride ; 2-butyl-3-(3-iodo-4-hydroxybenzoyl)benzofuran ;
10 4',4-dihydroxy 3',3,5-triiodo-diphenylmethan ; 3,5-diiodo-4-(2-N, N-
diethylaminoethoxy)phenyl- ; -(2-butylbenzofur-3-yl)methanol hydrochloride ; 2-methyl-
3-(3,5-diiodo-4-(2-N,N-diethylamino-ethoxy)-benzoyl)benzofuran hydrochloride ; 2-n-
butyl-3-(3,5-diiodo-4-carboxymethoxy-benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4-
hydroxy-benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4-carboxymethoxy-
15 benzyl)benzofuran ; 4'hydroxy-3'-iodo-3,5 diiodo-4-(2-N,N-dimethylamino-
ethoxy)benzophenon hydrochloride ; 2-butyl-3-(3-iodo-4-hydroxybenzoyl)benzofuran ;
3,5-diethyl,3'-isopropyl thyronine (DIET) ; 4',4-dihydroxy-3',3,5-triiodo- diphenylmethan ;
and IpTA₂ (3,5 diiodo- 3'isopropyl thyroacetic acid) and pharmacologically acceptable
salts and derivatives, such as metabolites, and effective isomers thereof.

20 Other suitable thyroid hormone-like compounds, are disclosed for example in US5284971,
US5401772, US3649679, US3357887, US412579, US4168385, US5179097, EP0580550,

EP018351 and H. A. Selenkow and S. P. Asper, Jr., *Physiol. Rev.* 35 426 (1955); C. S. Pitman and J. A. Pitman In *Handbook of Physiology, Section 7: Endocrinology, Vol. 3*, R. O. Greep and E. B. Astwood, Eds., *Thyroid* American Physiological Society, Washington D.C., 1974, p. 233; E. C. Jorgensen, *Pharm. Ther. B*, 2, 661 (1976); and E. C. Jorgensen, "Thyroid Hormones and Analogs. II. Structure-Activity Relationships," in *Hormonal Proteins and Peptides, Vol. 6. Thyroid Hormones*, C. H. Li, Ed., Academic, New York, 1978, p. 108. The choice of other suitable thyroid hormone-like compounds for use in the compositions and methods of the present invention is within the scope of the skilled worker.

10 Preferably, the composition is in the form of a cream although other forms of preparation which can be readily applied to the skin, such as lotions, topical sprays, liposomes, solutions or emulsions, are contemplated. Preferably the composition includes suitable epidermal penetration enhancing agents.

15 Preferably, the composition comprises less than about 50mg /100ml , more preferably less than about 10mg /100ml of the said at least one thyroid hormone or thyroid hormone-like compound. Preferably the composition comprises a concentration 5×10^8 times or less the receptor dissociation constant, K_d of the said at least one thyroid hormone or thyroid hormone-like compound. Preferably the composition is used to supply an
20 effective amount of the thyroid hormone or thyroid hormone-like compound which generally ranges from 500mg/m² to 0.1mg/m² in one or more applications, preferably 250mg/m² to 1mg/m² per day in one or more applications.

The effective concentration will depend on factors such as metabolism of the compound and its effective octanol/water partition coefficient and which can be readily determined by the skilled addressee. The composition of the invention may also include other ingredients such as Vitamin D, glucocorticoids and retinoids or analogues thereof to potentiate and modify the effects of the thyroid hormone or thyroid hormone-like compound for increased benefit. In particular when the composition is formulated for lipolytic activity it may contain derivatives of medicinal herbs such as *Guto Kola*, (*Centella asiatica*), *Cola nitida*, *Khella* (*Amni visnaga*), cola nut, *Camellia Suiensis*, Guavana, clove, coffee. The composition may also include BHT (butylated hydroxy toluene) or BHA (butylated hydroxy anisole) as a hindered phenol to decrease iodine decomposition or substances. Furthermore, the composition may include compounds which facilitate passage of the thyroid hormone through the skin and compounds which act as sunscreens such as PABA. Preferably, the composition also includes a suitable antioxidant such as Tinuvin P or BHA. The choice of such compounds is within the scope of the skilled addressee. See for example Hermens W. A. J. J Pharmaceutisch Weekblad Scientific Edition 14(4A) 1992.

Preferably, the thyroid hormone or thyroid hormone-like compound is not halogenated as such compounds are less prone to photodecomposition. The pharmacologically acceptable base is preferably an oil in water emulsion or an alcoholic solution with glycerol.

The said at least one thyroid hormone compound is preferably at least partially dissolved in a solvent. The solvent is preferably an organic solvent selected from alcohol and alcohol

and water solution. More preferably, the organic solvent is selected from isopropanol, isopropanol and water, ethanol, and ethanol and water solutions containing at least 20% alcohol.

5 According to a further aspect of the invention there is provided a unit dose package containing a single dose of a composition in accordance with the first aspect of the invention.

10 According to a further aspect of the invention there is provided a method of improving the condition or appearance of the skin of a subject, the method comprising the steps of: providing a composition in accordance with the first aspect of the invention; and applying the said composition to the skin of the subject.

15 The method improves conditions selected from for example, stria, cellulite, roughened skin, actinic skin damage, intrinsically aged skin, photodamaged skin, lichen planus, ichthyosis, acne, psoriasis, wrinkled skin (whether deep or superficial), Dernier's disease, eczema, atopic dermatitis, seborrhoeic dermatitis scleroderma, collagen deficient skin, corticosteroid atrophy, chloracne, pityriasis, hyperkeratinizing disorders, keloids and skin scarring.

20 Preferably, the composition is applied from twice a day to every three days.

According to a further aspect of the invention there is provided a method of reducing

cutaneous or subcutaneous fat deposits in a subject, the method comprising the steps of:
providing a composition in accordance with the first aspect of the invention; and
applying the said composition to skin of the subject in the vicinity of the deposits to be
treated.

5 In a preferred embodiment, the fat deposits cause cellulite.

Preferably, the composition is applied to the skin from between twice a day to every three
days.

10 Preferably, the subject is a mammal, more preferably a human. The thyroid hormones and
thyroid hormone-like compound can be active in all organisms which contain thyroid
hormone receptors, notably amphibians, birds and mammals.

15 According to another aspect of the invention there is provided the use of a thyroid
hormone or thyroid like compound in the preparation of a composition for topical
application to the skin of a subject in order to improve the condition of that skin or reduce
cutaneous or subcutaneous fat deposits.

20 DETAILED DESCRIPTION OF THE INVENTION

Compositions in accordance with the invention and methods for their use will now be
described, by way of example only, of with reference to the accompanying drawings,
Figure no. 1-8.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a graph showing the comparative effect of betamethasone and Triac on the Skin-2 model;

5 Fig. 2 is a graph showing the comparative effect of vitamin D3 and Triac on the Skin-2 model;

Fig. 3 is a graph showing the comparative effect of retinoic acid and Triac on the Skin-2 model;

10

Fig. 4 is a graph showing the effect of retinoic acid on the skin-2 model in three studies;

Fig. 5 is a graph showing the effect of Triac on the skin-2 model in three studies;

15 Fig. 6 is a photograph of a volunteer's waist and hip area in which a composition of the invention has been applied to the left and right side, the line drawing below emphasizing the slimming effects of the composition;

20 Fig. 7 is a photograph of a volunteer's waist hip area in which a composition of the invention has been applied to the right side the line drawing below emphasizing the slimming effects of the composition; and

Fig. 8 is a photograph of a volunteer's waist and hip area in which a composition of the invention has been applied to the right side the line drawing below emphasizing the slimming effects of the composition.

5 **EXAMPLE 1**

***IN VITRO* TESTS WITH A SKIN A MODEL**

Regulation of epidermal genes which regulate collagen production and promote epidermal differentiation.

10 Terminal differentiation of the epidermal layer of the skin is thought to be related at least in part to the activity of transglutaminase K and the production of cornified envelopes (Febs Letter 258 p35-38, 1989, and J. Invest. Derm. 90 p472). It is thought that the ability of a retinoid to down regulate transglutaminase K in cultured cells is an indication of its ability to effectively treat psoriasis (EP00465343). TGF beta 1 and 2 are thought to promote
15 terminal differentiation and inhibit basal cell proliferation (Fuchs E. J. Cell Biol. 111 p2807). A protease, stratum corneum chymotryptic enzyme, SCCE, is produced by keratinocytes and is thought to promote shedding of skin cells in the upper granular layer of the epidermis and be related to epidermal differentiation (Egulrud et al, ACTA DERM Venereol. Vol 73 p 181-184 1993; Sondell *et al*, J. Invest Derm 1995, p 819-823).
20 Further, in hyperproliferating skin, the keratins 1 and 10 (differentiation markers) are reduced and the hyperproliferation keratins 16 and 6 are increased (West *et al* 1992, J. Invest. Derm.1 p 95). Retinoic acid effects on skin keratinocytes in culture reflect a

decrease in the differentiation markers and variable changes in keratins 6 and 16 and they also decrease transglutaminase K *in vitro*. Both these markers, the keratins and transglutaminase K have been considered in-vitro measures of retinoic acid analogs dermatologic potency and usefulness (Kopan and Fuchs, J.Cell Biol 105 p 427-440, 1987 and Griffiths et al, Br J Derm 1992, 127 suppl 4 p 21. Paradoxically, however, retinoids are active against hyperproliferating disorders and increase the keratin 1 and 10 differentiation markers and transglutaminase K *in vivo* after topical application. (Griffiths *et al*, Br. J. Derm 1992, 127 suppl 4 p21. In keratinocyte cultures, thyroid hormone decreases keratin genes K5, K14 and K10 (6,10). Thyroid hormone modulation of the keratin 1 gene has not been previously reported.

Collagen production in the skin occurs from a variety of collagen genes, with the procollagen A-1 and A-3 genes most studied. Collagen is decreased in glucocorticoid treated skin (7) and in photodamaged skin (24). It is thought that overproduction of collagen in the hyperproliferative state may contribute to keloidal scar production.

Furthermore, CTGF, a PDGF like peptide (PDGF-L) that is produced in response to TGF beta-1 appears to be present in increased amounts in fibrosing disorders such as scleroderma. In cultured human fibroblasts, thyroid hormone administration decreases collagen production (de Rycker et al, FEBS Lett, vol 174 p34-37 1984).

No universally accepted model of human skin exists. A novel synthetic human skin, Skin-2 model ZK1301 (Advanced Tissue Sciences, La Jolla (USA)) is composed of a three dimensional human skin culture consisting of a dermal fibroblast layer and human foreskin

keratinocytes which be grown with an air-keratinocyte interface to promote normal differentiation and cornification of the model skin. The Skin-2 model is widely accepted as an in-vitro model to assess cutaneous toxicity (Rheins *et al*, Toxic, in Vitro, 8, no. 5 p1007-1014 1994 and is approved by the Canadian and U.S. FDA as an appropriate model for testing skin toxicity. Such a model has the following advantages:

- 1) The keratinocytes differentiate in a manner very similar to the *in vivo* state. A stratified multilayered epithelium with all the markers and properties of such epithelium forms. This never happens in typical keratinocyte culture.
- 2) The presence of fibroblasts allows the detection of fibroblast markers including collagen. The interplay between keratinocytes and fibroblasts which occurs *in vivo* also is mimicked in the SKIN² model, which allows paracrine functioning of the cell types. We assessed the ability of multiple thyroid hormone receptor binding ligands, and several therapeutically useful model compounds including retinoic acid to alter mRNA production of a variety of genes present in fibroblasts and keratinocytes present in the Skin-2 model.

Materials and Methods

The following were components of the Skin² kits: 9x9 mm skin tissues on agarose, 6-well plates, and Millicell inserts. Two media based on Dulbecco's Modification of Eagle's medium were also included: Maintenance medium (containing 5% fetal calf serum) and serum-free assay medium.

The following were supplied by other sources: "Stripped" (Samuels, H. *et al*, Endocrinology **105**, p80-85, 1979) fetal calf serum and all substances to be tested were

from Karo Bio All-trans-retinoic acid, 1,25-(OH)₂-vitamin D₃, and betamethasone were purchased from Sigma Chemicals (Stockholm). Upon arrival the skin tissues were placed dermal-side down into the center of a Millicell in a 6-well plate well containing prewarmed maintenance medium. The tissues were incubated at 37°C in an atmosphere of 5% CO₂ in air. After 24 h the maintenance medium was exchanged.

5

Following another 24 h the Maintenance medium was removed and replaced by Serum-free assay medium containing 5% "stripped" fetal calf serum. Substances were added within 1 h after medium exchange and the tissues were incubated for 10 or 48 h in the presence of the substances. Medium and substances were changed after 24 h incubation.

10 The cells were grown at an air - liquid interface. At the end of the 48 h-incubation period two tissues were pooled together in a sterile plastic centrifugation tube. The tissue was snap frozen on solid ice (-60°C) and stored at -70°C until used. Duplicate samples were included for each treatment.

15 **Analysis of mRNA expression in Skin² by reversed-transcriptase coupled to polymerase chain reaction (RT-PCR)**

Total RNA was extracted from Skin² -samples and human skin biopsies using Ultraspec II (Biotech Laboratories, Inc., Houston, TX). One ml of Ultraspec II was added to each sample which were homogenized by using a Polytron for 2x20 sec at setting 6. Total RNA
20 was extracted according to the protocol supplied by the manufacturer. The amount of RNA was quantitated by measuring the absorbance at 260 nm. The A₂₆₀/A₂₈₀ -ratio of the extracted RNA was generally between 1.75 and 2.0. Three µg RNA was reversed

transcribed into cDNA in a 30 μ l mixture containing 50 mM Tris-HC (pH 8.3), 75 mM KC, 3 mM $MgCl_2$, 10 mM dithiothreitol, 0.5 mM of each dNTP, 200 U M-MLV reversed transcriptase (Life Technologies), 25 U placental Rnase inhibitor (Boehringer-Mannheim) and oligo d(T)15 as primer. After incubation at 37°C for 60 min, the reaction was stopped by heating at 75°C for 10 min and the mixture stored at -70°C until cDNA amplification was performed.

Polymerase chain reaction

The following PCR mixture (24 μ l) was prepared immediately before use: 10 mM Tris-HC (pH 8.3), 50 mM KC, 1.5 mM $MgCl_2$, 200 μ M of each dNTP, 0.5 μ M primers (see Table 1), and 0.5 U Taq DNA polymerase licensed for PCR (Life Technologies). The tubes were placed in a Thermal cycler (Perkin-Elmer) programmed as follows: (a) 90°C for 90 s; (b) variable number of cycles (see Table 1) of the following sequential steps: 60 s at 94°C, 75 s at annealing temp (see Table 1), 90 s at 72°C; and (c) 7 min at 72°C.

After mixing 7.5 μ l of PCR-products with 2 μ l of loading buffer, samples were separated by electrophoresis on a 1.2 % agarose gel containing ethidium bromide, and visualized by UV transillumination. Gels were recorded by videoprints.

The amount of product was estimated on the videopoint or directly on the gel. The amount of transcripts in each lane were compared in relation to two control samples run in parallel.

The expression of certain genes was not modulated by test compounds, and so these genes were not selected as markers in subsequent experiments

Table 1

Gene	Annealing	PCR-cycles	Product Size (bp)
	Temp		
Fibronectin	60°C	22-25	794
IL-6	60°C	22-25	639
IL-8	60°C	25	275
ICAM-1	60°C	30	727
TGF β 1	60°C	25	338
TGF β 2	56°C	40	575
Keratin 1	60°C	24-27	480
Keratin 10	60°C	27-30	439
Keratin 5	60°C	25	559
Keratin 14	60°C	25	651
Keratin 6	60°C	25	464
Keratin 19	60°C	20	400
Keratin 16	60°C	22-25	725
SCCE	60°C	22	463
Collagenase	60°C	30	463
Involucrin	60°C	25	541
Filaggrin	60°C	29	526
Loricrin	60°C	33	663
Procollagen 1A1	60°C	20-22	620
Procollagen 1A2	60°C	23	712
Procollagen 3A1	60°C	20-24	524
TGk	60°C	22-30	652
CTGF	60°C	25	515
ThR α	60°C	32	623
ThR β	60°C	32	578
CRBPI	60°C	25	388
CRABPII	60°C	22-25	402
RAR α	60°C	35	817
RAR β	60°C	35	769
RAR	60°C	30	765
RXR α	60°C	30	743
VDR	60°C	30	888
cyclophilin	60°C	20-22	424
GAPDH	60°C	24-27	893

Key

IL-6 interleukin-6, IL-8 interleukin-8, ICAM-1 intracellular adhesion molecule-1, TGF β transforming growth factor, SCCE stratum corneum chymotryptic enzyme, TG_k keratinocyte transglutaminase, CTGF connective tissue growth factor, ThR thyroid hormone receptor, CRBP cellular retinol-binding protein CRABP II cellular retinoic acid-binding protein, RAR retinoic acid receptor, RXR retinoid X receptor (9-cis-RA receptor), VDR vitamin D₃ receptor, GAPDH glyceraldehyde-3-phosphate dehydrogenase.

The effect of a thyroid hormone, tri-iodothyroacetic acid (Triac), was first studied and compared to known medically useful compounds which affect epidermal physiology. These drugs were retinoic acid, betamethasone, and 1,25 OH vitamin D-₃. The semi quantitative results are shown in Table 2 and comparisons between Triac and the other drugs are displayed in fig. 1, (betamethasone), Fig. 2 (Vit D₃) and Fig. 3 (all trans Retinoic acid). Triac at 50 nMolar concentration, approximately 1000 times its affinity constant for the receptor, appears to strikingly reduce keratin 1 and 10, transglutaminase K, and SCCE. Triac also markedly accentuates Collagen A-1 and 3A-1, along with TGF-beta-2 transcripts. In comparison with betamethasone, Triac increases collagen production and TGF beta-2 but does not strongly inhibit IL-6. The keratin findings are similar. In comparison with Triac, Vit D-3 does not inhibit the keratin gene transcripts, or SCCE or transglutaminase K., but the effect on collagen genes is similar. Retinoic acid and Triac appear very similar with the exception of only SCCE and CRAB PII. At a higher concentration, 1 μ Molar, Triac continues to display the same effects although the collagen

and keratin response is somewhat reduced. It is a surprising finding of the present invention that low doses of thyroid hormone compounds are dermatologically effective.

These results are consistent with known results of these drugs in other model systems. For example Vitamin D-3 is not known to affect keratinization of cultured keratinocytes.

5 Betamethasone decreases epidermal collagen. Retinoic acid is known to decrease transglutaminase Ki and keratins 1 and 10 in culture. These results therefore suggest that Triac should have similar properties as these other medically important classes of drugs. In fact a combination of a thyroid hormone with a glucocorticoid should avoid the collagen loss associated with topical steroid application and add an antiinflammatory effect not seen
10 with a thyroid compound.

The results of three experiments with Triac at 50 nM dose and retinoic acid at 1 μ Molar dose are shown for comparison in figures 4 and 5. The two hormones appear very similar, but can be differentiated by the lack of inhibition of SCCE by RA in this model, and the
15 modest fall in transcripts for the CRAB PII retinoid binding protein induced by Triac. Both compounds inhibit keratin 1 and more modestly, keratin 10, increase TGF-beta-2, CTGF, collagen and inhibit transglutaminase K.

A group of thyroid hormone receptor binding compounds were therefore tested in this
20 model. Eight different compounds which span a range of different structures, including nonhalogenated compounds and compounds containing bromine instead of iodine, all of which bind to the receptor were assayed in the Skin-2 system. One compound, L-T-1, as

described in GB7822745, GB859546 and US3198702 as part of a family of molecules which have topical utility, which bind very poorly to the receptor was also tested. The compounds were all tested at concentration ranges above their binding affinity for the receptor except for L-T-1 which binds poorly to the receptor even at the tested ten micromolar concentration. Table 3 displays the results for these compounds along with their K_i (binding affinity) to the human thyroid receptor and the tested concentration of chemical. Affinities for the human thyroid receptor alpha-1 were similar. Again, a reduction in transcripts for keratin 1 (8/8 compounds), keratin 10 (5/8), and transglutaminase K (4/8) was seen, along with increased collagen a-1 (7/8) and collagen 3a (6/8) and CTGF (7/8). For the most part, an inhibition of SCCE was seen, although in some instances a very modest change was displayed by some compounds. The compound (L-T-I), which did not bind to the endogenous receptor, showed no inhibition of keratin 1 or 10, a positive effect on transglutaminase K and SCCE which is opposite to the thyroid response and retinoic acid response, and only modest effects on collagen.

Certain of the compounds, notably compound number 5 displayed a relative selectivity for keratin 1, transglutaminase K and SCCE responses over collagen responses. Therefore it seems likely that some of the compounds will display a relative efficacy more weighted toward regulation of epidermal differentiation than collagen production and potential wound healing effects or amelioration of dermal states characterized by collagen deficient skin.

Although the effects of these thyroid compounds as a group reflect specific and

reproducible changes in the transcripts of epidermally related genes which affect differentiation, the *in vitro* direction of the response for SCCE, Transglutaminase K and keratin 1 is the opposite to that which might be considered therapeutically useful. Since a similar result is seen for retinoic acid (Koppam *et al*; Griffiths *et al supra*), these two entities are therefore quite similar in their effects. Surprisingly the collagen response to thyroid hormone was the opposite to that reported in the literature (de Ryk *et al supra*). Because of the paradoxically opposite effects of retinoids on skin related proteins and genes when given *in vitro* as compared to *in vivo* testing, and the concomitant medically beneficial usefulness of retinoids. It was considered that thyroid regulation would be subject to the same paradox. therefore Triac was tested on human volunteers.

EXAMPLE 2

HUMAN STUDY: THYROID HORMONE CONTROLS GENE TRANSCRIPTION IN SKIN

Three adult male volunteers ranging in age from 37-46 yrs were treated topically with a cream containing either 200 mg/100 ml or 20 mg/100 ml Triac. The cream was applied in an amount sufficient to just cover an approximately 6 cm² area on the buttocks. A similar sized area on the contralateral side, treated with a dermatologically useful cream, served as control. After application, the areas were covered with Tegaderm (3M) to prevent loss of cream and to enhance penetration. Control and Triac-treated areas were biopsied 96 h following this single treatment. The degree of erythema of each subject was judged on a subjective scale 1 to 4. Epidermis and papillary dermis from control and treated skin were obtained by manually cutting superficially with a razor-blade following 1 % lidoacaine

anesthesia. Two pieces of tissue measuring 2 x 2 cm and approximately 0.2 mm in depth were obtained for RNA-preparation. The tissue was snap frozen on solid ice (-60°C) and stored at -70°C until used.

5 A large number of transcripts were tested in three male subjects and the results are shown in table 4. The change in transcription of the genes for SCCE, Keratin 1 and 10, and transglutaminase K was now unexpectedly positive, the opposite of what was found in the *in vitro* assay. These changes reflect an increase in the differentiation markers and suggest a change to a more terminally differentiated state. The effect on collagen and CTGF remains the same *in vivo* as *in vitro* when using the Skin-2 model. Thus, at least for gene
10 products which are related to epidermal differentiation the thyroid response *in vitro* is opposite to that *in vivo*, an identical finding as has been seen for the medically important retinoid compounds. Moreover, the unexpected increase in collagen formation suggest utility to help rebuild photodamaged adult human skin (Talwar *et al*, J. Inv. Derm, 105 p285-290, 1995).

15 EXAMPLE 3

THYROID HORMONES ARE PHYSIOLOGICALLY ACTIVE WHEN APPLIED TO THE SKIN.

20 Triac (Tri iodo thyroid acetic acid) or DIMIT (dimethyl isopropyl thyronine) or esters and ethers thereof are mixed in a concentration range of 10 000 000 times K_{diss} to 1000 times K_{diss} , 100 micromolar to 1 nanomolar, in a suitable pharmacological base, such as Johnson and Johnson PurposeTM or CurityTM skin lotion and applied to hairless mice strain SKH/hr

1 for 8 weeks. Punch biopsies are obtained and ultrasound measurements were made of the skin using a 10 MHz B-mode ultrasound (18). As compared to control animals, thyroid hormone treated animals have an increase in the thickness of the epidermal area and a slight decrease in the dermal portion of the skin. An increased cellularity of epidermal cell layers is found, with a decrease in the regularity of the rete pattern.

5

EXAMPLE 4

WOUND HEALING

Wounds are produced in rats and rabbits as in (19). The tensile strength of the wounds are determined at five, ten and twenty days and collagen formation in the wound determined by SDS-gel electrophoresis (20,22,23,24). Wound healing is also measured by two dimensional A and B mode ultrasound. The wounds to which thyroid hormone is applied have increased tensile strength and close more quickly. Ultrasound measurements disclosed a more rapid granulation base and more rapid wound closure.

10

15

EXAMPLE 5

PHOTODAMAGED SKIN

Hairless mice SKH-1 are UV-B irradiated according to the schedule of (22). After 12 weeks of irradiation, significant wrinkling results. The mice are treated with the thyroid hormone Triac-containing cream for a period of 16 weeks after irradiation. The degree of wrinkling appearing on the irradiated mice is compared to untreated, irradiated animals to which the appropriate pharmaceutical base is not applied. The thyroid hormone containing composition of the invention produces a significant decrease in the wrinkle pattern of the

20

animals and an increase in skin collagen.

EXAMPLE 6

IMPROVEMENT IN THE APPEARANCE OF CELLULITE AND/OR REDUCTION SUBCUTANEOUS FAT DEPOSITS AND DECREASE IN SUB- 5 CUTANEOUS, DERMAL AND SUBDERMAL FAT.

The thyroid compounds reverse T-3, T-3, and Triac were dissolved in 70% isopropanol-water at a concentration of 0.5 to 7 mg/ml⁻¹.

10 A hydrophillic ointment (USP) or non-USP (Fougera brand) consisting of an oil in water emulsion with suitable fatty acid modifiers in 30 ml to 100 ml amounts was placed in a suitable stirring vessel. The dissolved thyroid compounds were sprayed over the surface of the cream and mixed manually, or with a mechanical stirrer, for several minutes to produce complete mixing. To adjust for batch to batch variations in the ointment base, water or isopropanol in amounts up to 20% of the volume were added to produce a mixture which
15 was both pleasing to touch and was easy to apply to the skin. Other solvents such as isopropanol/water, ethanol or ethanol/water were also tested for dissolution.

The cream was applied daily, twice a day or up to every three days to various parts of the body. Exercise, especially of the tested area, through dancing or mild calisthenics which
20 produced increased warmth and blood flow to the area appeared to accelerate the effects of the cream.

EXAMPLE 6A**RIGHT BUTTOCKS**

Triac, T-3 And Reverse T-3 were applied separately to the right buttock. An observer noted a decrease in the overall volume of the buttocks and a elevation of the gluteal posterior thigh fold by 1/2 to 1cm. Results were noted after 10 days of application.

5 Measurements of hip circumference showed a 0.75 inch increase in circumference after 7 days after stopping the application.

EXAMPLE 6B**RIGHT THIGH**

10 T-3 and Triac were separately applied to a subject's right thigh for two periods of 3 weeks.

Results

The circumference of the right thigh was measured 5 cm beneath gluteal fold decreased, compared with the untreated left thigh as a control,

Beginning: Right thigh measured 49 cm; Left thigh measured 47.5 cm

15 After 20 days T₃ treated Right thigh measured 18.75 inches; Left thigh measured 18.5 inches.

Triac cream was then applied to Right thigh. After three weeks measurements of both thighs were the same.

There was an one pound decrease in body weight over this period.

20

EXAMPLE 6C**RIGHT INFRA RENAL AND SUPRA ILLIAC CREST FAT PADS**

Triac cream. Test 1: applied for two weeks to right side.

Results:

Observation shows a decrease in fat pad size. Measurement of skin creases from right to left side showed: R 5.75cm and L 7.5cm. Application stopped for two weeks and restarted with reverse T-3 cream. Effects appear similar after ten days. Photographs were taken of these areas. (See Fig. 6)

EXAMPLE 6D

RIGHT SUPRA ILLIAC CREST AND OVER ABDOMINAL RECTUS MUSCLE

Triac cream was applied to right supra illiac crest and right abdominal area.

Initial measurements: waist 28 inches, hips measured one inch below umbillicus, 36 inches

After two weeks: waist 27", hips measured one inch below umbillicus 35.25 inches

After 10 more days: waist 27.5" hips measured one inch below umbillicus 34 inches.

There was a body weight loss of approximately two pounds over an eight week period.

Photographs were taken of these areas as described below. Clothes fitted appreciably more easily and the appearance of diminished fat easily noted by other observers.

See Figs. 6 and 7.

Fig. 6 shows the results of applying Triac and subsequently T₃ cream daily to the right side alone. Application of the Triac cream continued for 3.5 weeks and then was stopped for 1-2 weeks and then T₃ cream was applied daily for ten days. T₃ cream was applied daily to both sides for 7 days and then to the right side only for a further 3 days.

Fig.7 shows the result of applying Triac cream to the right side of a volunteer on a daily basis for 3 weeks.

Fig. 8 shows the effect of applying T₃ cream to the right side of a volunteer for 3 weeks.

5

Thyroid gland size and radial pulse rate were measured bi-monthly. No changes were observed. No hair loss, abdominal distress, cardiac arrhythmia or diarrhoea were observed. No adverse changes to the underlying skin were noted.

10

The composition of the present invention may be conveniently supplied in a unit dose pack comprising a plastic container which may for example be bubble, or blow moulded or injected, together with a tear off plastic or foil top, the pack containing a unit dose of the composition.

15

EXAMPLE 7

HUMAN STUDY: TREATMENT OF PSORIASIS

20

Patients with characterized multilateral psoriasis were subjected to a pharmacological washout period of two weeks followed by treatment of one lesion with an hydrophilic ointment containing 0.04% Triac or vehicle alone an another lesion by application of ointment twice per day. Treatment duration was 8 weeks. Clinical results were measured using a validated five point scale for the severity index of scaling, erythma and infiltration size. All observations were performed by blinded observers at two week intervals. Sixty

percent of treated patients had statistically significant and clinically significant reductions in their severity scores.

REFERENCES

1. Lavin, T.N. Mechanisms of Thyroid Hormone action. In the textbook of Endocrinology (DeGroot, Ed.), 2nd Edition, W. B. Saunders, pub. (1989).
2. Drozdzm M *et al.* Endokrinologie 1979 Feb; **73**(1) 105-11
3. Murata Y *et al* J Clin Endocrinol Metab 1987 Feb; **64**(2): 334-9
- 5 4. Watxke, H., *et al* Thrombosis Research. **46**(2): 347-53, 1987 Apr 15
5. Murata Y *et al* JCEM 1983 Vol. **57** p. 1233-1239
6. Lee J *et al* Endocrinology **130** p 2733-2738, 1992
7. Ceccarelli, P *et al* JCEM **65** p 242-246, 1987
8. Tomio-Canic M *et al* Journal of Investigative Dermatology **99** p 842-847, 1992
- 10 9. Blumenberg M *et al.* J. Invest Dermatol 1992 Jun; **98**(6 Suppl):42S-49S
10. Ohtsuki M *et al* J Dermatol 1992 Nov **19**(11) p 774-80
11. Holt, P.J.A *et al* British Journal of Dermatology **95** p 513-518, 1976
12. Cronrath CM *et al* Endocrinology, **120**(1) page 43-8, 1987 Jan
13. Towle H. C, Mariash C. N Federation Proceedings **45**(9) p 2406-11, 1986 Aug.
- 15 14. Lemmen C. *et al* Biological Chemistry Hoppe-Seyler **367**(7) p 533-537, 1986
15. Amorosa L. F *et al* Biochim Biophys Acta 1984 Feb 9, **792**(2) p 192-8
16. Armer P *et al* Diabetes **33**(4) p 369-375, 1984
17. Coronary Dru Project. JAMA **220** p 996-1008, 1972
18. Akesson, A *et al* Acta Radiologica Diagnosis **27** p 91-94, 12986
- 20 19. Hunt, T *et al* Annals Surgery **170** p 633-641, 1969
20. Varani, J *et al* J. Invest Dermatol **94** p 717-723, 1990

21. Loireau A *et al* Biochem Pharmacol **35** p 1691-1696, 1986
22. Moloney S. J *et al* Photochem Photobiol **56** p 505-511, 1992
23. Schwartz E *et al* J. Investl. Dermatol **102** p 241-246, 1994
24. Griffiths C. E. M *et al* NEJM **329** p 530-535, 1993
25. Roti, ~~E~~ *et al* Endocrine Reviews **14** p 401-423, 1993
- 5 26. Lev-Ran A Perspectives in Biology & Medicine **37** p 486-494, 1994
27. Apriletti J. *et al* J. Biol. Chem. **263** p 9409-9417, 1988

CLAIMS

1. A skin treatment composition for topical application, the composition comprising at
5 least one thyroid hormone compound or thyroid hormone-like compound as herein defined
together with a pharmacologically acceptable base.

2. A skin treatment composition for topical application, the composition comprising at
least one thyroid hormone compound or thyroid hormone-like compound as herein defined
10 together with a pharmacologically acceptable base in which application of the composition to
the skin effects an improvement in the skin's condition without resulting in systemic
metabolism of the compound.

3. A skin treatment composition for topical application, the composition comprising at
15 least one thyroid hormone compound or thyroid hormone-like compound as herein defined
together with a pharmacologically acceptable base in which a medically or cosmetically
sufficient amount of thyroid hormone compound or thyroid hormone-like compound enters
the skin but in which substantially no thyroid hormone compound or thyroid hormone-like
compound subsequently has a serum concentration which is physiologically adverse after
20 topical application of the composition.

4. A skin treatment composition for topical application, the composition consisting
solely of a thyroid hormone compound or thyroid hormone-like compound as herein defined
together with a pharmacologically acceptable base composition.

5. A skin treatment composition according to one of claims 1 to 4 in which the thyroid hormone compound is selected from Tri-iodothyronine (T3); D and L tetraiodothyronine - thyroxine (T4); 3,3',5' tri-iodothyronine (reverse T3) ; 3,3'- diiodothyronine ; T3 T4 analogues such as 3,5,3'-Triiodothyroacetic acid ; 3,5,3'- Tetraiodothyroacetic acid ; 3,5,3'- Triiodo-L-thyronine ; 3,5,3'-Triiodo-L-thyronine methyl ester ; 3,5,3'-Triiodo-L-thyronine hydrochloride ; L-thyroxine ; L-thyroxine hydrochloride ; L-T3 ; T4Fo ; Tetrac ; Triac ;

5 Tetratrop ; Triprop ; T4Bu ; T3Bu ; Thyroxamine ; Triiodothyronamine ; L-3'-T1 ; L-3'-T1 ; L-3,5'-T2 ; L-3,3'-T2 ; L- 3,3',5'-T3 ; DL-Br2I ; L-Br2iPr ; L-Me2I ; L-Me3 ; L-Me4 ; L-Me2iPr ; DL-IMeI ;

L-3,5-Dimethyl-3'-isopropylthyronine (DIMIT) ; DL-BPT4 ; B-triac ; BP-tetrac ; DL- SBT3 ;

10 DL-SBT4 ; DL-MBT3 ; MB-tetrac ; T2 ; T2F ; T2Cl ; T2Br ; T3 ; T2Me ; T2Et ; T2iPr ; T2nPr ; T2sBu ; T2tBu ; T2iBu ; T2Phe ; T2OH ; T2NO2 ; T2F2 ; T2Cl2 ; T4 ; T2Me2 ; 3,5,3',5'-tetraiodo-D-thyronine ; 3,5,3'-Triiodo-D-thyronine ; 3,5- Diiodo-4-hydroxyphenylpropionic acid (DIHPA) ; Aryloxamic acids ; (arylamino) acetic acids ; arylpropionic acids ; arylthioacetic acids ; (aryloxy)acetic acid ; 3,3'- T2 ; 3,5-T2 ; 3'-5'-T2 ;

15 (5-Benzyloxy-2-methoxyphenyl)-(2-methoxypyrimidin-5-yl)- methanol ; Benzyloxy-2-methoxyphenyl)-(6-methylpyridin-3-yl)methanol ; (5- Benzyloxy-2-methoxyphenyl)-(5-bromo-2-methoxypyridin-4-yl)methanol ; (5- benzyloxy-2-methoxyphenyl)-(2,6-difluoropyridin-3-yl)methanol ; (5-Benzyloxy-2- methoxyphenyl)-(2-methoxypyridin-4-yl)methanol ; 4-Methoxy-3-[(2- methoxypyrimidin-5-yl)methyl]phenol ; 4-Methoxy-3-[(6-methylpyrid-3- yl)methyl]phenol ; 5-Benzyloxy-2-methoxybenzyl Bromide ; (5-Benzyloxy-2-methoxyphenyl)-(6-chloropyridazin-3-yl)-acetonitrile ; 4-Benzyloxy-2-[2- methoxythiazol-5-yl)methyl]anisole ; 6-[(5-Hydroxy-2- methoxyphenyl)methyl]thiazol-2-(3H) ; 3'-

20

Heteroarylmethyl-4'-)-methyl-3,5-dinitro- N-trifluoro-acetyl-L-thyronine Ethyl Esters ; 3'-heteroarylmethyl-3,5-di-iodo-4')- methyl-N-trifluoro-acetyl-L-thyronine Ethyl Esters ; 3'-heteroarylmethyl analogues of 3,3',5-tri-iodo-L-thyronine (T3) ; 3'-substituted derivatives of the thyroid hormone 3,3',5-triiodo-L-thyronine (T3) ; L-3'-T1 ; L-3,5'-T2 ; L-3,3'-T2 ; L-3,3',5'-T3 ; DL-Br2I ; L-Br2IPr ; L-Me2I ; L-Me3 ; L-Me4 ; L-Me2iPr ; DL-IMeI ; L-3,5-

5 Dimethyl-3'-isopropylthyronine (DIMIT) ; DL-BPT4 ; B-triac ; BP-tetrac ; DL-SBT3 ; DL-SBT4 ; DL-MBT3 ; MB-tetrac ; T2 ; T2F ; T2Cl ; T2Br ; T3 ; T2Me ; T2Et ; T2iPr ; T2nPr ; T2sBu ; T2tBu ; T2iBu ; T2Phe ; T2OH ; T2NO2 ; T2F2 ; T2Cl2 ; T4 ; T2Me2 ; 3,5,3',5'-tetraiodo-D-thyronine ; 3,5,3'-Triiodo-D-thyronine ; 3,5- Diiodo-4-hydroxyphenylpropionic acid (DIHPA) ; Aryloxamic acids ; (arylamino)acetic acids ; arylpropionic acids ;

10 arylthioacetic acids ; (aryloxy)acetic acid ; 3,3'-T2 ; 3,5-T2 ; 3'-5'-T2 ; α -methyl-3,5,3'-triiodothyroacetic acid, α - methyl-3,5,3'-triiodothyropropionic acid, and α -methyl-3,5,3',5'-tetraiodothyropropionic acid ; methylene- and carbonyl-bridged analogs of iodinated thyronines thyroacetic acids ; Iodinated benzofurans ; 3,5-diiodo-4-(2-N,N-diethylaminoethoxy)phenyl-(2-butylbenzofur-3-yl)methanol hydrochloride ; 2- methyl-3-(3,5-

15 diiodo-4-(2-N,N-diethylamino- : ethoxy)-benzoyl)benzofuran hydrochloride ; 2-n-butyl-3-(3,5-diiodo-4-carboxymethoxy-benzoyl)benzofuran ; 2- methyl-3-(3,5-diiodo-4-hydroxy-benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4- carboxymethoxy-benzyl)benzofuran ; [4'-hydroxy-3'-iodo-3,5 diiodo-4-(2-N,N- dimethylamino- ; (ethoxy)benzophenon hydrochloride ; 2-butyl-3-(3-iodo-4- hydroxybenzoyl)benzofuran ; 4',4-dihydroxy 3',5-triiodo-

20 diphenylmethan ; 3,5-- diiodo-4-(2-N, N-diethylaminoethoxy)phenyl- ; -(2-butylbenzofur-3-yl)methanol hydrochloride ; 2-methyl-3-(3,5-diiodo-4-(2-N,N-diethylamino-ethoxy)-benzoyl)benzofuran hydrochloride ; 2-n-butyl-3-(3,5-diiodo-4-carboxymethoxy-

benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4-hydroxy-benzoyl)benzofuran ; 2- methyl-3-(3,5-diiodo-4-carboxymethoxy-benzyl)benzofuran ; 4'-hydroxy-3'-iodo-3,5 diiodo-4-(2-N,N-dimethylamino-ethoxy)benzophenon hydrochloride ; 2-butyl-3-(3- iodo-4-hydroxybenzoyl)benzofuran ; 4',4'-dihydroxy-3',5'-triiodo-diphenylmethan ; 3,5-diethyl,3'-isopropyl thyronine (DIET) ; and IpTA2 (3,5 diiodo- 3'isopropyl thyroacetic acid) and
5 pharmacologically acceptable salts and derivatives thereof.

6. A composition according to any one of claims 1 to 5 comprising a concentration of 5×10^8 times K_d or less of the said at least one thyroid hormone compound or thyroid hormone- like compound.

10 7. A composition according to any preceding claim in which the said at least one thyroid hormone compound or thyroid hormone-like compound is in chemically pure form.

15 8. A composition according to any preceding claim in which the pharmacologically acceptable base is selected from oil in water emulsions, sprays, liposomes and solutions.

9. A composition according to any preceding claim in which the said at least one thyroid hormone compound is at least partially dissolved in a solvent.

20 10. A composition according to claim 9 in which the solvent is an organic solvent.

11. A composition according to claim 10 in which the organic solvent is selected from

alcohol and alcohol and water solutions.

12. A composition according to claim 11 in which the organic solvent is selected from isopropanol, isopropanol and water, ethanol, and ethanol and water solutions.

5 13. A composition according to any preceding claim for the treatment of a condition selected from stria, cellulite, roughened skin, actinic skin damage, intrinsically aged skin, photodamaged skin, lichen planus, ichthyosis, acne, psoriasis, wrinkled skin, Dernier's disease, eczema, atopic dermatitis, seborrhoeic dermatitis scleroderma, collagen deficient skin, corticosteroid atrophy, chloracne, pityriasis, and skin scarring.

10 14. A composition according to any preceding claim comprising a thyroid hormone or a thyroid hormone-like compound together with at least one of a Vitamin D analogue, a glucocorticoid or a retinoic acid receptor binding compound.

15 15. A unit dose package containing a single dose of a composition according to claim any preceding claim.

20 16. A method of modulating the expression of genes in the skin, the method comprising applying a composition comprising at least one thyroid hormone compound or thyroid hormone-like compound as herein defined together with a pharmacologically acceptable base to the skin.

17. A method according to claim 16 in which the gene to modulated is selected from genes encoding keratin 1, keratin 10, TGF beta-2, TGF-alpha, TGF beta-1, SCCE, Transglutaminase K, Keratin growth factor (KGF), procollagen 1A1, procollagen 3A-1, keratin 16, connective tissue growth factor CTGF, CRABP-II.

5 18. A method of improving the skin of a subject, the method comprising the steps of: providing a composition in accordance with any one of claims 1 to 13; and applying the said composition to the skin of the subject.

10 19. A method according to claim 18 in which the condition of the skin to be improved is selected from stria, cellulite, roughened skin, actinic skin damage, intrinsically aged skin, photodamaged skin, lichen planus, ichthyosis, acne, psoriasis, wrinkled skin, Dernier's disease, eczema, atopic dermatitis, seborrhoeic dermatitis scleroderma, collagen deficient skin, corticosteroid atrophy, chloracne, pityriasis, and skin scarring.

15 20. A method according to claim 18 or 19 in which the composition is applied from twice a day to every three days.

20 21. A method of reducing cutaneous or subcutaneous fat deposits in a subject, the method comprising the steps of providing a composition in accordance with any one of claims 1 -14; and applying the said composition to skin of the subject in the vicinity of the deposits to be treated.

22. A method according to claim 21 in which the composition is applied to the skin from between twice a day to every three days.

23. The use of a thyroid hormone or thyroid hormone-like compound in the preparation of a composition for topical application for the treatment of a skin condition.

5

24. A use according to claim 23 in which the condition is selected from stria, cellulite, roughened skin, actinic skin damage, intrinsically aged skin, photodamaged skin, lichen planus, ichthyosis, acne, psoriasis, wrinkled skin, Dernier's disease, eczema, atopic dermatitis, seborrhoeic dermatitis scleroderma, collagen deficient skin, corticosteroid atrophy, chloracne, pityriasis, and skin scarring.

10

25. A use according to claim 23-24 in which the thyroid hormone is selected from Triiodothyronine (T3); D and L tetraiodothyronine - thyroxine (T4); 3,3',5' tri-iodothyronine (reverse T3) ; 3,3'-diiodothyronine ; T3 T4 analogues such as 3,5,3'-Triiodothyroacetic acid ; 3,5,3'-Tetraiodothyroacetic acid ; 3,5,3'- Triiodo-L-thyronine ; 3,5,3'-Triiodo-L-thyronine methyl ester ; 3,5,3'-Triiodo-L- thyronine hydrochloride ; L-thyroxine ; L-thyroxine hydrochloride ; L-T3 ; T4Fo ; Tetrac ; Triac ; Tetraprop ; Triprop ; T4Bu ; T3Bu ; Thyroxamine ; Triiodothyronamine ; L-3'-T1 ; L-3'-T1 ; L-3,5'-T2 ; L-3,3'-T2 ; L-3,3',5'-T3 ; DL- Br2I ; L-Br2iPr ; L-Me2I ; L-Me3 ; L-Me4 ; L-Me2iPr ; DL-IMe1 ; 1-3,5-Dimethyl- 3'-isopropylthyronine (DIMIT) ; DL-BPT4 ; B-triac ; BP-tetrac ; DL-SBT3 ; DL- SBT4 ; DL-MBT3 ; MB-tetrac ; T2 ; T2F ; T2Cl ; T2Br ; T3 ; T2Me ; T2Et ; T2iPr ; T2nPr ; T2sBu ; T2tBu ; T2iBu ; T2Phe ; T2OH ; T2NO2 ; T2F2 ; T2Cl2 ; T4 ; T2Me2 ; 3,5,3',5'-tetraiodo-D-

15

20

thyronine ; 3,5,3'-Triiodo-D-thyronine ; 3,5-Diiodo-4- hydroxyphenylpropionic acid (DIHPA) ; Aryloxamic acids ; (arylamino) acetic acids ; arylpropionic acids ; arylthioacetic acids ; (aryloxy)acetic acid ; 3,3'-T2 ; 3,5-T2 ; 3'-5'-T2 ; (5-Benzyloxy-2-methoxyphenyl)-(2-methoxypyrimidin-5-yl)- methanol ; Benzyloxy-2-methoxyphenyl)-(6-methylpyridin-3-yl)methanol ; (5-Benzyloxy-2-methoxyphenyl)-(5-bromo-2-methoxypyridin-4-yl)methanol ;

5 (5- benzyloxy-2-methoxyphenyl)-(2,6-difluoropyridin-3-yl)methanol ; (5-Benzyloxy-2-methoxyphenyl)-(2-methoxypyridin-4-yl)methanol ; 4-Methoxy-3-[(2-methoxypyrimidin-5-yl)methyl]phenol ; 4-Methoxy-3-[(6-methylpyrid-3- yl)methyl]phenol ; 5-Benzyloxy-2-methoxybenzyl Bromide ; (5-Benzyloxy-2- methoxyphenyl)-(6-chloropyridazin-3-yl)-acetonitrile ; 4-Benzyloxy-2-[2- methoxythiazol-5-yl)methyl]anisole ; 6-[(5-Hydroxy-2-

10 methoxyphenyl)methyl]thiazol-2-(3H) ; 3'-Heteroarylmethyl-4'-)-methyl-3,5-dinitro- N-trifluoro-acetyl-L-thyronine Ethyl Esters ; 3'-heteroarylmethyl-3,5-di-iodo-4'-)- methyl-N-trifluoro-acetyl-L-thyronine Ethyl Esters ; 3'-heteroarylmethyl analogues of 3,3',5-tri-iodo-L-thyronine (T3) ; 3'-substituted derivatives of the thyroid hormone 3,3',5-triiodo-L-thyronine (T3) ; L-3'-T1 ; L-3,5'-T2 ; L-3,3'-T2 ; L- 3,3',5'-T3 ; DL-Br2I ; L-Br2IPr ; L-Me2I ; L-Me3 ;

15 L-Me4 ; L-Me2iPr ; DL-IMeI ; L-3,5-Dimethyl-3'-isopropylthyronine (DIMITT) ; DL-BPT4 ; B-triac ; BP-tetrac ; DL-SBT3 ; DL-SBT4 ; DL-MBT3 ; MB-tetrac ; T2 ; T2F ; T2Cl ; T2Br ; T3 ; T2Me ; T2Et ; T2iPr ; T2nPr ; T2sBu ; T2tBu ; T2iBu ; T2Phe ; T2OH ; T2NO2 ; T2F2 ; T2Cl2 ; T4 ; T2Me2 ; 3,5,3',5'-tetraiodo-D-thyronine ; 3,5,3'-Triiodo-D-thyronine ; 3,5-Diiodo-4-hydroxyphenylpropionic acid (DIHPA) ; Aryloxamic acids ; (arylamino)acetic acids

20 ; arylpropionic acids ; arylthioacetic acids ; (aryloxy)acetic acid ; 3,3'-T2 ; 3,5-T2 ; 3'-5'-T2 ; α -methyl-3,5,3'-triiodothyroacetic acid, α - methyl-3,5,3'-triiodothyropropionic acid, and α -methyl-3,5,3',5'- tetraiodothyropropionic acid ; methylene- and carbonyl-bridged analogs of

iodinated thyronines thyroacetic acids ; Iodinated benzofurans ; 3,5-diiodo-4-(2-N,N-
 diethylaminoethoxy)phenyl-(2-butylbenzofur-3-yl)methanol hydrochloride ; 2- methyl-3-(3,5-
 diiodo-4-(2-N,N-diethylamino- ; ethoxy)-benzoyl)benzofuran hydrochloride ; 2-n-butyl-3-
 (3,5-diiodo-4-carboxymethoxy-benzoyl)benzofuran ; 2- methyl-3-(3,5-diiodo-4-hydroxy-
 benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4- carboxymethoxy-benzyl)benzofuran ; [4'-
 5 hydroxy-3'-iodo-3,5 diiodo-4-(2-N,N- dimethylamino- ; ethoxy)benzophenon hydrochloride ;
 2-butyl-3-(3-iodo-4- hydroxybenzoyl)benzofuran ; 4',4-dihydroxy 3',5-triiodo-
 diphenylmethan ; 3,5- diiodo-4-(2-N, N-diethylaminoethoxy)phenyl- ; -(2-butylbenzofur-3-
 yl)methanol hydrochloride ; 2-methyl-3-(3,5-diiodo-4-(2-N,N-diethylamino-ethoxy)-
 benzoyl)benzofuran hydrochloride ; 2-n-butyl-3-(3,5-diiodo-4-carboxymethoxy-
 10 benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4-hydroxy-benzoyl)benzofuran ; 2- methyl-3-
 (3,5-diiodo-4-carboxymethoxy-benzyl)benzofuran ; 4'hydroxy-3'-iodo-3,5 diiodo-4-(2-N,N-
 dimethylamino-ethoxy)benzophenon hydrochloride ; 2-butyl-3-(3- iodo-4-
 hydroxybenzoyl)benzofuran ; 4',4-dihydroxy-3',5-triiodo-diphenylmethan ; 3,5-diethyl,3'-
 isopropyl thyronine (DIET) ; and IpTA2 (3,5 diiodo- 3'isopropyl thyroacetic acid) and
 15 pharmacologically acceptable salts and derivatives thereof.

26. The use of a thyroid hormone or thyroid hormone-like compound in the preparation of
 a composition for topical application for the reduction of cutaneous or subcutaneous fat
 deposits.

27. The use according to claim 26 in which the fat deposits cause cellulite.

28. A use according to claim 26 or 27 in which the thyroid hormone is selected from Triiodothyronine (T3); D and L tetraiodothyronine - thyroxine (T4); 3,3',5' tri- iodothyronine (reverse T3) ; 3,3'-diiodothyronine ; T3 T4 analogues such as 3,5,3'- Triiodothyroacetic acid ; 3,5,3'-Tetraiodothyroacetic acid ; 3,5,3'-Triiodo-L- thyronine ; 3,5,3'-Triiodo-L-thyronine methyl ester ; 3,5,3'-Triiodo-L-thyronine hydrochloride ; L-thyroxine ; L-thyroxine hydrochloride ; L-T3 ; T4Fo ; Tetrac ; Triac ; Tetraprop ; Triprop ; T4Bu ; T3Bu ; Thyroxamine ; Triiodothyronamine ; L- 3'-T1 ; L-3'-T1 ; L-3,5'-T2 ; L-3,3'-T2 ; L-3,3',5'-T3 ; DL-Br2I ; L-Br2iPr ; L-Me2I ; L-Me3 ; L-Me4 ; L-Me2iPr ; DL-IMeI ; 1-3,5-Dimethyl-3'-isopropylthyronine (DIMIT) ; DL-BPT4 ; B-triac ; BP-tetrac ; DL-SBT3 ; DL-SBT4 ; DL-MBT3 ; MB- tetrac ; T2 ; T2F ; T2Cl ; T2Br ; T3 ; T2Me ; T2Et ; T2iPr ; T2nPr ; T2sBu ; T2tBu ; T2iBu ; T2Phe ; T2OH ; T2NO2 ; T2F2 ; T2Cl2 ; T4 ; T2Me2 ; 3,5,3',5'-tetraiodo-D-thyronine ; 3,5,3'-Triiodo-D-thyronine ; 3,5-Diiodo-4-hydroxyphenylpropionic acid (DIHPA) ; Aryloxamic acids ; (arylamino) acetic acids ; arylpropionic acids ; arylthioacetic acids ; (aryloxy)acetic acid ; 3,3'-T2 ; 3,5-T2 ; 3'-5'-T2 ; (5- Benzyloxy-2-methoxyphenyl)-(2-methoxypyrimidin-5-yl)-methanol ; Benzyloxy-2- methoxyphenyl)-(6-methylpyridin-3-yl)methanol ; (5-Benzyloxy-2-methoxyphenyl)- (5-bromo-2-methoxypyridin-4-yl)methanol ; (5-benzyloxy-2-methoxyphenyl)-(2,6- difluoropyridin-3-yl)methanol ; (5-Benzyloxy-2-methoxyphenyl)-(2-methoxypyridin- 4-yl)methanol ; 4-Methoxy-3-[(2-methoxypyrimidin-5-yl)methyl]phenol ; 4- Methoxy-3-[(6-methylpyrid-3-yl)methyl]phenol ; 5-Benzyloxy-2-methoxybenzyl Bromide ; (5-Benzyloxy-2-methoxyphenyl)-(6-chloropyridazin-3-yl)-acetonitrile ; 4- Benzyloxy-2-[2-methoxythiazol-5-yl)methyl]anisole ; 6-[(5-Hydroxy-2-methoxyphenyl)methyl]thiazol-2-(3H) ; 3'-Heteroarylmethyl-4'-)-methyl-3,5-dinitro- N-trifluoro-acetyl-L-thyronine Ethyl Esters : 3'-heteroarylmethyl-3,5-di-iodo-4'-)- methyl-N-

trifluoro-acetyl-L-thyronine Ethyl Esters ; 3'-heteroarylmethyl analogues of 3,3',5-tri-iodo-L-thyronine (T3) ; 3'-substituted derivatives of the thyroid hormone 3,3',5-triiodo-L-thyronine (T3) ; L-3'-T1 ; L-3,5'-T2 ; L-3,3'-T2 ; L- 3,3',5'-T3 ; DL-Br2I ; L-Br2IPr ; L-Me2I ; L-Me3 ; L-Me4 ; L-Me2iPr ; DL-IMe1 ; L-3,5-Dimethyl-3'-isopropylthyronine (DIMIT) ; DL-BPT4 ; B-triac ; BP-tetrac ; DL-SBT3 ; DL-SBT4 ; DL-MBT3 ; MB-tetrac ; T2 ; T2F ; T2Cl ; T2Br ; T3 ; T2Me ; T2Et ; T2iPr ; T2nPr ; T2sBu ; T2tBu ; T2iBu ; T2Phe ; T2OH ; T2NO2 ; T2F2 ; T2Cl2 ; T4 ; T2Me2 ; 3,5,3',5'-tetraiodo-D-thyronine ; 3,5,3'-Triiodo-D-thyronine ; 3,5-Diiodo-4-hydroxyphenylpropionic acid (DIHPA) ; Aryloxamic acids ; (arylamino)acetic acids ; arylpropionic acids ; arylthioacetic acids ; (aryloxy)acetic acid ; 3,3'-T2 ; 3,5-T2 ; 3'-5'-T2 ; α -methyl-3,5,3'-triiodothyroacetic acid, α -methyl-3,5,3'-triiodothyropropionic acid, and α -methyl-3,5,3',5'-tetraiodothyropropionic acid ; methylene- and carbonyl-bridged analogs of iodinated thyronines thyroacetic acids ; Iodinated benzofurans ; 3,5-diiodo-4-(2-N,N-diethylaminoethoxy)phenyl-(2-butylbenzofur-3-yl)methanol hydrochloride ; 2-methyl-3-(3,5-diiodo-4-(2-N,N-diethylamino-ethoxy)-benzoyl)benzofuran hydrochloride ; 2-n-butyl-3-(3,5-diiodo-4-carboxymethoxy-benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4-hydroxy-benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4-carboxymethoxy-benzyl)benzofuran ; [4'-hydroxy-3'-iodo-3,5 diiodo-4-(2-N,N-dimethylamino-ethoxy)benzophenon hydrochloride ; 2-butyl-3-(3-iodo-4-hydroxybenzoyl)benzofuran ; 4',4-dihydroxy 3',5-triiododiphenylmethan ; 3,5-diiodo-4-(2-N,N-diethylaminoethoxy)phenyl- ; -(2-butylbenzofur-3-yl)methanol hydrochloride ; 2-methyl-3-(3,5-diiodo-4-(2-N,N-diethylamino-ethoxy)-benzoyl)benzofuran hydrochloride ; 2-n-butyl-3-(3,5-diiodo-4-carboxymethoxy-benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4-hydroxy-benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4-carboxymethoxy-benzyl)benzofuran ; 4'-hydroxy-3'-iodo-3,5 diiodo-4-(2-N,N-

dimethylamino-ethoxy)benzophenon hydrochloride ; 2-butyl-3-(3- iodo-4-hydroxybenzoyl)benzofuran ; 3,5-diethyl,3'-isopropyl thyronine (DIET) ; 4',4-dihydroxy-3,3',5-triiodo-diphenylmethan ; and IpTA2 (3,5 diiodo- 3'isopropyl thyroacetic acid) and pharmacologically acceptable salts and derivatives thereof.

5 29. A composition according to any one of claims 1 to 14 comprising less than or equal to about 50mg/100ml of thyroid hormone compound.

30. A composition according to claim 29 comprising less than or equal to about 20mg/100ml of thyroid hormone compound.

10

TABLE 2
COMPARISON OF TRIAC WITH OTHER DERMATOLOGICALLY ACTIVE DRUGS

drug	Genes Tested											
	k1	k10	k16	k19	transgK	scce	tgfbeta-2	IL-6	col 1A-1	col 3A-1	ctgf(pdgf-L)	crabp-II
vit D 1 μ Molar	0	-1	0	0	-1	0	2	-1	2	2	0	-1
Triac 50 nM	-3	-2	-1	-1	-3	-2	2	-0.5	2	2	1	-1
Triac 1 μ M	-2	-2	-0.5	-1	-3	-2	2	-0.5	2	1	0.5	-1
betameth 1 μ M	-3	-0.5	-1	-0.5	-1	-1	0	-2	0.5	-0.5	1	-1
RA 1 μ M	-3	-1	-0.5	-1	-3	-0.5	2	-1	2	1	1	1

2/12

TABLE 3
TRANSCRIPTIONAL RESPONSES TO THYROID HORMONE RECEPTOR BINDING ENTITIES

1 μ MOLAR CONCENTRATION

Ki (nM)	compound number	Genes tested						
		k1	k10	k16	trans	gk	scce	col a-1
0.1	1	-2	-0.5	0	0	0.5	1	2
0.1	2	-1	0	0	0.5	0.5	2	1
10	3	-2	-1	0	1	0	2	0.5
20	4	-2	-0.5	0	0	0	1	0
20000	L-T-1	0	0	0	1	1	0.5	0.5
0.04	Triac 50nM	-2	-2	0	0	0	2	1
	Triac 1 μ M	-1	-1	-1	-0.5	0	1	1
	8	-1	-1			0	0	0
0.04	Triac 50nM	-2	0	0	-2	-2	0	0
	Triac 1 μ M	-1	1	0	-0.5	-1	0.5	0.5
	8	-2	0	-0.5	-2	-2	0	0
	75	-2	-1	0	-2	-1	1	0.5
	0.1	-1	1	0.5	-1	-1	1	1
	0.08	-2	1	0.5	-1	0.5	0.5	1


3/12

Key to Table 3


Number	Name	Conc	Ki (Kd) (Nmol/l)
1	Triiodothyronine	1 μ M	0.1
2	Tri-form	1 μ M	0.1
3	Thyroxine	1 μ M	10
4	KB 131-007	1 μ M	20
5	SKF 94-901	1 μ M	8
6	DIMIT	1 μ M	75
7	CIBA 71	1 μ M	0.1
8	KB 131 026	1 μ M	0.1
	L-TI**	10 μ M	20000

* N-[3,5-Dimethy-4-(4'-hydroxy-3' -isopropylphenoxy)-phenyl]oxamic Acid


**3-iodo-L-Thronine, (Henning Berlin Germany)




1) Triiodothyronine




2) Tri-form




3) Thyroxine




4) KB 131-007




5) Tri-form



6) DIMIT



7) CIBA 71



8) KB 131-026

4/12

TABLE 4

Subject		A	A	B	B	C	C	C
Transcript	cycles	C	TR 1	C	TR 1	C	TR 0.1	TR 1
GAPDH	24	0	0	0	0	ND	ND	ND
cyclophilin	20	0	0	0	0	ND	ND	ND
5 Keratin 5	19	0	+	0	+	0	0	0
Keratin 14	19	0	+	0	+	0	0	0
Keratin 1	17	0	++	0	+	0	0	+
Keratin 10	19	0	(+)	0	(+)	0	0	0
TGase-K	32	0	0	0	(+)	0	+	0
0 Involucrin	25	0	0	0	0	ND	ND	ND
RXR α	27	0	(+)	0	(+)	ND	ND	ND
SCCE	25	0	+	0	++	0	+	+
ICAM-1	35	nd	nd	nd	nd	ND	ND	ND
IL-6	25	nd	nd	nd	nd	ND	ND	ND
5 5 α -red.I	30	0	0	0	-	ND	ND	ND
5 α -red. II	35	nd	nd	nd	nd	ND	ND	ND
Col1A1	25	0	++	0	++	0	+	+
Col3A1	22	0	++	0	+	0	+	+
Collase	35	nd	nd	nd	nd	ND	ND	ND
20 CTGF	30	0	+	0	++	0	-	-
Fibronec	22	0	+	0	+	0	0	-
CRABP II	25	0	(-)	0	-			

25 nd= not detected. ND= not determined

30

5/12

Figure 1

study 2	k1	k10	k16	k19	transgk	scce	lgfbeta-2	il-6	col a-1	col a-3	clgl(pdgl-L)	crapb-II	fibronectin
triac 50 nM	-3	-2	-1	-1	-3	-2	2	-0.5	2	2	1	-1	0
betameth 1 uM	-3	-0.5	-1	-0.5	-1	-1	0	-2	0.5	-0.5	1	-1	0

betamethasone, triac 50 nM





Figure 2

study 2	k1	k10	k16	k19	trans gksce	tgfbeta-2 il-6	col a-1	col a-3	ctgf(pdgf-L)	crabp-II	fibronectin
vitD-3 1 uM	0	-1	0	0	-1	2	2	2	0	-1	-0.5
triac 50 nM	-3	-2	-1	-1	-3	2	2	2	1	-1	0

vit D-3 1 uM , triac 50 nM




7/12

06/05/96

Figure 3

study 2	k1	k10	k16	k19	transgK	scce	lgfbeta-2	il-6	col a-1	col a-3	ctgf(pdgf-L)	crabp-II	fibronectin
triac 50 nM	-3	-2	-1	-1	-3	-2	2	-0.5	2	2	1	-1	0
RA 1 uM	-3	-1	-0.5	-1	-3	-0.5	2	-1	2	1	1	1	-0.5




8/12

06/05/96

Figure 4

RA 1 uM	k1	k10	k16	k19	transK	scce	il-6	tgfbeta-2	col a-1	col a-3	cigf(pdgt-L)	fibronectin	crabp-II
study 2	-3	-1	-0.5	-1	-3	-0.5	-1	2	2	1	1	-0.5	1
study 3.1	-3	-1	0	1	-1	2	-1	2	2	2	2	2	1
study 3.2b	-3	-2			-2	0	-1	-0.5	-1	0.5	-1	-1	0

RA 1 uM




9/12

Figure 5

trial	50 nM	k1	k10	k16	k19	trans	scce	il-6	tgfbeta	col a-1	col a-3	ctgf(pdgr-L)	fibronectin	crabp-II
study 2	-3	-2	-1	-1	-1	-3	-2	-0.5	1.5	2	2	1	0	-1
study 3.1	-2	0	0	0	0	-2	-2	0	1	0	0	0	0	-1
study 3.2b	-2	-2				0	0	1		2	1	2	2	0

trial 50 nM

6/4/96



10/12




Fig 6

RIGHTSIDE: TRIAM CREAM APPLIED DAILY FOR 3 WEEKS
 STOPPED 1-2 WEEKS
 TO CREAM APPLIED DAILY FOR 10 DAYS
 LEFT SIDE: CREAM APPLIED DAILY FOR 7 DAYS
 (TO CREAM BOTH SIDES FOR 7 DAYS)

11/12







Fig 7

TIRAC CREAM APPLIED DAILY FOR 3 WEEKS.

12/12



T₃ Cream applied daily to right side

This Page Blank (uspto)

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 7/48		A2	(11) International Publication Number: WO 96/40048
			(43) International Publication Date: 19 December 1996 (19.12.96)
(21) International Application Number: PCT/US96/09975 (22) International Filing Date: 7 June 1996 (07.06.96) (30) Priority Data: 08/481,698 7 June 1995 (07.06.95) US (60) Parent Application or Grant (63) Related by Continuation US 08/481,698 (CIP) Filed on 7 June 1995 (07.06.95) (71) Applicant (for all designated States except US): KARO BIO AB [SE/SE]; Novum, S-141 57 Huddinge (SE). (72) Inventors; and (75) Inventors/Applicants (for US only): LAVIN, Thomas, N. [US/US]; 10 Canterbury Lane, Watchung, NJ 07060 (US). VAHLQUIST, Anders, B. [SE/SE]; Institutionen for Dermatologi, Linköpings Universitetsjukhus, S-581 85 Linköping (SE). (74) Agents: HOSCHEIT, Dale, H. et al.; Banner & Allegretti, Ltd., Suite 1100, 1001 G Street, N.W., Washington, DC 20001 (US).		(81) Designated States: AU, CA, JP, KP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i>	

(54) Title: NOVEL USES FOR THYROID HORMONES OR THYROID HORMONE-LIKE COMPOUNDS

(57) Abstract

This invention relates to the use of topically applied thyroid hormones and thyroid hormone-like compounds which are receptor binding ligands, either agonists or antagonists, to improve the appearance of the skin and underlying subcutaneous fat and improve certain medical conditions when applied topically. These compounds can be used to treat skin conditions such as stria, cellulite, roughened skin, actinic skin damage, intrinsically aged skin, photodamaged skin, lichen planus, ichthyosis, acne, psoriasis, wrinkled skin, and to diminish the size and improve the appearance of skin scarring from surgical or naturally occurring wounds, and to reduce the incidence of hyperkeratotic scarring. These hormones or hormone analogs will also increase the rate of epithelialization and collagen production. The thyroid agonists and antagonists may also promote differentiation and amelioration of dedifferentiated skin in premalignant lesions. The thyroid agonists and antagonists can be active in all organisms which contain the thyroid hormone receptors, notably amphibians, birds and subjects. Combination with Vitamin D analogs glucocorticoid and retinoids will potentiate and modify the effects of the thyroid hormones for increased benefit. Side effects of thyroid hormones which occur when the hormone is given orally and prevent usefulness for the above conditions are prevented when the hormone is topically applied.

- 2 -

Eczema (dermatitis) is an itchy inflammation of the superficial skin layers caused by an outside agent or by endogenous factors. The terms dermatitis and eczema are used interchangeably.

5 The obvious treatment of eczema is to try to avoid precipitating factors.

10 Additionally, eczema is usually treated with topical steroids such as hydrocortisone, clobetasone butyrate, betamethasone and clobetasol propionate. The side effects of steroid use, particularly in the long term are well known and consist of skin atrophy, risk for systemic absorption of the drug and rebound phenomena when the drug is withdrawn.

15 There is a need for improved or alternate compositions for the treatment of dermatitis skin conditions such as psoriasis and eczema. New principles for treating eczema in particular should aim at reducing the reactivity of cutaneous cells, inhibiting cytokine release and improving the epidermal barrier recovery.

20 The structurally similar thyroid hormones triiodothyronine (T_3) and thyroxine (T_4) have a very wide range of effects. In adult mammals they influence nearly all organs, the metabolism of nutrients, basal metabolic rate and oxygen consumption. In humans, the deficiency or excess of circulating thyroid hormones results in the well characterised syndromes, hypo- and hyperthyroidism. Small concentrations of thyroid hormone metabolites which are also endocrinologically active exist. Among these
25 compounds are tri-iodothyroacetic acid("Triac") and tri-iodopropionic acid ("Tri-prop").

30 Thyroid hormones exert many of their actions by binding to a family of receptor proteins termed the *C-erb-A* family. In humans, this receptor

SUBSTITUTE SHEET (RULE 26)

NOVEL USES FOR THYROID HORMONES OR THYROID HORMONE-LIKE COMPOUNDS

5 TECHNICAL FIELD

This invention relates to skin care preparations containing thyroid hormones, thyroid hormone metabolites, derivatives of those compounds and other thyroid hormone receptor binding chemical entities and to the use of such compositions including to correct skin abnormalities, to
10 improve the appearance of the skin, and to control subcutaneous fat deposition when applied to the skin.

BACKGROUND

A wide variety of skin care preparations are currently available. There are
15 currently available several preparations for the treatment of cellulite, a dimpling of the skin over excess superficial fat deposits, but these are believed to have doubtful efficacy. A wide variety of medically useful skin preparations are also currently available, comprising primarily glucocorticoids and retinoid topical medicaments, both of which have
20 varying side-effects and usefulness. There is a considerable number of skin conditions and diseases such as stria, cellulite, roughened skin, actinic skin damage, intrinsically aged skin, photodamaged skin, lichen planus, ichthyosis, acne, psoriasis, wrinkled skin, eczema, seborrheic dermatitis, scleroderma, hyperkeratinizing disorders, keloids and skin
25 scarring.

- 4 -

collagen in the skin of guinea pigs (2). Fibronectin production is decreased in human fibroblasts and fibroblast glycosaminoglycans are either decreased or unchanged depending on the experimental conditions used (3,4,5,7,7a). Keratin gene expression for both the basal cell keratin K5 and K14 genes and the differentiation specific K10 gene is negatively regulated by thyroid hormones (9,8) in keratinocyte culture. These effects are mirrored by similar cell culture responses to retinoic acid (9) or the retinoid Tretinoin (19).

Histological studies of skin from individuals who have an excess of thyroid hormone show an increased number of cell layers in the skin, reflected by mean epidermal cell number, increased protein turnover with increased proline incorporation and generalized increases in epidermal proliferation compared to normal skin (11). In individuals who have a lack of thyroid hormone, the skin is atrophic with thinning of the epidermis and a decrease in cellularity. In human clinical biology, thyroid hormone excess leads to a general smoothing of the skin and the loss of wrinkles especially over the olecranon (elbow) surface.

Thyroid hormones also accelerate fat synthesis and lipolysis (breakdown). In rats which have an excess of thyroid hormone either chemically or by natural means, fat stores are in general decreased (12,13), although in humans clinical observation of thyroid hormone excess discloses either an increase or decrease in weight. The synthesis of fats may be increased (14,15) or decreased (12,13,16,21). Attempts to utilize the effects of excess oral thyroid hormone for weight loss in humans have in general failed because of severe adverse side effects (25,26).

Orally given thyroid hormone compound or thyroid hormone-like compounds in excess of normal bodily requirements or medical conditions

SUBSTITUTE SHEET (RULE 26)

- 3 -

protein family is now known to comprise several members, notably the human thyroid receptor alpha-1, the human thyroid receptor alpha -2 which binds the hormone poorly or not at all, the human thyroid receptor β -1, and the human thyroid receptor β -2. These proteins are part of a larger
5 superfamily of steroid hormone receptors which comprises the glucocorticoid receptors, the retinoic acid receptors, the vitamin D receptors, and the insect moulting receptors - the receptors for ecdysone and the insect juvenile hormones. Receptors for thyroid hormones are found in human skin, human fibroblasts and keratinocytes and they are
10 also found in all other tissues within the human body (1).

In addition to the naturally occurring thyroid hormones, a large number of chemical compounds which bind to the thyroid hormone receptor and which produce thyroid hormone-like effects have been synthesized see for
15 example US5401772.

Thyroid hormones, in many cases, act indirectly by influencing the effects of other hormones and tissues (1). For example in the rat, thyroid administration increases pituitary growth hormone production which in turn
20 affects hepatic protein production including that of alpha-2 euglobulin. Functionally, in the rat, growth hormone may act as a second message for thyroid hormone(1). The biology of thyroid hormones has been extensively studied after oral administration, which makes the relationship between a direct effect of thyroid hormones and an indirect effect mediated
25 by thyroid hormone modulation of other autocrine, paracrine or endocrine factors difficult to ascertain.

Orally administered thyroid hormones influence the connective tissue biology of the skin. When given orally, thyroid hormones induce an
30 increase in neutral salt and acid soluble collagen, but decrease insoluble

SUBSTITUTE SHEET (RULE 26)

- 6 -

None of the above publications disclose or suggest the usefulness of compounds selected from those that bind the thyroid hormone receptor. The relationship between Triac and thyroid hormones is not made in any of these patents and no data is presented to show the relationship of the above mentioned compounds to the thyroid hormone dependent endocrine system via an effect mediated through the human thyroid receptor. In fact, FR2354101 discloses the use of Triac as an inhibitor of phosphodiesterase and its effect to increase cyclic AMP. This effect occurs only at dose ranges of approximately 10^{-4} M in *in vitro* experiments using isolated adipocytes. In concert with this mode of activity, the prior art literature makes claims for effective concentrations of chemical entity for anti-cellulite effects as greater than 50 mg of Triac or Triac derivative per 100 ml of vehicle and usually between 100 and 200 mg / 100 gms of excipient.

FR96.171 discloses the topical cellular growth accelerating activity and mitogenic of thyroxine (0.001-0.008 mg. %) in a propylene glycol diethyl ether vehicle in rat skin. No mention is made of other compounds which have thyroid hormone receptor binding activity such as Triac or Tri-iodothyronine, or other thyromimetic compounds known at the time (Journal of Medicinal Chemistry, 6, p 554-563, 1963). No teaching concerning the effects of thyroid hormone receptor binding entities on epidermal differentiation, gene expression or keratinization is made. GB782,745 and 859,546 describe the topical usefulness of compounds of a class which partially overlap with chemical entities which bind to the thyroid hormone receptor, but includes compounds including L-T-1 with no thyroid hormone receptor binding activity, and only a small subset of compounds which do recognize the receptor. In these patents, no claims are made for chemical entities characterized by binding to the thyroid hormone receptor or having thyroid hormone like activity. US3198702

SUBSTITUTE SHEET (RULE 26)

- 5 -

which are associated with excess thyroid hormone such as Grave's disease or toxic nodular goitre produce an acceleration of heart beat with associated heart failure, cardiac arrhythmias, osteoporosis, increased intestinal motility leading to diarrhoea, psychiatric abnormalities, and an increase in the basal metabolic rate. Attempts to use oral thyroid hormones for diminishing lipid levels in man resulted in increased cardiac deaths (17).

RO76691 and 76692 respectively disclose an anti-wrinkle cream comprising a crude preparation from animal endocrine glands, including the thyroid gland, and a method of obtaining lipid extracts from animal byproducts respectively. No data on the efficacy of the anti-wrinkle cream is provided nor is the thyroid hormone content of the cream provided or even mentioned. In particular, there is no suggestion in those patents of the efficacy of the compositions, methods, and uses of the present invention.

The use of Triac and its salts for a reduction of cellulite is disclosed in FR 2.153.202 (7134447). FR2197577 (72.30781) discloses various derivatives of Triac, including para hydroxy esters thereof, as having utility for the same indication. EP060776 discloses activity of an isopropyl derivative of Triac for the same indication. CH642851 (1168/80) discloses the utility of a liposome formulation of Triac together with glycosoaminoglycans for reducing cellulite. GB1354263 also discloses the use of Triac itself for reducing fat deposits. GB1400851 relates to the synthesis of ethyl esters and alkyl carboxy acids derivatives of Triac and their use in reducing cellulite in combination with leeches, hyaluronidase, proteases, and lipase.

SUBSTITUTE SHEET (RULE 26)

- 8 -

thyroid hormone receptor TR- θ or β with a chemical affinity constant, K_d , lower than $1\mu\text{M}$ when tested in receptor binding assay, described by Lavin (27) using pure or substantially pure natural or recombinant thyroid hormone θ or β receptor containing the ligand binding domain or thyroid hormone receptor containing preparations such as rat nuclei. Such ligands may be considered hormones when they have similar agonistic effects as the natural hormone or may be considered antagonists when the compounds antagonize the effects of the natural hormones. Partial agonist/antagonists also may exist. (Suitable ligands may be agonists or antagonists).

The topically-applied thyroid hormones, or thyroid hormone-like compounds used in the compositions and methods of the present invention are advantageous in that they enable the use of these chemical compounds to control subcutaneous or dermal fat stores, to improve the appearance of the skin, or normalize the physiology of the skin under pathophysiologic conditions without causing the undue adverse effects of orally administered thyroid hormone. In particular, the method of delivery of the thyroid hormone and thyroid hormone-like compounds avoids liver and kidney metabolism of the hormones, blood circulation of the hormones to other tissues and binding to blood carrier proteins which can alter efficacy.

The thyroid hormone or thyroid hormone-like compound is preferably in pure form, i.e not contaminated with other similar compounds.

The said at least one thyroid hormone compound or thyroid hormone-like compound may be selected from, for example, one of the following illustrative list of compounds:

SUBSTITUTE SHEET (RULE 26)

- 7 -

discloses a method of treating burns comprising the topical application of certain thyroxin analogues which are a subset of the same class of compounds claimed to have activity in GB 782745 and 859546.

- 5 No prior art document discloses the skin differentiating and collagen promoting effects of thyroid hormone or its analogues.

SUMMARY OF THE INVENTION

- 10 According to one aspect of the invention there is provided a composition for topical application, the composition comprising at least one thyroid hormone compound or thyroid hormone-like compound together with a pharmacologically acceptable base.
- 15 The topically-applied thyroid hormones, or thyroid hormone-like compounds used in the compositions and methods of the present invention are advantageous in that they enable the use of these chemical compounds to control subcutaneous or dermal fat stores to improve the appearance of the skin, or normalize the physiology of the skin under
- 20 pathophysiologic conditions without causing the undue adverse effects of orally administered thyroid hormone in a direct thyroid hormone dependent manner avoiding renal and hepatic metabolism of the thyroid hormone receptor binding chemical entity. In particular, the method of delivery of the thyroid hormone and thyroid hormone-like compounds avoids liver and
- 25 kidney metabolism of the hormones, blood circulation of the hormones to other tissues and binding to blood carrier proteins which can alter efficacy.

- 30 For the purposes of this invention a "thyroid hormone" or "thyroid hormone-like compound", which terms are used interchangeably herein, is any chemical entity, including peptides, which at least partially binds to

SUBSTITUTE SHEET (RULE 26)

- 10 -

hormone 3,3',5-triiodo- L-thyronine (T_3) ; L-3'- T_1 ; L-3,5'- T_2 ; L- 3,3'- T_2 ;
 L-3,3',5'- T_3 ; DL- Br_2I ; L- Br_2IPr ; L- Me_2I ; L- Me_3 ; L- Me_4 ; L- Me_2iPr ; DL- $IMeI$;
 ; L-3,5-Dimethyl-3'-isopropylthyronine (DIMIT) ; DL- BPT_4 ; B-triac ;
 BP-tetrac ; DL- SBT_3 ; DL- SBT_4 ; DL- MBT_3 ; MB-tetrac ; T_2 ; T_2F ; T_2Cl ;
 5 T_2Br ; T_3 ; T_2Me ; T_2Et ; T_2iPr ; T_2nPr ; T_2sBu ; T_2tBu ; T_2iBu ; T_2Phe ; T_2OH ;
 ; T_2NO_2 ; T_2F_2 ; T_2Cl_2 ; T_4 ; T_2Me_2 ; 3,5,3',5'- tetraiodo-D-thyronine ;
 3,5,3'-Triiodo-D-thyronine ; 3,5-Diiodo-4-hydroxyphenylpropionic acid
 (DIHPA) ; Aryloxamic acids ; (arylamino)acetic acids ; arylpropionic acids ;
 arylthioacetic acids ; (aryloxy)acetic acid ; 3,3'- T_2 ; 3,5- T_2 ; 3'-5'- T_2 ;
 10 θ -methyl-3,5,3'- triiodothyroacetic acid,
 θ -methyl-3,5,3'-triiodothyropropionic acid, and θ -methyl-3,5,3',5'-
 tetraiodothyropropionic acid ; methylene- and carbonyl-bridged analogs of
 iodinated thyronines thyroacetic acids ; Iodinated benzofurans ;
 3,5-diiodo-4-(2-N,N-
 15 diethylaminoethoxy)phenyl-(2-butylbenzofur-3-yl)methanol hydrochloride ;
 2-methyl-3- (3,5-diiodo-4-(2-N,N-diethylamino- ;
 ethoxy)-benzoyl)benzofuran hydrochloride ; 2-n-
 butyl-3-(3,5-diiodo-4-carboxymethoxy-benzoyl)benzofuran ;
 2-methyl-3-(3,5-diiodo-4- hydroxy-benzoyl)benzofuran ;
 20 2-methyl-3-(3,5-diiodo-4-carboxymethoxy- benzyl)benzofuran ;
 [4'-hydroxy-3'-iodo-3,5 diiodo-4-(2-N,N-dimethylamino- ;
 ethoxy)benzophenon hydrochloride ;
 2-butyl-3-(3-iodo-4-hydroxybenzoyl)benzofuran ; 4',4-dihydroxy
 3'3,5-triiodo-diphenylmethan ; 3,5-diiodo-4-(2-N, N-
 25 diethylaminoethoxy)phenyl- ; -(2-butylbenzofur-3-yl)methanol
 hydrochloride ; 2-methyl-
 3-(3,5-diiodo-4-(2-N,N-diethylamino-ethoxy)-benzoyl)benzofuran
 hydrochloride ; 2-n-
 butyl-3-(3,5-diiodo-4-carboxymethoxy-benzoyl)benzofuran ;
 30 2-methyl-3-(3,5-diiodo-4- hydroxy-benzoyl)benzofuran ;

SUBSTITUTE SHEET (RULE 26)

- 9 -

Triiodothyronine (T_3); L and D tetraiodothyronine - thyroxine (T_4); 3,3',5' tri-
 iodothyronine (reverse T_3) ; 3,3'-diiodothyronine ; T_3 T_4 analogues such as
 3,5,3'- Triiodothyroacetic acid ; 3,5,3'-Tetraiodothyroacetic acid ;
 3,5,3'-Triiodo-L-thyronine ; 3,5,3'-Triiodo-L-thyronine methyl ester ;
 5 3,5,3'-Triiodo-L-thyronine hydrochloride ; L- thyroxine ; L-thyroxine
 hydrochloride ; L- T_3 , T_4 Fo ; Tetrac ; Triac ; Tetraprop ; Triprop ; T_4 Bu ;
 T_3 Bu ; Thyroxamine ; Triiodothyronamine ; L-3'- T_1 , L-3'- T_1 ; L-3,5'- T_2 ;
 L-3,3'- T_2 ; L-3,3',5'- T_3 ; DL- Br_2 I ; L- Br_2 iPr ; L- Me_2 I ; L- Me_3 ; L- Me_4 ; L- Me_2 iPr
 ; DL-IMel ; 1-3,5- Dimethyl-3'-isopropylthyronine (DIMIT) ; DL-BPT $_4$; B-triac
 10 ; BP- tetrac ; DL-SBT $_3$; DL- SBT $_4$; DL-MBT $_3$; MB-tetrac ; T_2 ; T_2 F ; T_2 Cl ;
 T_2 Br ; T_3 ; T_2 Me ; T_2 Et ; T_2 iPr ; T_2 nPr ; T_2 sBu ; T_2 tBu ; T_2 iBu ; T_2 Phe ; T_2 OH
 ; T_2 NO $_2$; T_2 F $_2$; T_2 Cl $_2$; T_4 ; T_2 Me $_2$; 3,5,3',5'- tetraiodo-D-thyronine ;
 3,5,3'-Triiodo-D-thyronine ; 3,5- Diiodo-4- hydroxyphenylpropionic acid
 (DIHPA) ; Aryloxamic acids ; (arylamino) acetic acids ; arylpropionic acids ;
 15 arylthioacetic acids ; (aryloxy)acetic acid ; 3,3'- T_2 ; 3,5- T_2 ; 3'-5'- T_2 ;
 (5-Benzyloxy-2-methoxyphenyl)-(2-methoxypyrimidin-5-yl)-methanol ;
 Benzyloxy-2- methoxyphenyl)-(6-methylpyridin-3-yl)methanol ;
 (5-Benzyloxy-2- methoxyphenyl)-(5-
 bromo-2-methoxypyridin-4-yl)methanol ; (5-benzyloxy-2-
 20 methoxyphenyl)-(2,6- difluoropyridin-3-yl)methanol ;
 (5-Benzyloxy-2-methoxyphenyl)- (2-methoxypyridin-4- yl)methanol ;
 4-Methoxy-3-[(2-methoxypyrimidin-5- yl)methyl]phenol ; 4-Methoxy-3-[(6-
 methylpyrid-3-yl)methyl]phenol ; 5-Benzyloxy-2- methoxybenzyl Bromide ;
 (5- Benzyloxy-2-methoxyphenyl)-(6-chloropyridazin-3-yl)- acetonitrile ;
 25 4-Benzyloxy-2-[2- methoxythiazol-5-yl)methyl]anisole ; 6-[(5-Hydroxy-2-
 methoxyphenyl)methyl]thiazol-2- (3H) ;
 3'-Heteroarylmethyl-4'-)-methyl-3,5-dinitro-N- trifluoro-acetyl-L-thyronine
 Ethyl Esters ; 3'-heteroarylmethyl-3,5-di-iodo-4'-)-methyl-N-
 trifluoro-acetyl-L-thyronine Ethyl Esters ; 3'-heteroarylmethyl analogues of
 30 3,3',5-tri- iodo-L-thyronine (T_3) ; 3'-substituted derivatives of the thyroid

SUBSTITUTE SHEET (RULE 26)

- 12 -

thyroid hormone or thyroid hormone-like compound. Preferably the composition comprises a concentration 5×10^8 times or less the receptor dissociation constant, K_d of the said at least one thyroid hormone compound or thyroid hormone-like compound. Preferably the composition is used to supply an effective amount of the thyroid hormone or thyroid hormone-like compound which generally ranges from 500mg/m^2 to 0.1mg/m^2 in one or more applications, preferably 250mg/m^2 to 1mg/m^2 per day in one or more applications.

The effective concentration will depend on factors such as metabolism of the compound and its effective octanol/water partition coefficient and which can be readily determined by the skilled addressee. The composition of the invention may also include other ingredients such as Vitamin D, glucocorticoids and retinoids or analogues thereof to potentiate and modify the effects of the thyroid hormone or thyroid hormone-like compound for increased benefit. In particular when the composition is formulated for lipolytic activity it may contain derivatives of medicinal herbs such as *Guto Kola*, (*Centella asiatica*), *Cola nitida*, *Khella* (*Amni visnaga*), cola nut, *Camellia Suiensis*, Guavana, clove, coffee. The composition may also include BHT (butylated hydroxy toluene) or BHA (butylated hydroxy anisole) as a hindered phenol to decrease iodine decomposition or substances. Furthermore, the composition may include compounds which facilitate passage of the thyroid hormone through the skin and compounds which act as sunscreens such as PABA. Preferably, the composition also includes a suitable antioxidant such as Tinuvin P or BHA. The choice of such compounds is within the scope of the skilled addressee. See for example Hermens W. A. J. J Pharmaceutisch Weekblad Scientific Edition 14(4A) 1992.

SUBSTITUTE SHEET (RULE 26)

- 11 -

2-methyl-3-(3,5-diiodo-4-carboxymethoxy- benzyl)benzofuran ;
4'hydroxy-3'-iodo-3,5 diiodo-4-(2-N,N-dimethylamino- ethoxy)benzophenon
hydrochloride ; 2-butyl-3-(3-iodo-4-hydroxybenzoyl)benzofuran ;
3,5-diethyl,3'-isopropyl thyronine (DIET) ; 4',4-dihydroxy-3'3,5-triiodo-
5 diphenylmethan ; and IpTA₂ (3,5 diiodo- 3'isopropyl thyroacetic acid) and
pharmacologically acceptable salts and derivatives, such as metabolites,
and effective isomers thereof.

Other suitable thyroid hormone-like compounds, are disclosed for example
10 in US5284971, US5401772, US3649679, US3357887, US412579,
US4168385, US5179097, EP0580550, EP018351 and H. A. Selenkow
and S. P. Asper. Jr., *Physiol. Rev.* **35** 426 (1955); C. S. Pitman and J. A.
Pitman In *Handbook of Physiology, Section 7: Endocrinology, Vol. 3*, R. O.
Greep and E. B. Astwood. Eds., *Thyroid* American Physiological Society,
15 Washington D.C., 1974, p. 233; E. C. Jorgensen, *Pharm. Ther. B*, **2**, 661
(1976); and E. C. Jorgensen, "Thyroid Hormones and Analogs. II.
Structure-Activity Relationships," in *Hormonal Proteins and Peptides, Vol.*
6. Thyroid Hormones, C. H. Li, Ed., Academic, New York, 1978, p. 108.
The choice of other suitable thyroid hormone-like compounds for use in the
20 compositions and methods of the present invention is within the scope of
the skilled worker.

Preferably, the composition is in the form of a cream although other forms
of preparation which can be readily applied to the skin, such as lotions,
25 topical sprays, liposomes, solutions or emulsions, are contemplated.
Preferably the composition includes suitable epidermal penetration
enhancing agents.

Preferably, the composition comprises less than about 50mg /100ml ,
30 more preferably less than about 10mg /100ml of the said at least one

SUBSTITUTE SHEET (RULE 26)

- 14 -

Preferably, the composition is applied from twice a day to every three days.

- 5 According to a further aspect of the invention there is provided a method of reducing cutaneous or subcutaneous fat deposits in a subject, the method comprising the steps of:
providing a composition in accordance with the first aspect of the invention; and
10 applying the said composition to skin of the subject in the vicinity of the deposits to be treated.

In a preferred embodiment, the fat deposits cause cellulite.

- 15 Preferably, the composition is applied to the skin from between twice a day to every three days.

- 20 Preferably, the subject is a mammal, more preferably a human. The thyroid hormones and thyroid hormone-like compound can be active in all organisms which contain thyroid hormone receptors, notably amphibians, birds and mammals.

- 25 According to another aspect of the invention there is provided the use of a thyroid hormone or thyroid like compound in the preparation of a composition for topical application to the skin of a subject in order to improve the condition of that skin or reduce cutaneous or subcutaneous fat deposits.

SUBSTITUTE SHEET (RULE 26)

- 13 -

Preferably, the thyroid hormone or thyroid hormone-like compound is not halogenated as such compounds are less prone to photodecomposition. The pharmacologically acceptable base is preferably an oil in water emulsion or an alcoholic solution with glycerol.

5

The said at least one thyroid hormone compound is preferably at least partially dissolved in a solvent. The solvent is preferably an organic solvent selected from alcohol and alcohol and water solutions. More preferably, the organic solvent is selected from isopropanol, isopropanol and water, ethanol, and ethanol and water solutions containing at least 20% alcohol.

10

According to a further aspect of the invention there is provided a unit dose package containing a single dose of a composition in accordance with the first aspect of the invention.

15

According to a further aspect of the invention there is provided a method of improving the condition or appearance of the skin of a subject, the method comprising the steps of:

20

providing a composition in accordance with the first aspect of the invention; and
applying the said composition to the skin of the subject.

25

The method improves conditions selected from for example, stria, cellulite, roughened skin, actinic skin damage, intrinsically aged skin, photodamaged skin, lichen planus, ichthyosis, acne, psoriasis, wrinkled skin (whether deep or superficial), Dernier's disease, eczema, atopic dermatitis, seborrhoeic dermatitis scleroderma, collagen deficient skin, corticosteroid atrophy, chloracne, pityriasis, hyperkeratinizing disorders, keloids and skin scarring.

30

SUBSTITUTE SHEET (RULE 26)

- 16 -

Fig. 8 is a photograph of a volunteer's waist and hip area in which a composition of the invention has been applied to the right side the line drawing below emphasizing the slimming effects of the composition.

5

EXAMPLE 1

IN VITRO TESTS WITH A SKIN A MODEL

Regulation of epidermal genes which regulate collagen production and promote epidermal differentiation.

10

15

20

25

Terminal differentiation of the epidermal layer of the skin is thought to be related at least in part to the activity of transglutaminase K and the production of cornified envelopes (Febs Letter **258** p35-38, 1989, and J. Invest. Derm. **90** p472). It is thought that the ability of a retinoid to down regulate transglutaminase K in cultured cells is an indication of its ability to effectively treat psoriasis (EP00465343). TGF beta 1 and 2 are thought to promote terminal differentiation and inhibit basal cell proliferation (Fuchs E. J. Cell Biol. **111** p2807). A protease, stratum corneum chymotryptic enzyme, SCCE, is produced by keratinocytes and is thought to promote shedding of skin cells in the upper granular layer of the epidermis and be related to epidermal differentiation (Egularud et al, ACTA DERM Venereol. Vol 73 p 181-184 1993; Sondell et al, J. Invest Derm 1995, p 819-823). Further, in hyperproliferating skin, the keratins 1 and 10 (differentiation markers) are reduced and the hyperproliferation keratins 16 and 6 are increased (West et al/ 1992, J. Invest. Derm. **1** p 95). Retinoic acid effects on skin keratinocytes in culture reflect a decrease in the differentiation markers and variable changes in keratins 6 and 16 and they also decrease transglutaminase K *in vitro*. Both these markers, the keratins and transglutaminase K have been considered in-vitro measures of retinoic acid

SUBSTITUTE SHEET (RULE 26)

- 15 -

DETAILED DESCRIPTION OF THE INVENTION

Compositions in accordance with the invention and methods for their use will now be described, by way of example only, of with reference to the accompanying drawings, Figure no. 1-8.

5

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a graph showing the comparative effect of betamethasone and Triac on the Skin-2 model;

10

Fig. 2 is a graph showing the comparative effect of vitamin D3 and Triac on the Skin-2 model;

Fig. 3 is a graph showing the comparative effect of retinoic acid and Triac on the Skin-2 model;

15

Fig. 4 is a graph showing the effect of retinoic acid on the skin-2 model in three studies;

Fig. 5 is a graph showing the effect of Triac on the skin-2 model in three studies;

20

Fig. 6 is a photograph of a volunteer's waist and hip area in which a composition of the invention has been applied to the left and right side, the line drawing below emphasizing the slimming effects of the composition;

25

Fig. 7 is a photograph of a volunteer's waist hip area in which a composition of the invention has been applied to the right side the line drawing below emphasizing the slimming effects of the composition; and

SUBSTITUTE SHEET (RULE 26)

- 18 -

1) The keratinocytes differentiate in a manner very similar to the *in vivo* state. A stratified multilayered epithelium with all the markers and properties of such epithelium forms. This never happens in typical keratinocyte culture.

5 2) The presence of fibroblasts allows the detection of fibroblast markers including collagen. The interplay between keratinocytes and fibroblasts which occurs *in vivo* also is mimicked in the SKIN² model, which allows paracrine functioning of the cell types. We assessed the ability of multiple thyroid hormone receptor binding ligands, and several therapeutically
10 useful model compounds including retinoic acid to alter mRNA production of a variety of genes present in fibroblasts and keratinocytes present in the Skin-2 model.

Materials and Methods

15 The following were components of the Skin² kits: 9x9 mm skin tissues on agarose, 6-well plates, and Millicell inserts. Two media based on Dulbecco's Modification of Eagle's medium were also included: Maintenance medium (containing 5% fetal calf serum) and serum-free assay medium.

20 The following were supplied by other sources: "Stripped" (Samuels, H. *et al*, Endocrinology **105**, p80-85, 1979) fetal calf serum and all substances to be tested were from Karo Bio AB. All-trans-retinoic acid, 1,25-(OH)₂-vitamin D₃, and betamethasone were purchased from Sigma
25 Chemicals (Stockholm). Upon arrival the skin tissues were placed dermal-side down into the center of a Millicell in a 6-well plate well containing prewarmed maintenance medium. The tissues were incubated at 37°C in an atmosphere of 5% CO₂ in air. After 24 h the maintenance medium was exchanged.

30 SUBSTITUTE SHEET (RULE 26)

- 17 -

analogs dermatologic potency and usefulness (Kopan and Fuchs, J. Cell Biol 105 p 427-440, 1987 and Griffiths et al, Br J Derm 1992, 127 suppl 4 p 21. Paradoxically, however, retinoids are active against hyperproliferating disorders and increase the keratin 1 and 10 differentiation markers and

5 tranylglutaminase K *in vivo* after topical application. (Griffiths et al, Br. J. Derm 1992, 127 suppl 4 p21. In keratinocyte cultures, thyroid hormone decreases keratin genes K5, K14 and K10 (6,10). Thyroid hormone modulation of the keratin 1 gene has not been previously reported.

10 Collagen production in the skin occurs from a variety of collagen genes, with the procollagen A-1 and A-3 genes most studied. Collagen is decreased in glucocorticoid treated skin (7) and in photodamaged skin (24). It is thought that overproduction of collagen in the hyperproliferative state may contribute to keloidal scar production. Furthermore, CTGF, a

15 PDGF like peptide (PDGF-L) that is produced in response to TGF beta-1 appears to be present in increased amounts in fibrosing disorders such as scleroderma. In cultured human fibroblasts, thyroid hormone administration decreases collagen production (de Rycker et al, FEBS Lett, vol 174 p34-37 1984).

20 No universally accepted model of human skin exists. A novel synthetic human skin, Skin- 2 model ZK1301 (Advanced Tissue Sciences, La Jolla (USA)) is composed of a three dimensional human skin culture consisting of a dermal fibroblast layer and human foreskin keratinocytes which can be

25 grown with an air-keratinocyte interface to promote normal differentiation and cornification of the model skin. The Skin-2 model is widely accepted as an in-vitro model to assess cutaneous toxicity (Rheins et al, Toxic, in Vitro, 8, no. 5 p1007-1014 1994 and is approved by the Canadian and U.S. FDA as an appropriate model for testing skin toxicity. Such a model

30 has the following advantages:

SUBSTITUTE SHEET (RULE 26)

- 20 -

0.5 μ M primers (see Table 1), and 0.5 U Taq DNA polymerase licensed for PCR (Life Technologies). The tubes were placed in a Thermal cycler (Perkin-Elmer) programmed as follows: (a) 90°C for 90 s; (b) variable number of cycles (see Table 1) of the following sequential steps: 60 s at 94°C, 75 s at annealing temp (see Table 1), 90 s at 72°C; and (c) 7 min at 72°C.

After mixing 7.5 μ l of PCR-products with 2 μ l of loading buffer, samples were separated by electrophoresis on a 1.2 % agarose gel containing ethidium bromide, and visualized by UV transillumination. Gels were recorded by videoprints.

The amount of product was estimated on the videopoint or directly on the gel. The amount of transcripts in each lane were compared in relation to two control samples run in parallel.

The expression of certain genes was not modulated by test compounds, and so these genes were not selected as markers in subsequent experiments

Table 1

Gene	Annealing Temp	PCR-cycles	Product Size (bp)
Fibronectin	60°C	22-25	794.0000000
IL-6	60°C	22-25	639.0000000
IL-8	60°C	25.0000000	275.0000000
ICAM-1	60°C	30.0000000	727.0000000
TGF β 1	60°C	25.0000000	338.0000000
TGF β 2	56°C	40.0000000	575.0000000
Keratin 1	60°C	24-27	480.0000000
Keratin 10	60°C	27-30	439.0000000
Keratin 5	60°C	25.0000000	559.0000000
Keratin 14	60°C	25.0000000	651.0000000
Keratin 6	60°C	25.0000000	464.0000000
Keratin 19	60°C	20.0000000	400.0000000
Keratin 16	60°C	22-25	725.0000000

SUBSTITUTE SHEET (RULE 26)

- 19 -

Following another 24 h the Maintenance medium was removed and replaced by Serum- free assay medium containing 5% "stripped" fetal calf serum. Substances were added within 1 h after medium exchange and the tissues were incubated for 10 or 48 h in the presence of the substances. Medium and substances were changed after 24 h incubation. The cells were grown at an air - liquid interface. At the end of the 48 h-incubation period two tissues were pooled together in a sterile plastic centrifugation tube. The tissue was snap frozen on solid ice (-60°C) and stored at -70°C until used. Duplicate samples were included for each treatment.

Analysis of mRNA expression in Skin² by reversed-transcriptase coupled to polymerase chain reaction (RT-PCR)

Total RNA was extracted from Skin² -samples and human skin biopsies using Ultraspec II (Biotech Laboratories, Inc., Houston, TX). One ml of Ultraspec II was added to each sample which were homogenized by using a Polytron for 2x20 sec at setting 6. Total RNA was extracted according to the protocol supplied by the manufacturer. The amount of RNA was quantitated by measuring the absorbance at 260 nm. The A₂₆₀/A₂₈₀ -ratio of the extracted RNA was generally between 1.75 and 2.0. Three µg RNA was reversed transcribed into cDNA in a 30 µl mixture containing 50 mM Tris-HC (pH 8.3), 75 mM KC, 3 mM MgC₂, 10 mM dithiothreitol, 0.5 mM of each dNTP, 200 U M-MLV reversed transcriptase (Life Technologies), 25 U placental Rnase inhibitor (Boehringer-Mannheim) and oligo d(T)₁₅ as primer. After incubation at 37°C for 60 min, the reaction was stopped by heating at 75°C for 10 min and the mixture stored at -70°C until cDNA amplification was performed.

Polymerase chain reation

The following PCR mixture (24 µl) was prepared immediately before use:
10 mM Tris-HC (pH 8.3), 50 mM KC, 1.5 mM MgCl, 200 µM of each dNTP,

SUBSTITUTE SHEET (RULE 26)

- 22 -

The effect of a thyroid hormone, tri-iodothyroacetic acid (Triac), was first studied and compared to known medically useful compounds which affect epidermal physiology. These drugs were retinoic acid, betamethasone, and 1,25 OH vitamin D₃. The semi quantitative results are shown in Table 2 and comparisons between Triac and the other drugs are displayed in fig. 1, (betamethasone), Fig. 2 (Vit D3) and Fig. 3 (all trans Retinoic acid). Triac at 50 nMolar concentration, approximately 1000 times its affinity constant for the receptor, appears to strikingly reduce keratin 1 and 10, transglutaminase K, and SCCE. Triac also markedly accentuates Collagen A-1 and 3A-1, along with TGF-beta-2 transcripts. In comparison with betamethasone, Triac increases collagen production and TGF beta-2 but does not strongly inhibit IL-6. The keratin findings are similar. In comparison with Triac, Vit D-3 does not inhibit the keratin gene transcripts, or SCCE or transglutaminase K., but the effect on collagen genes is similar. Retinoic acid and Triac appear very similar with the exception of only SCCE and CRAB PII. At a higher concentration, 1 μ Molar, Triac continues to display the same effects although the collagen and keratin response is somewhat reduced. It is a surprising finding of the present invention that low doses of thyroid hormone compounds are dermatologically effective.

These results are consistent with known results of these drugs in other model systems. For example Vitamin D-3 is not known to affect keratinization of cultured keratinocytes. Betamethasone decreases epidermal collagen. Retinoic acid is known to decrease transglutaminase Ki and keratins 1 and 10 in culture. These results therefore suggest that Triac should have similar properties as these other medically important classes of drugs. In fact a combination of a thyroid hormone with a glucocorticoid should avoid the collagen loss associated with topical steroid application and add an antiinflammatory effect not seen with a thyroid compound.

SUBSTITUTE SHEET (RULE 26)

- 21 -

Gene	Annealing Temp	PCR-cycles	Product Size (bp)
SCCE	60°C	22.0000000	463.0000000
Collagenase	60°C	30.0000000	463.0000000
Involucrin	60°C	25.0000000	541.0000000
Filaggrin	60°C	29.0000000	526.0000000
Loricrin	60°C	33.0000000	663.0000000
Procollagen 1A1	60°C	20-22	620.0000000
Procollagen 1A2	60°C	23.0000000	712.0000000
Procollagen 3A1	60°C	20-24	524.0000000
TGk	60°C	22-30	652.0000000
CTGF	60°C	25.0000000	515.0000000
ThR θ	60°C	32.0000000	623.0000000
ThR β	60°C	32.0000000	578.0000000
CRBPI	60°C	25.0000000	388.0000000
CRABPII	60°C	22-25	402.0000000
RAR θ	60°C	35.0000000	817.0000000
RAR β	60°C	35.0000000	769.0000000
RAR	60°C	30.0000000	765.0000000
RXR θ	60°C	30.0000000	743.0000000
VDR	60°C	30.0000000	888.0000000
cyclophilin	60°C	20-22	424.0000000
GAPDH	60°C	24-27	893.0000000

Key

IL-6 interleukin-6, IL-8 interleukin-8, ICAM-1 intracellular adhesion molecule-1, TGF β transforming growth factor, SCCE stratum corneum chymotryptic enzyme, TG_k keratinocyte transglutaminase, CTGF connective tissue growth factor, ThR thyroid hormone receptor, CRBP cellular retinol-binding protein CRABP II cellular retinoic acid-binding protein, RAR retinoic acid receptor, RXR retinoid X receptor (9-cis-RA receptor), VDR vitamin D₃ receptor, GAPDH glyceraldehyde-3-phosphate dehydrogenase.

SUBSTITUTE SHEET (RULE 26)

- 24 -

thyroid response and retinoic acid response, and only modest effects on collagen.

5 Certain of the compounds, notably compound number 5 displayed a relative selectively for keratin 1, transglutaminase K and SCCE responses over collagen responses. Therefore it seems likely that some of the compounds will display a relative efficacy more weighted toward regulation of epidermal differentiation than collagen production and potential would healing effects or amelioration of dermal states characterized by collagen
10 deficient skin.

Although the effects of these thyroid compounds as a group reflect specific and reproducible changes in the transcripts of epidermally related genes which affect differentiation, the *in vitro* direction of the response for SCCE,
15 Transglutaminase K and keratin 1 is the opposite to that which might be considered therapeutically useful. Since a similar result is seen for retinoic acid (Koppam *et al*; Griffiths *et al supra*), these two entities are therefore quite similar in their effects. Surprisingly the collagen response to thyroid hormone was the opposite to that reported in the literature (de Ryk *et al
20 supra*). Because of the paradoxically opposite effects of retinoids on skin related proteins and genes when given *in vitro* as compared to *in vivo* testing, and the concomitant medically beneficial usefulness of retinoids. It was considered that thyroid regulation would be subject to the same paradox. therefore Triac was tested on human volunteers.

25 EXAMPLE 2

HUMAN STUDY: THYROID HORMONE CONTROLS GENE TRANSCRIPTION IN SKIN

30 Three adult male volunteers ranging in age from 37-46 yrs were treated topically with a cream containing either 200 mg/100 ml or 20 mg/100 ml

SUBSTITUTE SHEET (RULE 26)

- 23 -

5 The results of three experiments with Triac at 50 nM dose and retinoic acid at 1 μ Molar dose are shown for comparison in figures 4 and 5. The two hormones appear very similar, but can be differentiated by the lack of inhibition of SCCE by RA in this model, and the modest fall in transcripts for the CRAB PII retinoid binding protein induced by Triac. Both compounds inhibit keratin 1 and more modestly, keratin 10, increase TGF-beta-2, CTGF, collagen and inhibit transglutaminase K.

10 A group of thyroid hormone receptor binding compounds were therefore tested in this model. Eight different compounds which span a range of different structures, including nonhalogenated compounds and compounds containing bromine instead of iodine, all of which bind to the receptor were assayed in the Skin-2 system. One compound, L-T-1, as described in

15 GB7822745, GB859546 and US3198702 as part of a family of molecules which have topical utility, which bind very poorly to the receptor was also tested. The compounds were all tested at concentration ranges above their binding affinity for the receptor except for L-T-1 which binds poorly to the receptor even at the tested ten micromolar concentration. Table 3 displays

20 the results for these compounds along with their K_i (binding affinity) to the human thyroid receptor and the tested concentration of chemical. Affinities for the human thyroid receptor alpha-1 were similar. Again, a reduction in transcripts for keratin 1 (8/8 compounds), keratin 10 (5/8), and transglutaminase K (4/8) was seen, along with increased collagen a-1 (7/8)

25 and collagen 3a (6/8) and CTGF (7/8). For the most part, an inhibition of SCCE was seen, although in some instances a very modest change was displayed by some compounds. The compound (L-T-I), which did not bind to the endogenous receptor, showed no inhibition of keratin 1 or 10, a positive effect on transglutaminase K and SCCE which is opposite to the

SUBSTITUTE SHEET (RULE 26)

- 26 -

EXAMPLE 3**THYROID HORMONES ARE PHYSIOLOGICALLY ACTIVE WHEN APPLIED TO THE SKIN.**

5 Triac (Tri iodo thyroid acetic acid) or DIMIT (dimethyl isopropyl thyronine) or esters and ethers thereof are mixed in a concentration range of 10 000 000 times K_{diss} to 1000 times K_{diss} , 100 micromolar to 1 nanomolar, in a suitable pharmacological base, such as Johnson and Johnson Purpose™ or Curity™ skin lotion and applied to hairless mice strain SKH/hr 1 for 8 weeks. Punch biopsies are obtained and ultrasound measurements were
10 made of the skin using a 10 MHz B-mode ultrasound (18). As compared to control animals, thyroid hormone treated animals have an increase in the thickness of the epidermal area and a slight decrease in the dermal portion of the skin. An increased cellularity of epidermal cell layers is found, with a decrease in the regularity of the rete pattern.

EXAMPLE 4**WOUND HEALING**

Wounds are produced in rats and rabbits as in (19). The tensile strength of the wounds are determined at five, ten and twenty days and collagen
20 formation in the wound determined by SDS-gel electrophoresis (20,22,23,24). Wound healing is also measured by two dimensional A and B mode ultrasound. The wounds to which thyroid hormone is applied have increased tensile strength and close more quickly. Ultrasound measurements disclosed a more rapid granulation base and more rapid
25 wound closure.

EXAMPLE 5**PHOTODAMAGED SKIN**

Hairless mice SKH-1 are UV-B irradiated according to the schedule of
30 (22). After 12 weeks of irradiation, significant wrinkling results. The mice

SUBSTITUTE SHEET (RULE 26)

- 25 -

5 Triac. The cream was applied in an amount sufficient to just cover an approximately 6 cm² area on the buttocks. A similar sized area on the contralateral side, treated with a dermatologically useful cream, served as control. After application, the areas were covered with Tegaderm (3M) to prevent loss of cream and to enhance penetration. Control and Triac-treated areas were biopsied 96 h following this single treatment. The degree of erythema of each subject was judged on a subjective scale 1 to 4. Epidermis and papillary dermis from control and treated skin were obtained by manually cutting superficially with a razor-blade following 1 % lidoacine anesthesia. Two pieces of tissue measuring 2 x 2 cm and approximately 0.2 mm in depth were obtained for RNA-preparation. The tissue was snap frozen on solid ice (-60°C) and stored at -70°C until used.

15 A large number of transcripts were tested in three male subjects and the results are shown in table 4. The change in transcription of the genes for SCCE, Keratin 1 and 10, and transglutaminase K was now unexpectedly positive, the opposite of what was found in the *in vitro* assay. These changes reflect an increase in the differentiation markers and suggest a change to a more terminally differentiated state. The effect on collagen and CTGF remains the same *in vivo* as *in vitro* when using the Skin-2 model. Thus, at least for gene products which are related to epidermal differentiation the thyroid response *in vitro* is opposite to that *in vivo*, an identical finding as has been seen for the medically important retinoid compounds. Moreover, the unexpected increase in collagen formation suggest utility to help rebuild photodamaged adult human skin (Talwar et al, J. Inv. Derm, 105 p285-290, 1995).

SUBSTITUTE SHEET (RULE 26)

- 28 -

EXAMPLE 6A**RIGHT BUTTOCKS**

5 Triac, T-3 And Reverse T-3 were applied separately to the right buttock. An observer noted a decrease in the overall volume of the buttocks and a elevation of the gluteal posterior thigh fold by 1/2 to 1cm. Results were noted after 10 days of application. Measurements of hip circumference showed a 0.75 inch increase in circumference after 7 days after stopping the application.

10 EXAMPLE 6B**RIGHT THIGH**

T-3 and Triac were separately applied to a subject's right thigh for two periods of 3 weeks.

Results

15 The circumference of the right thigh was measured 5 cm beneath gluteal fold decreased, compared with the untreated left thigh as a control, Beginning: Right thigh measured 49 cm; Left thigh measured 47.5 cm After 20 days T₃ treated Right thigh measured 18.75 inches; Left thigh measured 18.5 inches.

20 Triac cream was then applied to Right thigh. After three weeks measurements of both thighs were the same.

There was an one pound decrease in body weight over this period.

EXAMPLE 6C**25 RIGHT INFRA RENAL AND SUPRA ILLIAC CREST FAT PADS**

Triac cream. Test 1: applied for two weeks to right side.

Results:

30 Observation shows a decrease in fat pad size. Measurement of skin creases from right to left side showed: R 5.75cm and L 7.5cm. Application stopped for two weeks and restarted with reverse T-3 cream. Effects

SUBSTITUTE SHEET (RULE 26)

- 27 -

are treated with the thyroid hormone Triac-containing cream for a period of 16 weeks after irradiation. The degree of wrinkling appearing on the irradiated mice is compared to untreated, irradiated animals to which the appropriate pharmaceutical base is not applied. The thyroid hormone containing composition of the invention produces a significant decrease in the wrinkle pattern of the animals and an increase in skin collagen.

EXAMPLE 6

IMPROVEMENT IN THE APPEARANCE OF CELLULITE AND/OR REDUCTION SUBCUTANEOUS FAT DEPOSITS AND DECREASE IN SUB- CUTANEOUS, DERMAL AND SUBDERMAL FAT.

The thyroid compounds reverse T-3, T-3, and Triac were dissolved in 70% isopropanol- water at a concentration of 0.5 to 7 mg/ml⁻¹.

A hydrophillic ointment (USP) or non-USP (Fougera brand) consisting of an oil in water emulsion with suitable fatty acid modifiers in 30 ml to 100 ml amounts was placed in a suitable stirring vessel. The dissolved thyroid compounds were sprayed over the surface of the cream and mixed manually, or with a mechanical stirrer, for several minutes to produce complete mixing. To adjust for batch to batch variations in the ointment base, water or isopropanol in amounts up to 20% of the volume were added to produce a mixture which was both pleasing to touch and was easy to apply to the skin. Other solvents such as isopropanol/water, ethanol or ethanol/water were also tested for dissolution.

The cream was applied daily, twice a day or up to every three days to various parts of the body. Exercise, especially of the tested area, through dancing or mild calisthenics which produced increased warmth and blood flow to the area appeared to accelerate the effects of the cream.

SUBSTITUTE SHEET (RULE 26)

- 30 -

Fig. 8 shows the effect of applying T₃ cream to the right side of a volunteer for 3 weeks.

5 Thyroid gland size and radial pulse rate were measured bi-monthly. No changes were observed. No hair loss, abdominal distress, cardiac arrhythmia or diarrhoea were observed. No adverse changes to the underlying skin were noted.

10 The composition of the present invention may be conveniently supplied in a unit dose pack comprising a plastic container which may for example be bubble, or blow moulded or injected, together with a tear off plastic or foil top, the pack containing a unit dose of the composition.

15 **EXAMPLE 7**

HUMAN STUDY: TREATMENT OF PSORIASIS

Patients with characterized multilateral psoriasis were subjected to a pharmacological washout period of two weeks followed by treatment of one lesion with an hydrophilic ointment containing 0.04% Triac or vehicle alone
20 an another lesion by application of ointment twice per day. Treatment duration was 8 weeks. Clinical results were measured using a validated five point scale for the severity index of scaling, erythma and infiltration size. All observations were performed by blinded observers at two week intervals. Sixty per cent of treated patients had statistically significant and
25 clinically significant reductions in their severity scores.

SUBSTITUTE SHEET (RULE 26)

- 29 -

appear similar after ten days. Photographs were taken of these areas.
(See Fig. 6)

EXAMPLE 6D

5

RIGHT SUPRA ILLIAC CREST AND OVER ABDOMINAL RECTUS MUSCLE

Triac cream was applied to right supra illiac crest and right abdominal
area.

10

Initial measurements: waist 28 inches, hips measured one inch below
umbillicus, 36 inches

After two weeks: waist 27", hips measured one inch below umbillicus 35.25
inches

15

After 10 more days: waist 27.5" hips measured one inch below umbillicus
34 inches.

There was a body weight loss of approximately two pounds over an eight
week period.

Photographs were taken of these areas as described below. Clothes fitted
appreciably more easily and the appearance of diminished fat easily noted
by other observers.

20

See Figs. 6 and 7.

Fig. 6 shows the results of applying Triac and subsequently T₃ cream daily
to the right side alone. Application of the Triac cream continued for 3.5
weeks and then was stopped for 1- 2 weeks and then T₃ cream was
applied daily for ten days. T₃ cream was applied daily to both sides for 7
days and then to the right side only for a further 3 days.

25

Fig.7 shows the result of applying Triac cream to the right side of a
volunteer on a daily basis for 3 weeks.

30

SUBSTITUTE SHEET (RULE 26)

- 32 -

23. Schwartz E *et al* J. Investl. Dermatol **102** p 241-246, 1994
24. Griffiths C. E. M *et al* NEJM **329** p 530-535, 1993
25. Roti, E *et al* Endocrine Reviews **14** p 401-423, 1993
26. Lev-Ran A Perspectives in Biology & Medicine **37** p 486-494, 1994
- 5 27. Apriletti J. *et al* J. Biol. Chem. **263** p 9409-9417, 1988

SUBSTITUTE SHEET (RULE 26)

REFERENCES

1. Lavin, T.N. Mechanisms of Thyroid Hormone action. In the textbook of Endocrinology (DeGroot, Ed.), 2nd Edition, W. B. Saunders, pub. (1989).
- 5 2. Drozd M *et al*. Endokrinologie 1979 Feb; **73**(1) 105-11
3. Murata Y *et al* J Clin Endocrinol Metab 1987 Feb; **64**(2): 334-9
4. Watzke, H., *et al* Thrombosis Research. **46**(2): 347-53, 1987 Apr 15
5. Murata Y *et al* JCEM 1983 Vol. **57** p. 1233-1239
6. Lee J *et al* Endocrinology **130** p 2733-2738, 1992
- 10 7. Ceccarelli, P *et al* JCEM **65** p 242-246, 1987
8. Tomio-Canic M *et al* Journal of Investigative Dermatology **99** p 842-847, 1992
9. Blumenberg M *et al*. J. Invest Dermatol 1992 Jun: **98**(6 Suppl):42S-49S
- 15 10. Ohtsuki M *et al* J Dermatol 1992 Nov **19**(11) p 774-80
11. Holt, P.J.A *et al* British Journal of Dermatology **95** p 513-518, 1976
12. Cronrath CM *et al* Endocrinology, **120**(1) page 43-8, 1987 Jan
13. Towle H. C, Mariash C. N Federation Proceedings **45**(9) p 2406-11, 1986 Aug.
- 20 14. Lemmen C. *et al* Biological Chemistry Hoppe-Seyler **367**(7) p 533-537, 1986
15. Amorosa L. F *et al* Biochim Biophys Acta 1984 Feb 9, **792**(2) p 192-8
16. Armer P *et al* Diabetes **33**(4) p 369-375, 1984
17. Coronary Dru Project, JAMA **220** p 996-1008, 1972
- 25 18. Akesson, A *et al* Acta Radiologica Diagnosis **27** p 91-94, 1986
19. Hunt, T *et al* Annals Surgery **170** p 633-641, 1969
20. Varani, J *et al* J. Invest Dermatol **94** p 717-723, 1990
21. Loireau A *et al* Biochem Pharmacol **35** p 1691-1696, 1986
22. Moloney S. J *et al* Photochem Photobiol **56** p 505-511, 1992

SUBSTITUTE SHEET (RULE 26)

- 34 -

4. A skin treatment composition for topical application, the composition consisting solely of a thyroid hormone compound or thyroid hormone-like compound as herein defined together with a pharmacologically acceptable base composition .

5. A skin treatment composition according to one of claims 1 to 4 in which the thyroid hormone compound is selected from Tri-iodothyronine (T3); D and L tetraiodothyronine - thyroxine (T4); 3,3',5' tri-iodothyronine (reverse T3) ; 3,3'-diiodothyronine ; T3 T4 analogues such as 3,5,3'-Triiodothyroacetic acid ; 3,5,3'-Tetraiodothyroacetic acid ; 3,5,3'- Triiodo-L-thyronine ; 3,5,3'-Triiodo-L-thyronine methyl ester ; 3,5,3'-Triiodo-L-thyronine hydrochloride ; L-thyroxine ; L-thyroxine hydrochloride ; L-T3 ; T4Fo ; Tetrac ; Triac ; Tetraprop ; Triprop ; T4Bu ; T3Bu ; Thyroxamine ; Triiodothyronamine ; L-3'-T1 ; L-3'-T1 ; L-3,5'-T2 ; L-3,3'-T2 ; L-3,3',5'-T3 ; DL-Br2I ; L-Br2iPr ; L-Me2I ; L-Me3 ; L-Me4 ; L- Me2iPr ; DL-IMeI ; L-3,5-Dimethyl-3'-isopropylthyronine (DIMIT) ; DL-BPT4 ; B-triac ; BP-tetrac ; DL-SBT3 ; DL-SBT4 ; DL-MBT3 ; MB-tetrac ; T2 ; T2F ; T2Cl ; T2Br ; T3 ; T2Me ; T2Et ; T2iPr ; T2nPr ; T2sBu ; T2tBu ; T2iBu ; T2Phe ; T2OH ; T2NO2 ; T2F2 ; T2Cl2 ; T4 ; T2Me2 ; 3,5,3',5'-tetraiodo-D-thyronine ; 3,5,3'-Triiodo-D-thyronine ; 3,5-Diiodo-4- hydroxyphenylpropionic acid (DIHPA) ; Aryloxamic acids ; (arylamino) acetic acids ; arylpropionic acids ; arylthioacetic acids ; (aryloxy)acetic acid ; 3,3'-T2 ; 3,5-T2 ; 3'-5'-T2 ; (5-Benzyloxy-2-methoxyphenyl)-(2-methoxypyrimidin-5-yl)-methanol ; Benzyloxy-2- methoxyphenyl)-(6-methylpyridin-3-yl)methanol ; (5-Benzyloxy-2-methoxyphenyl)-(5- bromo-2-methoxypyridin-4-yl)methanol ; (5-benzyloxy-2-methoxyphenyl)-(2,6- difluoropyridin-3-yl)methanol ; (5-Benzyloxy-2-

SUBSTITUTE SHEET (RULE 26)

- 33 -

CLAIMS

- 5
1. A skin treatment composition for topical application, the composition comprising at least one thyroid hormone compound or thyroid hormone-like compound as herein defined together with a pharmacologically acceptable base.
- 10
2. A skin treatment composition for topical application, the composition comprising at least one thyroid hormone compound or thyroid hormone-like compound as herein defined together with a pharmacologically acceptable base in which application of the composition to the skin effects an improvement in the skin's condition without resulting in systemic metabolism of the compound.
- 15
3. A skin treatment composition for topical application, the composition comprising at least one thyroid hormone compound or thyroid hormone-like compound as herein defined together with a pharmacologically acceptable base in which a medically or cosmetically sufficient amount of thyroid hormone compound
- 20
- or thyroid hormone -like compound enters the skin but in which substantially no thyroid hormone compound or thyroid hormone-like compound subsequently has a serum concentration which is physiologically adverse after topical application of the composition.

SUBSTITUTE SHEET (RULE 26)

- 36 -

ethoxy)-benzoyl)benzofuran hydrochloride ; 2-n-butyl-3-(3,5-diiodo-4-carboxymethoxy-benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4-hydroxy- benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4-carboxymethoxy-benzyl)benzofuran; ; [4'- hydroxy-3'-iodo-3,5 diiodo-4-(2-N,N-dimethylamino- ; (ethoxy)benzophenon hydrochloride ; 2-butyl-3-(3-iodo-4-hydroxybenzoyl)benzofuran ; 4',4-dihydroxy 3'3,5-triiodo- diphenylmethan ; 3,5--diiodo-4-(2-N, N-diethylaminoethoxy)phenyl- ; -(2-butylbenzofur-3- yl)methanol hydrochloride ; 2-methyl-3-(3,5-diiodo-4-(2-N,N-diethylamino-ethoxy)-benzoyl)benzofuran hydrochloride ; 2-n-butyl-3-(3,5-diiodo-4-carboxymethoxy-benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4-hydroxy-benzoyl)benzofuran ; 2-methyl-3- (3,5-diiodo-4-carboxymethoxy-benzyl)benzofuran ; 4'hydroxy-3'-iodo-3,5 diiodo-4-(2-N,N- dimethylamino-ethoxy)benzophenon hydrochloride ; 2-butyl-3-(3-iodo-4- hydroxybenzoyl)benzofuran ; 4',4-dihydroxy-3'3,5-triiodo-diphenylmethan ; 3,5-diethyl,3'- isopropyl thyronine (DIET) ; and IpTA2 (3,5 diiodo- 3'isopropyl thyroacetic acid) and pharmacologically acceptable salts and derivatives thereof.

6. A composition according to any one of claims 1 to 5 comprising a concentration of 5×10^8 times Kd or less of the said at least one thyroid hormone compound or thyroid hormone- like compound.

7. A composition according to any preceding claim in which the said at least one thyroid hormone compound or thyroid hormone-like compound is in chemically pure form.

SUBSTITUTE SHEET (RULE 26)

- 35 -

methoxyphenyl)-(2-methoxypyridin-4-yl)methanol ; 4-Methoxy-3-[(2-methoxypyrimidin-5-yl)methyl]phenol ; 4-Methoxy-3-[(6-methylpyrid-3-yl)methyl]phenol ; 5-Benzyloxy-2-methoxybenzyl Bromide ; (5-Benzyloxy-2-methoxyphenyl)-(6-chloropyridazin-3-yl)-acetonitrile ; 4-Benzyloxy-2-[2-methoxythiazol-5-yl)methyl]anisole ; 6-[(5-Hydroxy-2-methoxyphenyl)methyl]thiazol-2-(3H) ; 3'-Heteroarylmethyl-4'-methyl-3,5-dinitro-N-trifluoro-acetyl-L-thyronine Ethyl Esters ; 3'-heteroarylmethyl-3,5-di-iodo-4'-methyl-N-trifluoro-acetyl-L-thyronine Ethyl Esters ; 3'-heteroarylmethyl analogues of 3,3',5-tri-iodo-L-thyronine (T3) ; 3'-substituted derivatives of the thyroid hormone 3,3',5-triiodo-L-thyronine (T3) ; L-3'-T1 ; L-3,5'-T2 ; L-3,3'-T2 ; L-3,3',5'-T3 ; DL-Br2I ; L-Br2IPr ; L-Me2I ; L-Me3 ; L-Me4 ; L-Me2iPr ; DL-IMeI ; L-3,5-Dimethyl-3'-isopropylthyronine (DIMIT) ; DL-BPT4 ; B-triac ; BP-tetrac ; DL-SBT3 ; DL-SBT4 ; DL-MBT3 ; MB-tetrac ; T2 ; T2F ; T2Cl ; T2Br ; T3 ; T2Me ; T2Et ; T2iPr ; T2nPr ; T2sBu ; T2tBu ; T2iBu ; T2Phe ; T2OH ; T2NO2 ; T2F2 ; T2Cl2 ; T4 ; T2Me2 ; 3,5,3',5'-tetraiodo-D-thyronine ; 3,5,3'-Triiodo-D-thyronine ; 3,5-Diiodo-4-hydroxyphenylpropionic acid (DIHPA) ; Aryloxamic acids ; (arylamino)acetic acids ; arylpropionic acids ; arylthioacetic acids ; (aryloxy)acetic acid ; 3,3'-T2 ; 3,5-T2 ; 3'-5'-T2 ; 0-methyl-3,5,3'-triiodothyroacetic acid, 0-methyl-3,5,3'-triiodothyropropionic acid, and 0-methyl-3,5,3',5'-tetraiodothyropropionic acid ; methylene- and carbonyl-bridged analogs of iodinated thyronines thyroacetic acids ; Iodinated benzofurans ; 3,5-diiodo-4-(2-N,N-diethylaminoethoxy)phenyl-(2-butylbenzofur-3-yl)methanol hydrochloride ; 2-methyl-3-(3,5-diiodo-4-(2-N,N-diethylamino-

SUBSTITUTE SHEET (RULE 26)

- 38 -

14. A composition according to any preceding claim comprising a thyroid hormone or a thyroid hormone-like compound together with at least one of a Vitamin D analogue, a glucocorticoid or a retinoic acid receptor binding compound.

5

15. A unit dose package containing a single dose of a composition according to claim any preceding claim.

10

16. A method of modulating the expression of genes in the skin, the method comprising applying a composition comprising at least one thyroid hormone compound or thyroid hormone-like compound as herein defined together with a pharmacologically acceptable base to the skin.

15

17. A method according to claim 16 in which the gene to modulated is selected from genes encoding keratin 1, keratin 10, TGF beta-2, TGF-alpha, TGF beta-1, SCCE, Transglutaminase K, Keratin growth factor (KGF), procollagen 1A1, procollagen 3A-1, keratin 16, connective tissue growth factor CTGF, CRABP-II.

20

18. A method of improving the skin of a subject, the method comprising the steps of:
providing a composition in accordance with any one of claims 1 to 13; and applying the said composition to the skin of the subject.

SUBSTITUTE SHEET (RULE 26)

- 37 -

8. A composition according to any preceding claim in which the pharmacologically acceptable base is selected from oil in water emulsions, sprays, liposomes and solutions.

5

9. A composition according to any preceding claim in which the said at least one thyroid hormone compound is at least partially dissolved in a solvent.

10

10. A composition according to claim 9 in which the solvent is an organic solvent.

11. A composition according to claim 10 in which the organic solvent is selected from alcohol and alcohol and water solutions.

15

12. A composition according to claim 11 in which the organic solvent is selected from isopropanol, isopropanol and water, ethanol, and ethanol and water solutions.

20

13. A composition according to any preceding claim for the treatment of a condition selected from stria, cellulite, roughened skin, actinic skin damage, intrinsically aged skin, photodamaged skin, lichen planus, ichthyosis, acne, psoriasis, wrinkled skin, Dernier's disease, eczema, atopic dermatitis, seborrhoeic dermatitis scleroderma, collagen deficient skin, corticosteroid atrophy, chloracne, pityriasis, and skin scarring.

SUBSTITUTE SHEET (RULE 26)

24. A use according to claim 23 in which the condition is selected from stria, cellulite, roughened skin, actinic skin damage, intrinsically aged skin, photodamaged skin, lichen planus, ichthyosis, acne, psoriasis, wrinkled skin, Dernier's disease, eczema, atopic dermatitis, seborrhoeic dermatitis scleroderma, collagen deficient skin, corticosteroid atrophy, chloracne, pityriasis, and skin scarring.

25. A use according to claim 23-24 in which the thyroid hormone is selected from Tri- iodothyronine (T3); D and L tetraiodothyronine - thyroxine (T4); 3,3',5'-tri-iodothyronine (reverse T3) ; 3,3'-diiodothyronine ; T3 T4 analogues such as 3,5,3'-Triiodothyroacetic acid ; 3,5,3'-Tetraiodothyroacetic acid ; 3,5,3'-Triiodo-L-thyronine ; 3,5,3'-Triiodo-L-thyronine methyl ester ; 3,5,3'-Triiodo-L-thyronine hydrochloride ; L-thyroxine ; L-thyroxine hydrochloride ; L-T3 ; T4Fo ; Tetrac ; Triac ; Tetraprop ; Triprop ; T4Bu ; T3Bu ; Thyroxamine ; Triiodothyronamine ; L-3'-T1 ; L-3'-T1 ; L-3,5'-T2 ; L-3,3'-T2 ; L-3,3',5'-T3 ; DL- Br2I ; L-Br2iPr ; L-Me2I ; L-Me3 ; L-Me4 ; L-Me2iPr ; DL-IMeI ; I-3,5-Dimethyl- 3'-isopropylthyronine (DIMIT) ; DL-BPT4 ; B-triac ; BP-tetrac ; DL-SBT3 ; DL- SBT4 ; DL- MBT3 ; MB-tetrac ; T2 ; T2F ; T2Cl ; T2Br ; T3 ; T2Me ; T2Et ; T2iPr ; T2nPr ; T2sBu ; T2tBu ; T2iBu ; T2Phe ; T2OH ; T2NO2 ; T2F2 ; T2Cl2 ; T4 ; T2Me2 ; 3,5,3',5'-tetraiodo-D- thyronine ; 3,5,3'-Triiodo-D-thyronine ; 3,5-Diiodo-4-hydroxyphenylpropionic acid (DIHPA) ; Aryloxamic acids ; (arylamino) acetic acids ; arylpropionic acids ; arylthioacetic acids ; (aryloxy)acetic acid ; 3,3'-T2 ; 3,5-T2 ; 3'-5'-T2 ; (5-Benzyloxy-2-methoxyphenyl)-(2- methoxypyrimidin-5-yl)- methanol ;

SUBSTITUTE SHEET (RULE 26)

- 39 -

19. A method according to claim 18 in which the condition of the skin to be improved is selected from stria, cellulite, roughened skin, actinic skin damage, intrinsically aged skin, photodamaged skin, lichen planus, ichthyosis, acne, psoriasis, wrinkled skin, Dernier's disease, eczema, atopic dermatitis, seborrhoeic dermatitis scleroderma, collagen deficient skin, corticosteroid atrophy, chloracne, pityriasis, and skin scarring.

20. A method according to claim 18 or 19 in which the composition is applied from twice a day to every three days.

21. A method of reducing cutaneous or subcutaneous fat deposits in a subject, the method comprising the steps of providing a composition in accordance with any one of claims 1 -14; and applying the said composition to skin of the subject in the vicinity of the deposits to be treated.

22. A method according to claim 21 in which the composition is applied to the skin from between twice a day to every three days.

23. The use of a thyroid hormone or thyroid hormone-like compound in the preparation of a composition for topical application for the treatment of a skin condition.

SUBSTITUTE SHEET (RULE 26)

- 42 -

iodinated thyronines thyroacetic acids ; iodinated benzofurans ;

3,5-diiodo-4-(2-N,N- diethylaminoethoxy)phenyl-(2-butylbenzofur-3-yl)methanol

hydrochloride ; 2- methyl-3-(3,5- diiodo-4-(2-N,N-diethylamino-

ethoxy)-benzoyl)benzofuran hydrochloride ; 2-n-butyl-3-

5 (3,5-diiodo-4-carboxymethoxy-benzoyl)benzofuran ; 2-

methyl-3-(3,5-diiodo-4-hydroxy- benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4-

carboxymethoxy-benzyl)benzofuran ; [4'- hydroxy-3'-iodo-3,5 diiodo-4-(2-N,N-

dimethylamino- ; ethoxy)benzophenon hydrochloride ; 2-butyl-3-(3-iodo-4-

hydroxybenzoyl)benzofuran ; 4',4-dihydroxy 3'3,5-triiodo- diphenylmethan ; 3,5-

10 diiodo-4-(2-N, N-diethylaminoethoxy)phenyl- ; -(2-butylbenzofur-3- yl)methanol

hydrochloride ; 2-methyl-3-(3,5-diiodo-4-(2-N,N-diethylamino-ethoxy)-

benzoyl)benzofuran hydrochloride ; 2-n-butyl-3-(3,5-diiodo-4-carboxymethoxy-

benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4-hydroxy-benzoyl)benzofuran ; 2-

methyl-3- (3,5-diiodo-4-carboxymethoxy-benzyl)benzofuran ; 4'hydroxy-3'-iodo-3,5

15 diiodo-4-(2-N,N- dimethylamino-ethoxy)benzophenon hydrochloride ; 2-butyl-3-(3-

iodo-4- hydroxybenzoyl)benzofuran ; 4',4-dihydroxy-3'3,5-triiodo-diphenylmethan ;

3,5-diethyl,3'- isopropyl thyronine (DIET) ; and IpTA2 (3,5 diiodo- 3'isopropyl

thyroacetic acid) and pharmacologically acceptable salts and derivatives thereof.

20 26. The use of a thyroid hormone or thyroid hormone-like compound in the preparation of a composition for topical application for the reduction of cutaneous or subcutaneous fat deposits.

SUBSTITUTE SHEET (RULE 26)

- 41 -

Benzyloxy-2-methoxyphenyl)-(6-methylpyridin-3-yl)methanol ;
(5-Benzyloxy-2-methoxyphenyl)-(5-bromo-2-methoxypyridin-4-yl)methanol ; (5-benzyloxy-2-methoxyphenyl)-(2,6-difluoropyridin-3-yl)methanol ; (5-Benzyloxy-2-methoxyphenyl)-(2-methoxypyridin-4-yl)methanol ;
5 4-Methoxy-3-[(2-methoxypyrimidin-5-yl)methyl]phenol ;
4-Methoxy-3-[(6-methylpyrid-3-yl)methyl]phenol ; 5-Benzyloxy-2-methoxybenzyl
Bromide ; (5-Benzyloxy-2-methoxyphenyl)-(6-chloropyridazin-3-yl)-acetonitrile ;
4-Benzyloxy-2-[2-methoxythiazol-5-yl)methyl]anisole ; 6-[(5-Hydroxy-2-methoxyphenyl)methyl]thiazol-2-(3H) ; 3'-Heteroaryl-methyl-4'-)-methyl-3,5-dinitro-
10 N- trifluoro-acetyl-L-thyronine Ethyl Esters ; 3'-heteroaryl-methyl-3,5-di-iodo-4'-)-methyl-N- trifluoro-acetyl-L-thyronine Ethyl Esters ; 3'-heteroaryl-methyl analogues
of 3,3',5-tri-iodo-L- thyronine (T3) ; 3'-substituted derivatives of the thyroid
hormone 3,3',5-triiodo-L-thyronine (T3) ; L-3'-T1 ; L-3,5'-T2 ; L-3,3'-T2 ; L-
3,3',5'-T3 ; DL-Br2I ; L-Br2IPr ; L-Me2I ; L-Me3 ; L-Me4 ; L-Me2iPr ; DL-IMeI ;
15 L-3,5-Dimethyl-3'-isopropylthyronine (DIMIT) ; DL-BPT4 ; B-triac ; BP-tetrac ;
DL-SBT3 ; DL-SBT4 ; DL-MBT3 ; MB-tetrac ; T2 ; T2F ; T2Cl ; T2Br ; T3 ; T2Me ;
T2Et ; T2iPr ; T2nPr ; T2sBu ; T2tBu ; T2iBu ; T2Phe ; T2OH ; T2NO2 ; T2F2 ;
T2Cl2 ; T4 ; T2Me2 ; 3,5,3',5'-tetraiodo-D-thyronine ; 3,5,3'-Triiodo-D-thyronine ;
3,5- Diiodo-4-hydroxyphenylpropionic acid (DIHPA) ; Aryloxamic acids ;
20 (arylamino)acetic acids ; arylpropionic acids ; arylthioacetic acids ; (aryloxy)acetic
acid ; 3,3'-T2 ; 3,5-T2 ; 3'-5'-T2 ; θ -methyl-3,5,3'-triiodothyroacetic acid, θ -
methyl-3,5,3'-triiodothyropropionic acid, and θ - methyl-3,5,3',5'-
tetraiodothyropropionic acid ; methylene- and carbonyl-bridged analogs of

SUBSTITUTE SHEET (RULE 26)

- 44 -

Bromide ; (5-Benzyloxy-2-methoxyphenyl)-(6-chloropyridazin-3-yl)- acetonitrile ; 4-Benzyloxy-2-[2-methoxythiazol-5-yl)methyl]anisole ; 6-[(5-Hydroxy-2-methoxyphenyl)methyl]thiazol-2-(3H) ; 3'-Heteroarylmethyl-4'-)-methyl-3,5-dinitro-N- trifluoro-acetyl-L-thyronine Ethyl Esters ; 3'-heteroarylmethyl-3,5-di-iodo-4'-)-methyl-N- trifluoro-acetyl-L-thyronine Ethyl Esters ; 3'-heteroarylmethyl analogues of 3,3',5-tri-iodo-L- thyronine (T3) ; 3'-substituted derivatives of the thyroid hormone 3,3',5-triiodo-L-thyronine (T3) ; L-3'-T1 ; L-3,5'-T2 ; L-3,3'-T2 ; L-3,3',5'-T3 ; DL-Br2I ; L-Br2IPr ; L-Me2I ; L-Me3 ; L-Me4 ; L-Me2iPr ; DL-IMeI ; L-3,5-Dimethyl-3'-isopropylthyronine (DIMIT) ; DL-BPT4 ; B-triac ; BP-tetrac ; DL-SBT3 ; DL-SBT4 ; DL-MBT3 ; MB-tetrac ; T2 ; T2F ; T2Cl ; T2Br ; T3 ; T2Me ; T2Et ; T2iPr ; T2nPr ; T2sBu ; T2tBu ; T2iBu ; T2Phe ; T2OH ; T2NO2 ; T2F2 ; T2Cl2 ; T4 ; T2Me2 ; 3,5,3',5'-tetraiodo-D-thyronine ; 3,5,3'-Triiodo-D-thyronine ; 3,5- Diiodo-4-hydroxyphenylpropionic acid (DIHPA) ; Aryloxamic acids ; (arylamino)acetic acids ; arylpropionic acids ; arylthioacetic acids ; (aryloxy)acetic acid ; 3,3'-T2 ; 3,5-T2 ; 3'-5'-T2 ; θ -methyl-3,5,3'-triiodothyroacetic acid, θ -methyl-3,5,3'-triiodothyropropionic acid, and θ - methyl-3,5,3',5'-tetraiodothyropropionic acid ; methylene- and carbonyl-bridged analogs of iodinated thyronines thyroacetic acids ; Iodinated benzofurans ; 3,5-diiodo-4-(2-N,N- diethylaminoethoxy)phenyl-(2-butylbenzofur-3-yl)methanol hydrochloride ; 2- methyl-3-(3,5- diiodo-4-(2-N,N-diethylamino-ethoxy)-benzoyl)benzofuran hydrochloride ; 2-n-butyl-3-(3,5-diiodo-4-carboxymethoxy-benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4-hydroxy- benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4-

SUBSTITUTE SHEET (RULE 26)

- 43 -

27. The use according to claim 26 in which the fat deposits cause cellulite.

28. A use according to claim 26 or 27 in which the thyroid hormone is selected from Tri- iodothyronine (T3); D and L tetraiodothyronine - thyroxine (T4); 3,3',5' tri-
5 iodothyronine (reverse T3) ; 3,3'-diiodothyronine ; T3 T4 analogues such as
3,5,3'- Triiodothyroacetic acid ; 3,5,3'-Tetraiodothyroacetic acid ; 3,5,3'-Triiodo-L-
thyronine ; 3,5,3'-Triiodo-L-thyronine methyl ester ; 3,5,3'-Triiodo-L-thyronine
hydrochloride ; L-thyroxine ; L-thyroxine hydrochloride ; L-T3 ; T4Fo ; Tetrac ; Triac
; Tetraprop ; Triprop ; T4Bu ; T3Bu ; Thyroxamine ; Triiodothyronamine ; L- 3'-T1 ;
10 L-3'-T1 ; L-3,5'-T2 ; L-3,3'-T2 ; L-3,3',5'-T3 ; DL-Br2I ; L-Br2iPr ; L-Me2I ; L-Me3 ;
L-Me4 ; L-Me2iPr ; DL-IMeI ; l-3,5-Dimethyl-3'- isopropylthyronine (DIMIT) ;
DL-BPT4 ; B-triac ; BP-tetrac ; DL-SBT3 ; DL-SBT4 ; DL- MBT3 ; MB- tetrac ; T2 ;
T2F ; T2Cl ; T2Br ; T3 ; T2Me ; T2Et ; T2iPr ; T2nPr ; T2sBu ; T2tBu ; T2iBu ;
T2Phe ; T2OH ; T2NO2 ; T2F2 ; T2Cl2 ; T4 ; T2Me2 ; 3,5,3',5'-tetraiodo-D-
15 thyronine ; 3,5,3'-Triiodo-D-thyronine ; 3,5-Diiodo-4-hydroxyphenylpropionic acid
(DIHPA) ; Aryloxamic acids ; (arylamino) acetic acids ; arylpropionic acids ;
arylthioacetic acids ; (aryloxy)acetic acid ; 3,3'-T2 ; 3,5-T2 ; 3'-5'-T2 ; (5-
Benzyloxy-2-methoxyphenyl)-(2- methoxypyrimidin-5-yl)-methanol ; Benzyloxy-2-
methoxyphenyl)-(6-methylpyridin-3- yl)methanol ; (5-Benzyloxy-2-methoxyphenyl)-
20 (5-bromo-2-methoxypyridin-4-yl)methanol ; (5-benzyloxy-2-methoxyphenyl)-(2,6-
difluoropyridin-3-yl)methanol ; (5-Benzyloxy-2- methoxyphenyl)-(2-methoxypyridin-
4-yl)methanol ; 4-Methoxy-3-[(2-methoxypyrimidin-5- yl)methyl]phenol ; 4-
Methoxy-3-[(6-methylpyrid-3-yl)methyl]phenol ; 5-Benzyloxy-2- methoxybenzyl

SUBSTITUTE SHEET (RULE 26)



- 45 -

carboxymethoxy-benzyl)benzofuran; ; [4'- hydroxy-3'-iodo-3,5 diiodo-4-(2-N,N-
dimethylamino- ; ethoxy)benzophenon hydrochloride ; 2-butyl-3-(3-iodo-4-
hydroxybenzoyl)benzofuran ; 4',4-dihydroxy 3'3,5-triiodo- diphenylmethan ; 3,5-
diiodo-4-(2-N, N-diethylaminoethoxy)phenyl- ; -(2-butylbenzofur-3- yl)methanol
5 hydrochloride ; 2-methyl-3-(3,5-diiodo-4-(2-N,N-diethylamino-ethoxy)-
benzoyl)benzofuran hydrochloride ; 2-n-butyl-3-(3,5-diiodo-4-carboxymethoxy-
benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4-hydroxy-benzoyl)benzofuran ; 2-
methyl-3- (3,5-diiodo-4-carboxymethoxy-benzyl)benzofuran ; 4'hydroxy-3'-iodo-3,5
10 diiodo-4-(2-N,N- dimethylamino-ethoxy)benzophenon hydrochloride ; 2-butyl-3-(3-
iodo-4- hydroxybenzoyl)benzofuran ; 3,5-diethyl,3'-isopropyl thyronine (DIET) ;
4',4-dihydroxy- 3'3,5-triiodo-diphenylmethan ; and IpTA2 (3,5 diiodo- 3'isopropyl
thyroacetic acid) and pharmacologically acceptable salts and derivatives thereof.

29. A composition according to any one of claims 1 to 14 comprising less than
15 or equal to about 50mg/100ml of thyroid hormone compound.

30. A composition according to claim 29 comprising less than or equal to about
20mg/100ml of thyroid hormone compound.

SUBSTITUTE SHEET (RULE 26)

FIG. 1




FIG. 2





FIG. 3



06/05/95

FIG. 4

RA 1 uM	k1	k10	k16	k19	transK	score	il-6	tgfbeta-2	cola-1	cola-3	ctgf(pdgt-L)	fibronectin	crabp-II
study 2	-3	-1	-0.5	-1	-3	-0.5	-1	2	2	1	1	-0.5	1
study 3.1	-3	-1	0	1	-1	2	-1	2	2	2	2	2	1
study 3.2b	-3	-2			-2	0	-1	-0.5	-1	0.5	-1	-1	0

RA 1uM





FIG. 5



6/8

FIG. 6



FIG. 6A




SUBSTITUTE SHEET (RULE 26)

7/8

FIG. 7



FIG. 7A






FIG. 8





FIG. 8A

This Page Blank (uspto)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 7/48, 31/195, 31/00, 38/22	A3	(11) International Publication Number: WO 96/40048 (43) International Publication Date: 19 December 1996 (19.12.96)
(21) International Application Number: PCT/US96/09975 (22) International Filing Date: 7 June 1996 (07.06.96) (30) Priority Data: 08/481,698 7 June 1995 (07.06.95) US (60) Parent Application or Grant (63) Related by Continuation US 08/481,698 (CIP) Filed on 7 June 1995 (07.06.95) (71) Applicant (for all designated States except US): KARO BIO AB [SE/SE]; Novum, S-141 57 Huddinge (SE). (72) Inventors; and (75) Inventors/Applicants (for US only): LAVIN, Thomas, N. [US/US]; 10 Canterbury Lane, Watchung, NJ 07060 (US). VAHLQUIST, Anders, B. [SE/SE]; Institutionem for Dermatologi, Linköpings Universitetsjukhus, S-581 85 Linköping (SE). (74) Agents: HOSCHEIT, Dale, H. et al.; Banner & Allegretti, Ltd., Suite 1100, 1001 G Street, N.W., Washington, DC 20001 (US).		(81) Designated States: AU, CA, JP, KP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i> (88) Date of publication of the international search report: 13 November 1997 (13.11.97)
(54) Title: NOVEL USES FOR THYROID HORMONES OR THYROID HORMONE-LIKE COMPOUNDS <div style="text-align: center;">  </div>		
(57) Abstract <p>This invention relates to the use of topically applied thyroid hormones and thyroid hormone-like compounds which are receptor binding ligands, either agonists or antagonists, to improve the appearance of the skin and underlying subcutaneous fat and improve certain medical conditions when applied topically. These compounds can be used to treat skin conditions such as stria, cellulite, roughened skin, actinic skin damage, intrinsically aged skin, photodamaged skin, lichen planus, ichthyosis, acne, psoriasis, wrinkled skin, and to diminish the size and improve the appearance of skin scarring from surgical or naturally occurring wounds, and to reduce the incidence of hyperkeratotic scarring. These hormones or hormone analogs will also increase the rate of epithelialization and collagen production. The thyroid agonists and antagonists may also promote differentiation and amelioration of dedifferentiated skin in premalignant lesions. The thyroid agonists and antagonists can be active in all organisms which contain the thyroid hormone receptors, notably amphibians, birds and subjects. Combination with Vitamin D analogs glucocorticoid and retinoids will potentiate and modify the effects of the thyroid hormones for increased benefit. Side effects of thyroid hormones which occur when the hormone is given orally and prevent usefulness for the above conditions are prevented when the hormone is topically applied.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

NOVEL USES FOR THYROID HORMONES OR THYROID HORMONE-LIKE COMPOUNDS

5 TECHNICAL FIELD

This invention relates to skin care preparations containing thyroid hormones, thyroid hormone metabolites, derivatives of those compounds and other thyroid hormone receptor binding chemical entities and to the use of such compositions including to correct skin abnormalities, to
10 improve the appearance of the skin, and to control subcutaneous fat deposition when applied to the skin.

BACKGROUND

A wide variety of skin care preparations are currently available. There are
15 currently available several preparations for the treatment of cellulite, a dimpling of the skin over excess superficial fat deposits, but these are believed to have doubtful efficacy. A wide variety of medically useful skin preparations are also currently available, comprising primarily glucocorticoids and retinoid topical medicaments, both of which have
20 varying side-effects and usefulness. There is a considerable number of skin conditions and diseases such as stria, cellulite, roughened skin, actinic skin damage, intrinsically aged skin, photodamaged skin, lichen planus, ichthyosis, acne, psoriasis, wrinkled skin, eczema, seborrhoeic dermatitis, scleroderma, hyperkeratinizing disorders, keloids and skin
25 scarring.

- 2 -

Eczema (dermatitis) is an itchy inflammation of the superficial skin layers caused by an outside agent or by endogenous factors. The terms dermatitis and eczema are used interchangeably.

5 The obvious treatment of eczema is to try to avoid precipitating factors.

 Additionally, eczema is usually treated with topical steroids such as hydrocortisone, clobetasone butyrate, betamethasone and clobetasol propionate. The side effects of steroid use, particularly in the long term are
10 well known and consist of skin atrophy, risk for systemic absorption of the drug and rebound phenomena when the drug is withdrawn.

 There is a need for improved or alternate compositions for the treatment of dermatitis skin conditions such as psoriasis and eczema. New principles
15 for treating eczema in particular should aim at reducing the reactivity of cutaneous cells, inhibiting cytokine release and improving the epidermal barrier recovery.

 The structurally similar thyroid hormones triiodothyronine (T_3) and
20 thyroxine (T_4) have a very wide range of effects. In adult mammals they influence nearly all organs, the metabolism of nutrients, basal metabolic rate and oxygen consumption. In humans, the deficiency or excess of circulating thyroid hormones results in the well characterised syndromes, hypo- and hyperthyroidism. Small concentrations of thyroid hormone
25 metabolites which are also endocrinologically active exist. Among these compounds are tri-iodothyroacetic acid("Triac") and tri-iodopropionic acid ("Tri-prop").

 Thyroid hormones exert many of their actions by binding to a family of
30 receptor proteins termed the *C-erb-A* family. In humans, this receptor

SUBSTITUTE SHEET (RULE 20)

- 3 -

protein family is now known to comprise several members, notably the human thyroid receptor alpha-1, the human thyroid receptor alpha -2 which binds the hormone poorly or not at all, the human thyroid receptor β -1, and the human thyroid receptor β -2. These proteins are part of a larger
5 superfamily of steroid hormone receptors which comprises the glucocorticoid receptors, the retinoic acid receptors, the vitamin D receptors, and the insect moulting receptors - the receptors for ecdysone and the insect juvenile hormones. Receptors for thyroid hormones are found in human skin, human fibroblasts and keratinocytes and they are
10 also found in all other tissues within the human body (1).

In addition to the naturally occurring thyroid hormones, a large number of chemical compounds which bind to the thyroid hormone receptor and which produce thyroid hormone-like effects have been synthesized see for
15 example US5401772.

Thyroid hormones, in many cases, act indirectly by influencing the effects of other hormones and tissues (1). For example in the rat, thyroid administration increases pituitary growth hormone production which in turn
20 affects hepatic protein production including that of alpha-2 euglobulin. Functionally, in the rat, growth hormone may act as a second message for thyroid hormone(1). The biology of thyroid hormones has been extensively studied after oral administration, which makes the relationship between a direct effect of thyroid hormones and an indirect effect mediated
25 by thyroid hormone modulation of other autocrine, paracrine or endocrine factors difficult to ascertain.

Orally administered thyroid hormones influence the connective tissue biology of the skin. When given orally, thyroid hormones induce an
30 increase in neutral salt and acid soluble collagen, but decrease insoluble

SUBSTITUTE SHEET (RULE 26)

- 4 -

collagen in the skin of guinea pigs (2). Fibronectin production is decreased in human fibroblasts and fibroblast glycosoaminoglycans are either decreased or unchanged depending on the experimental conditions used (3,4,5,7,7a). Keratin gene expression for both the basal cell keratin K5 and K14 genes and the differentiation specific K10 gene is negatively regulated by thyroid hormones (9,8) in keratinocyte culture. These effects are mirrored by similar cell culture responses to retinoic acid (9) or the retinoid Tretinoin (19).

10 Histological studies of skin from individuals who have an excess of thyroid hormone show an increased number of cell layers in the skin, reflected by mean epidermal cell number, increased protein turnover with increased proline incorporation and generalized increases in epidermal proliferation compared to normal skin (11). In individuals who have a lack of thyroid hormone, the skin is atrophic with thinning of the epidermis and a decrease in cellularity. In human clinical biology, thyroid hormone excess leads to a general smoothing of the skin and the loss of wrinkles especially over the olecranon (elbow) surface.

20 Thyroid hormones also accelerate fat synthesis and lipolysis (breakdown). In rats which have an excess of thyroid hormone either chemically or by natural means, fat stores are in general decreased (12,13), although in humans clinical observation of thyroid hormone excess discloses either in increase of decrease in weight. The synthesis of fats may be increased (14,15) or decreased (12,13,16,21). Attempts to utilize the effects of excess oral thyroid hormone for weight loss in humans have in general failed because of severe adverse side effects (25,26).

30 Orally given thyroid hormone compound or thyroid hormone-like compounds in excess of normal bodily requirements or medical conditions

SUBSTITUTE SHEET (RULE 26)

- 5 -

which are associated with excess thyroid hormone such as Grave's disease or toxic nodular goitre produce an acceleration of heart beat with associated heart failure, cardiac arrhythmias, osteoporosis, increased intestinal motility leading to diarrhoea, psychiatric abnormalities, and an increase in the basal metabolic rate. Attempts to use oral thyroid hormones for diminishing lipid levels in man resulted in increased cardiac deaths (17).

RO76691 and 76692 respectively disclose an anti-wrinkle cream comprising a crude preparation from animal endocrine glands, including the thyroid gland, and a method of obtaining lipoid extracts from animal byproducts respectively. No data on the efficacy of the anti-wrinkle cream is provided nor is the thyroid hormone content of the cream provided or even mentioned. In particular, there is no suggestion in those patents of the efficacy of the compositions, methods, and uses of the present invention.

The use of Triac and its salts for a reduction of cellulite is disclosed in FR 2.153.202 (7134447). FR2197577 (72.30781) discloses various derivatives of Triac, including para hydroxy esters thereof, as having utility for the same indication. EP060776 discloses activity of an isopropyl derivative of Triac for the same indication. CH642851 (1168/80) discloses the utility of a liposome formulation of Triac together with glycosoaminoglycans for reducing cellulite. GB1354263 also discloses the use of Triac itself for reducing fat deposits. GB1400851 relates to the synthesis of ethyl esters and alkyl carboxy acids derivatives of Triac and their use in reducing cellulite in combination with leeches, hyaluronidase, proteases, and lipase.

SUBSTITUTE SHEET (RULE 26)

- 6 -

None of the above publications disclose or suggest the usefulness of compounds selected from those that bind the thyroid hormone receptor. The relationship between Triac and thyroid hormones is not made in any of these patents and no data is presented to show the relationship of the above mentioned compounds to the thyroid hormone dependent endocrine system via an effect mediated through the human thyroid receptor. In fact, FR2354101 discloses the use of Triac as an inhibitor of phosphodiesterase and its effect to increase cyclic AMP. This effect occurs only at dose ranges of approximately 10^{-4} M in *in vitro* experiments using isolated adipocytes. In concert with this mode of activity, the prior art literature makes claims for effective concentrations of chemical entity for anti-cellulite effects as greater than 50 mg of Triac or Triac derivative per 100 ml of vehicle and usually between 100 and 200 mg / 100 gms of excipient.

FR96.171 discloses the topical cellular growth accelerating activity and mitogenic of thyroxine (0.001-0.008 mg. %) in a propylene glycol diethyl ether vehicle in rat skin. No mention is made of other compounds which have thyroid hormone receptor binding activity such as Triac or

Tri-iodothyronine, or other thyromimetic compounds known at the time (Journal of Medicinal Chemistry, 6, p 554-563, 1963). No teaching concerning the effects of thyroid hormone receptor binding entities on epidermal differentiation, gene expression or keratinization is made.

GB782,745 and 859,546 describe the topical usefulness of compounds of a class which partially overlap with chemical entities which bind to the thyroid hormone receptor, but includes compounds including L-T-1 with no thyroid hormone receptor binding activity, and only a small subset of compounds which do recognize the receptor. In these patents, no claims are made for chemical entities characterized by binding to the thyroid hormone receptor or having thyroid hormone like activity. US3198702

SUBSTITUTE SHEET (RULE 26)

- 7 -

discloses a method of treating burns comprising the topical application of certain thyroxin analogues which are a subset of the same class of compounds claimed to have activity in GB 782745 and 859546.

- 5 No prior art document discloses the skin differentiating and collagen promoting effects of thyroid hormone or its analogues.

SUMMARY OF THE INVENTION

- 10 According to one aspect of the invention there is provided a composition for topical application, the composition comprising at least one thyroid hormone compound or thyroid hormone-like compound together with a pharmacologically acceptable base.

- 15 The topically-applied thyroid hormones, or thyroid hormone-like compounds used in the compositions and methods of the present invention are advantageous in that they enable the use of these chemical compounds to control subcutaneous or dermal fat stores to improve the appearance of the skin, or normalize the physiology of the skin under
- 20 pathophysiologic conditions without causing the undue adverse effects of orally administered thyroid hormone in a direct thyroid hormone dependent manner avoiding renal and hepatic metabolism of the thyroid hormone receptor binding chemical entity. In particular, the method of delivery of the thyroid hormone and thyroid hormone-like compounds avoids liver and
- 25 kidney metabolism of the hormones, blood circulation of the hormones to other tissues and binding to blood carrier proteins which can alter efficacy.

- 30 For the purposes of this invention a "thyroid hormone" or "thyroid hormone-like compound", which terms are used interchangeably herein, is any chemical entity, including peptides, which at least partially binds to

SUBSTITUTE SHEET (RULE 26)

- 8 -

thyroid hormone receptor TR- θ or β with a chemical affinity constant, K_d , lower than $1\mu\text{M}$ when tested in receptor binding assay, described by Lavin (27) using pure or substantially pure natural or recombinant thyroid hormone θ or β receptor containing the ligand binding domain or thyroid hormone receptor containing preparations such as rat nuclei. Such ligands may be considered hormones when they have similar agonistic effects as the natural hormone or may be considered antagonists when the compounds antagonize the effects of the natural hormones. Partial agonist/antagonists also may exist. (Suitable ligands may be agonists or antagonists).

The topically-applied thyroid hormones, or thyroid hormone-like compounds used in the compositions and methods of the present invention are advantageous in that they enable the use of these chemical compounds to control subcutaneous or dermal fat stores, to improve the appearance of the skin, or normalize the physiology of the skin under pathophysiologic conditions without causing the undue adverse effects of orally administered thyroid hormone. In particular, the method of delivery of the thyroid hormone and thyroid hormone-like compounds avoids liver and kidney metabolism of the hormones, blood circulation of the hormones to other tissues and binding to blood carrier proteins which can alter efficacy.

The thyroid hormone or thyroid hormone-like compound is preferably in pure form, i.e not contaminated with other similar compounds.

The said at least one thyroid hormone compound or thyroid hormone-like compound may be selected from, for example, one of the following illustrative list of compounds:

SUBSTITUTE SHEET (RULE 26)

- 9 -

Triiodothyronine (T_3); L and D tetraiodothyronine - thyroxine (T_4); 3,3',5' tri-
 iodothyronine (reverse T_3) ; 3,3'-diiodothyronine ; T_3 T_4 analogues such as
 3,5,3'- Triiodothyroacetic acid ; 3,5,3'-Tetraiodothyroacetic acid ;
 3,5,3'-Triiodo-L-thyronine ; 3,5,3'-Triiodo-L-thyronine methyl ester ;
 5 3,5,3'-Triiodo-L-thyronine hydrochloride ; L- thyroxine ; L-thyroxine
 hydrochloride ; L- T_3 , T_4 Fo ; Tetrac ; Triac ; Tetraprop ; Triprop ; T_4 Bu ;
 T_3 Bu ; Thyroxamine ; Triiodothyronamine ; L-3'- T_1 , L-3'- T_1 ; L-3,5'- T_2 ;
 L-3,3'- T_2 ; L-3,3',5'- T_3 ; DL- Br_2 I ; L- Br_2 iPr ; L- Me_2 I ; L- Me_3 ; L- Me_4 ; L- Me_2 iPr
 ; DL-IMeI ; l-3,5- Dimethyl-3'-isopropylthyronine (DIMIT) ; DL-BPT $_4$; B-triac
 10 ; BP- tetrac ; DL-SBT $_3$; DL- SBT $_4$; DL-MBT $_3$; MB-tetrac ; T_2 ; T_2 F ; T_2 Cl ;
 T_2 Br ; T_3 ; T_2 Me ; T_2 Et ; T_2 iPr ; T_2 nPr ; T_2 sBu ; T_2 tBu ; T_2 iBu ; T_2 Phe ; T_2 OH
 ; T_2 NO $_2$; T_2 F $_2$; T_2 Cl $_2$; T_4 ; T_2 Me $_2$; 3,5,3',5'- tetraiodo-D-thyronine ;
 3,5,3'-Triiodo-D-thyronine ; 3,5- Diiodo-4- hydroxyphenylpropionic acid
 (DIHPA) ; Aryloxamic acids ; (arylamino) acetic acids ; arylpropionic acids ;
 15 arylthioacetic acids ; (aryloxy)acetic acid ; 3,3'- T_2 ; 3,5- T_2 ; 3'-5'- T_2 ;
 (5-Benzyloxy-2-methoxyphenyl)-(2-methoxypyrimidin-5-yl)-methanol ;
 Benzyloxy-2- methoxyphenyl)-(6-methylpyridin-3-yl)methanol ;
 (5-Benzyloxy-2- methoxyphenyl)-(5-
 bromo-2-methoxypyridin-4-yl)methanol ; (5-benzyloxy-2-
 20 methoxyphenyl)-(2,6- difluoropyridin-3-yl)methanol ;
 (5-Benzyloxy-2-methoxyphenyl)- (2-methoxypyridin-4- yl)methanol ;
 4-Methoxy-3-[(2-methoxypyrimidin-5- yl)methyl]phenol ; 4-Methoxy-3-[(6-
 methylpyrid-3-yl)methyl]phenol ; 5-Benzyloxy-2- methoxybenzyl Bromide ;
 (5- Benzyloxy-2-methoxyphenyl)-(6-chloropyridazin-3-yl)- acetonitrile ;
 25 4-Benzyloxy-2-[2- methoxythiazol-5-yl)methyl]anisole ; 6-[(5-Hydroxy-2-
 methoxyphenyl)methyl]thiazol-2- (3H) ;
 3'-Heteroarylmethyl-4'-)-methyl-3,5-dinitro-N- trifluoro-acetyl-L-thyronine
 Ethyl Esters ; 3'-heteroarylmethyl-3,5-di-iodo-4'-)-methyl-N-
 trifluoro-acetyl-L-thyronine Ethyl Esters ; 3'-heteroarylmethyl analogues of
 30 3,3',5-tri- iodo-L-thyronine (T_3) ; 3'-substituted derivatives of the thyroid

SUBSTITUTE SHEET (RULE 26)

- 10 -

- hormone 3,3',5-triiodo- L-thyronine (T_3) ; L-3'- T_1 ; L-3,5'- T_2 ; L- 3,3'- T_2 ; L-3,3',5'- T_3 ; DL- Br_2I ; L- Br_2I Pr ; L- Me_2I ; L- Me_3 ; L- Me_4 ; L- Me_2i Pr ; DL-IMel ; L-3,5-Dimethyl-3'-isopropylthyronine (DIMIT) ; DL-BPT $_4$; B-triac ; BP-tetrac ; DL-SBT $_3$; DL-SBT $_4$; DL-MBT $_3$; MB-tetrac ; T_2 ; T_2F ; T_2Cl ;
- 5 T_2Br ; T_3 ; T_2Me ; T_2Et ; T_2i Pr ; T_2n Pr ; T_2s Bu ; T_2t Bu ; T_2i Bu ; T_2Phe ; T_2OH ; T_2NO_2 ; T_2F_2 ; T_2Cl_2 ; T_4 ; T_2Me_2 ; 3,5,3',5'- tetraiodo-D-thyronine ; 3,5,3'-Triiodo-D-thyronine ; 3,5-Diiodo-4-hydroxyphenylpropionic acid (DIHPA) ; Aryloxamic acids ; (arylamino)acetic acids ; arylpropionic acids ; arylthioacetic acids ; (aryloxy)acetic acid ; 3,3'- T_2 ; 3,5- T_2 ; 3'-5'- T_2 ;
- 10 θ -methyl-3,5,3'- triiodothyroacetic acid, θ -methyl-3,5,3'-triiodothyropropionic acid, and θ -methyl-3,5,3',5'- tetraiodothyropropionic acid ; methylene- and carbonyl-bridged analogs of iodinated thyronines thyroacetic acids ; Iodinated benzofurans ; 3,5-diiodo-4-(2-N,N-
- 15 diethylaminoethoxy)phenyl-(2-butylbenzofur-3-yl)methanol hydrochloride ; 2-methyl-3- (3,5-diiodo-4-(2-N,N-diethylamino- ; ethoxy)-benzoyl)benzofuran hydrochloride ; 2-n-butyl-3-(3,5-diiodo-4-carboxymethoxy-benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4- hydroxy-benzoyl)benzofuran ;
- 20 2-methyl-3-(3,5-diiodo-4-carboxymethoxy- benzyl)benzofuran ; [4'-hydroxy-3'-iodo-3,5 diiodo-4-(2-N,N-dimethylamino- ; ethoxy)benzophenon hydrochloride ; 2-butyl-3-(3-iodo-4-hydroxybenzoyl)benzofuran ; 4',4-dihydroxy 3',5-triiodo-diphenylmethan ; 3,5-diiodo-4-(2-N, N-
- 25 diethylaminoethoxy)phenyl- ; -(2-butylbenzofur-3-yl)methanol hydrochloride ; 2-methyl- 3-(3,5-diiodo-4-(2-N,N-diethylamino-ethoxy)-benzoyl)benzofuran hydrochloride ; 2-n-butyl-3-(3,5-diiodo-4-carboxymethoxy-benzoyl)benzofuran ;
- 30 2-methyl-3-(3,5-diiodo-4- hydroxy-benzoyl)benzofuran ;

SUBSTITUTE SHEET (RULE 26)

- 11 -

2-methyl-3-(3,5-diiodo-4-carboxymethoxy- benzyl)benzofuran ;
4'hydroxy-3'-iodo-3,5 diiodo-4-(2-N,N-dimethylamino- ethoxy)benzophenon
hydrochloride ; 2-butyl-3-(3-iodo-4-hydroxybenzoyl)benzofuran ;
3,5-diethyl,3'-isopropyl thyronine (DIET) ; 4',4-dihydroxy-3'3,5-triiodo-
5 diphenylmethan ; and IpTA₂ (3,5 diiodo- 3'isopropyl thyroacetic acid) and
pharmacologically acceptable salts and derivatives, such as metabolites,
and effective isomers thereof.

Other suitable thyroid hormone-like compounds, are disclosed for example
10 in US5284971, US5401772, US3649679, US3357887, US412579,
US4168385, US5179097, EP0580550, EP018351 and H. A. Selenkow
and S. P. Asper. Jr., *Physiol. Rev.* **35** 426 (1955); C. S. Pitman and J. A.
Pitman In *Handbook of Physiology*, Section 7: Endocrinology, Vol. 3, R. O.
Greep and E. B. Astwood. Eds., *Thyroid* American Physiological Society,
15 Washington D.C., 1974, p. 233; E. C. Jorgensen, *Pharm. Ther. B*, **2**, 661
(1976); and E. C. Jorgensen, "Thyroid Hormones and Analogs. II.
Structure-Activity Relationships," in *Hormonal Proteins and Peptides*, Vol.
6. *Thyroid Hormones*, C. H. Li, Ed., Academic, New York, 1978, p. 108.
The choice of other suitable thyroid hormone-like compounds for use in the
20 compositions and methods of the present invention is within the scope of
the skilled worker.

Preferably, the composition is in the form of a cream although other forms
of preparation which can be readily applied to the skin, such as lotions,
25 topical sprays, liposomes, solutions or emulsions, are contemplated.
Preferably the composition includes suitable epidermal penetration
enhancing agents.

Preferably, the composition comprises less than about 50mg /100ml ,
30 more preferably less than about 10mg /100ml of the said at least one

SUBSTITUTE SHEET (RULE 26)

- 12 -

thyroid hormone or thyroid hormone-like compound. Preferably the composition comprises a concentration 5×10^8 times or less the receptor dissociation constant, K_d of the said at least one thyroid hormone compound or thyroid hormone-like compound. Preferably the composition is used to supply an effective amount of the thyroid hormone or thyroid hormone-like compound which generally ranges from 500mg/m² to 0.1mg/m² in one or more applications, preferably 250mg/m² to 1mg/m² per day in one or more applications.

10 The effective concentration will depend on factors such as metabolism of the compound and its effective octanol/water partition coefficient and which can be readily determined by the skilled addressee. The composition of the invention may also include other ingredients such as Vitamin D, glucocorticoids and retinoids or analogues thereof to potentiate and modify the effects of the thyroid hormone or thyroid hormone-like compound for increased benefit. In particular when the composition is formulated for lipolytic activity it may contain derivatives of medicinal herbs such as *Guto Kola*, (*Centella asiatica*), *Cola nitida*, *Khella* (*Amni visnaga*), cola nut, *Camellia Suiensis*, Guavana, clove, coffee. The composition may also include BHT (butylated hydroxy toluene) or BHA (butylated hydroxy anisole) as a hindered phenol to decrease iodine decomposition or substances. Furthermore, the composition may include compounds which facilitate passage of the thyroid hormone through the skin and compounds which act as sunscreens such as PABA. Preferably, the composition also includes a suitable antioxidant such as Tinuvin P or BHA. The choice of such compounds is within the scope of the skilled addressee. See for example Hermens W. A. J. J Pharmaceutisch Weekblad Scientific Edition 14(4A) 1992.

SUBSTITUTE SHEET (RULE 26)

- 13 -

Preferably, the thyroid hormone or thyroid hormone-like compound is not halogenated as such compounds are less prone to photodecomposition. The pharmacologically acceptable base is preferably an oil in water emulsion or an alcoholic solution with glycerol.

5

The said at least one thyroid hormone compound is preferably at least partially dissolved in a solvent. The solvent is preferably an organic solvent selected from alcohol and alcohol and water solutions. More preferably, the organic solvent is selected from isopropanol, isopropanol and water, ethanol, and ethanol and water solutions containing at least 20% alcohol.

10

According to a further aspect of the invention there is provided a unit dose package containing a single dose of a composition in accordance with the first aspect of the invention.

15

According to a further aspect of the invention there is provided a method of improving the condition or appearance of the skin of a subject, the method comprising the steps of:

20

providing a composition in accordance with the first aspect of the invention; and
applying the said composition to the skin of the subject.

25

The method improves conditions selected from for example, stria, cellulite, roughened skin, actinic skin damage, intrinsically aged skin, photodamaged skin, lichen planus, ichthyosis, acne, psoriasis, wrinkled skin (whether deep or superficial), Dernier's disease, eczema, atopic dermatitis, seborrhoeic dermatitis scleroderma, collagen deficient skin, corticosteroid atrophy, chloracne, pityriasis, hyperkeratinizing disorders, keloids and skin scarring.

30

SUBSTITUTE SHEET (RULE 26)

- 14 -

Preferably, the composition is applied from twice a day to every three days.

- 5 According to a further aspect of the invention there is provided a method of reducing cutaneous or subcutaneous fat deposits in a subject, the method comprising the steps of:
providing a composition in accordance with the first aspect of the invention; and
10 applying the said composition to skin of the subject in the vicinity of the deposits to be treated.

In a preferred embodiment, the fat deposits cause cellulite.

- 15 Preferably, the composition is applied to the skin from between twice a day to every three days.

- Preferably, the subject is a mammal, more preferably a human. The thyroid hormones and thyroid hormone-like compound can be active in all
20 organisms which contain thyroid hormone receptors, notably amphibians, birds and mammals.

- According to another aspect of the invention there is provided the use of a thyroid hormone or thyroid like compound in the preparation of a
25 composition for topical application to the skin of a subject in order to improve the condition of that skin or reduce cutaneous or subcutaneous fat deposits.

SUBSTITUTE SHEET (RULE 26)

- 15 -

DETAILED DESCRIPTION OF THE INVENTION

Compositions in accordance with the invention and methods for their use will now be described, by way of example only, of with reference to the accompanying drawings, Figure no. 1-8.

5

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a graph showing the comparative effect of betamethasone and Triac on the Skin-2 model;

10

Fig. 2 is a graph showing the comparative effect of vitamin D3 and Triac on the Skin-2 model;

Fig. 3 is a graph showing the comparative effect of retinoic acid and Triac on the Skin-2 model;

15

Fig. 4 is a graph showing the effect of retinoic acid on the skin-2 model in three studies;

20

Fig. 5 is a graph showing the effect of Triac on the skin-2 model in three studies;

Fig. 6 is a photograph of a volunteer's waist and hip area in which a composition of the invention has been applied to the left and right side, the line drawing below emphasizing the slimming effects of the composition;

25

Fig. 7 is a photograph of a volunteer's waist hip area in which a composition of the invention has been applied to the right side the line drawing below emphasizing the slimming effects of the composition; and

SUBSTITUTE SHEET (RULE 26)

- 16 -

Fig. 8 is a photograph of a volunteer's waist and hip area in which a composition of the invention has been applied to the right side the line drawing below emphasizing the slimming effects of the composition.

5

EXAMPLE 1

IN VITRO TESTS WITH A SKIN A MODEL

Regulation of epidermal genes which regulate collagen production and promote epidermal differentiation.

10

Terminal differentiation of the epidermal layer of the skin is thought to be related at least in part to the activity of transglutaminase K and the production of cornified envelopes (Febs Letter **258** p35-38, 1989, and J. Invest. Derm. **90** p472). It is thought that the ability of a retinoid to down regulate transglutaminase K in cultured cells is an indication of its ability to effectively treat psoriasis (EP00465343). TGF beta 1 and 2 are thought to promote terminal differentiation and inhibit basal cell proliferation (Fuchs E. J. Cell Biol. **111** p2807). A protease, stratum corneum chymotryptic enzyme, SCCE, is produced by keratinocytes and is thought to promote shedding of skin cells in the upper granular layer of the epidermis and be related to epidermal differentiation (Egulrud et al, ACTA DERM Venereol. Vol 73 p 181-184 1993; Sondell et al, J. Invest Derm 1995, p 819-823). Further, in hyperproliferating skin, the keratins 1 and 10 (differentiation markers) are reduced and the hyperproliferation keratins 16 and 6 are increased (West et al/ 1992, J. Invest. Derm. **1** p 95). Retinoic acid effects on skin keratinocytes in culture reflect a decrease in the differentiation markers and variable changes in keratins 6 and 16 and they also decrease transglutaminase K *in vitro*. Both these markers, the keratins and transglutaminase K have been considered in-vitro measures of retinoic acid

15

20

25

SUBSTITUTE SHEET (RULE 26)

- 17 -

analogs dermatologic potency and usefulness (Kopan and Fuchs, J. Cell Biol 105 p 427-440, 1987 and Griffiths et al, Br J Derm 1992, 127 suppl 4 p 21. Paradoxically, however, retinoids are active against hyperproliferating disorders and increase the keratin 1 and 10 differentiation markers and

5 transglutaminase K *in vivo* after topical application. (Griffiths et al, Br. J. Derm 1992, 127 suppl 4 p21. In keratinocyte cultures, thyroid hormone decreases keratin genes K5, K14 and K10 (6,10). Thyroid hormone modulation of the keratin 1 gene has not been previously reported.

10 Collagen production in the skin occurs from a variety of collagen genes, with the procollagen A-1 and A-3 genes most studied. Collagen is decreased in glucocorticoid treated skin (7) and in photodamaged skin (24). It is thought that overproduction of collagen in the hyperproliferative state may contribute to keloidal scar production. Furthermore, CTGF, a

15 PDGF like peptide (PDGF-L) that is produced in response to TGF beta-1 appears to be present in increased amounts in fibrosing disorders such as scleroderma. In cultured human fibroblasts, thyroid hormone administration decreases collagen production (de Rycker et al, FEBS Lett, vol 174 p34-37 1984).

20 No universally accepted model of human skin exists. A novel synthetic human skin, Skin- 2 model ZK1301 (Advanced Tissue Sciences, La Jolla (USA)) is composed of a three dimensional human skin culture consisting of a dermal fibroblast layer and human foreskin keratinocytes which can be

25 grown with an air-keratinocyte interface to promote normal differentiation and cornification of the model skin. The Skin-2 model is widely accepted as an in-vitro model to assess cutaneous toxicity (Rheins et al, Toxic, in Vitro, 8, no. 5 p1007-1014 1994 and is approved by the Canadian and U.S. FDA as an appropriate model for testing skin toxicity. Such a model

30 has the following advantages:

SUBSTITUTE SHEET (RULE 26)

- 18 -

1) The keratinocytes differentiate in a manner very similar to the *in vivo* state. A stratified multilayered epithelium with all the markers and properties of such epithelium forms. This never happens in typical keratinocyte culture.

2) The presence of fibroblasts allows the detection of fibroblast markers including collagen. The interplay between keratinocytes and fibroblasts which occurs *in vivo* also is mimicked in the SKIN² model, which allows paracrine functioning of the cell types. We assessed the ability of multiple thyroid hormone receptor binding ligands, and several therapeutically useful model compounds including retinoic acid to alter mRNA production of a variety of genes present in fibroblasts and keratinocytes present in the Skin-2 model.

Materials and Methods

The following were components of the Skin² kits: 9x9 mm skin tissues on agarose, 6-well plates, and Millicell inserts. Two media based on Dulbecco's Modification of Eagle's medium were also included: Maintenance medium (containing 5% fetal calf serum) and serum-free assay medium.

The following were supplied by other sources: "Stripped" (Samuels, H. *et al*, Endocrinology **105**, p80-85, 1979) fetal calf serum and all substances to be tested were from Karo Bio AB. All-trans-retinoic acid, 1,25-(OH)₂-vitamin D₃, and betamethasone were purchased from Sigma Chemicals (Stockholm). Upon arrival the skin tissues were placed dermal-side down into the center of a Millicell in a 6-well plate well containing prewarmed maintenance medium. The tissues were incubated at 37°C in an atmosphere of 5% CO₂ in air. After 24 h the maintenance medium was exchanged.

SUBSTITUTE SHEET (RULE 26)

- 19 -

Following another 24 h the Maintenance medium was removed and replaced by Serum- free assay medium containing 5% "stripped" fetal calf serum. Substances were added within 1 h after medium exchange and the tissues were incubated for 10 or 48 h in the presence of the substances. Medium and substances were changed after 24 h incubation. The cells were grown at an air - liquid interface. At the end of the 48 h-incubation period two tissues were pooled together in a sterile plastic centrifugation tube. The tissue was snap frozen on solid ice (-60°C) and stored at -70°C until used. Duplicate samples were included for each treatment.

Analysis of mRNA expression in Skin² by reversed-transcriptase coupled to polymerase chain reaction (RT-PCR)

Total RNA was extracted from Skin² -samples and human skin biopsies using Ultraspec II (Biotechx Laboratories, Inc., Houston, TX). One ml of Ultraspec II was added to each sample which were homogenized by using a Polytron for 2x20 sec at setting 6. Total RNA was extracted according to the protocol supplied by the manufacturer. The amount of RNA was quantitated by measuring the absorbance at 260 nm. The A260/A280 -ratio of the extracted RNA was generally between 1.75 and 2.0. Three µg RNA was reversed transcribed into cDNA in a 30 µl mixture containing 50 mM Tris-HC (pH 8.3), 75 mM KC, 3 mM MgC2, 10 mM dithiothreitol, 0.5 mM of each dNTP, 200 U M-MLV reversed transcriptase (Life Technologies), 25 U placental Rnase inhibitor (Boehringer-Mannheim) and oligo d(T)15 as primer. After incubation at 37°C for 60 min, the reaction was stopped by heating at 75°C for 10 min and the mixture stored at -70°C until cDNA amplification was performed.

Polymerase chain reation

The following PCR mixture (24 µl) was prepared immediately before use: 10 mM Tris-HC (pH 8.3), 50 mM KC, 1.5 mM MgCl, 200 µM of each dNTP,

SUBSTITUTE SHEET (RULE 26)

- 20 -

0.5 μ M primers (see Table 1), and 0.5 U Taq DNA polymerase licensed for PCR (Life Technologies). The tubes were placed in a Thermal cycler (Perkin-Elmer) programmed as follows: (a) 90°C for 90 s; (b) variable number of cycles (see Table 1) of the following sequential steps: 60 s at 94°C, 75 s at annealing temp (see Table 1), 90 s at 72°C; and (c) 7 min at 72°C.

After mixing 7.5 μ l of PCR-products with 2 μ l of loading buffer, samples were separated by electrophoresis on a 1.2 % agarose gel containing ethidium bromide, and visualized by UV transillumination. Gels were recorded by videoprints.

The amount of product was estimated on the videopoint or directly on the gel. The amount of transcripts in each lane were compared in relation to two control samples run in parallel.

The expression of certain genes was not modulated by test compounds, and so these genes were not selected as markers in subsequent experiments

Table 1

Gene	Annealing Temp	PCR-cycles	Product Size (bp)
Fibronectin	60°C	22-25	794.0000000
IL-6	60°C	22-25	639.0000000
IL-8	60°C	25.0000000	275.0000000
ICAM-1	60°C	30.0000000	727.0000000
TGF β 1	60°C	25.0000000	338.0000000
TGF β 2	56°C	40.0000000	575.0000000
Keratin 1	60°C	24-27	480.0000000
Keratin 10	60°C	27-30	439.0000000
Keratin 5	60°C	25.0000000	559.0000000
Keratin 14	60°C	25.0000000	651.0000000
Keratin 6	60°C	25.0000000	464.0000000
Keratin 19	60°C	20.0000000	400.0000000
Keratin 16	60°C	22-25	725.0000000

SUBSTITUTE SHEET (RULE 26)

- 21 -

20

5

10

15

20

25

Gene	Annealing Temp	PCR-cycles	Product Size (bp)
SCCE	60°C	22.0000000	463.0000000
Collagenase	60°C	30.0000000	463.0000000
Involucrin	60°C	25.0000000	541.0000000
Filaggrin	60°C	29.0000000	526.0000000
Loricrin	60°C	33.0000000	663.0000000
Procollagen 1A1	60°C	20-22	620.0000000
Procollagen 1A2	60°C	23.0000000	712.0000000
Procollagen 3A1	60°C	20-24	524.0000000
TGk	60°C	22-30	652.0000000
CTGF	60°C	25.0000000	515.0000000
ThR θ	60°C	32.0000000	623.0000000
ThR β	60°C	32.0000000	578.0000000
CRBPI	60°C	25.0000000	388.0000000
CRABPII	60°C	22-25	402.0000000
RAR θ	60°C	35.0000000	817.0000000
RAR β	60°C	35.0000000	769.0000000
RAR	60°C	30.0000000	765.0000000
RXR θ	60°C	30.0000000	743.0000000
VDR	60°C	30.0000000	888.0000000
cyclophilin	60°C	20-22	424.0000000
GAPDH	60°C	24-27	893.0000000

Key

IL-6 interleukin-6, IL-8 interleukin-8, ICAM-1 intracellular adhesion molecule-1, TGF β transforming growth factor, SCCE stratum corneum chymotryptic enzyme, TG κ keratinocyte transglutaminase, CTGF connective tissue growth factor, ThR thyroid hormone receptor, CRBP cellular retinol-binding protein CRABP II cellular retinoic acid-binding protein, RAR retinoic acid receptor, RXR retinoid X receptor (9-cis-RA receptor), VDR vitamin D₃ receptor, GAPDH glyceraldehyde-3-phosphate dehydrogenase.

35

SUBSTITUTE SHEET (RULE 26)

- 22 -

The effect of a thyroid hormone, tri-iodothyroacetic acid (Triac), was first studied and compared to known medically useful compounds which affect epidermal physiology. These drugs were retinoic acid, betamethasone, and 1,25 OH vitamin D₃. The semi quantitative results are shown in Table 2 and comparisons between Triac and the other drugs are displayed in fig. 1, (betamethasone), Fig. 2 (Vit D3) and Fig. 3 (all trans Retinoic acid). Triac at 50 nMolar concentration, approximately 1000 times its affinity constant for the receptor, appears to strikingly reduce keratin 1 and 10, transglutaminase K, and SCCE. Triac also markedly accentuates Collagen A-1 and 3A-1, along with TGF-beta-2 transcripts. In comparison with betamethasone, Triac increases collagen production and TGF beta-2 but does not strongly inhibit IL-6. The keratin findings are similar. In comparison with Triac, Vit D-3 does not inhibit the keratin gene transcripts, or SCCE or transglutaminase K., but the effect on collagen genes is similar. Retinoic acid and Triac appear very similar with the exception of only SCCE and CRAB PII. At a higher concentration, 1 μ Molar, Triac continues to display the same effects although the collagen and keratin response is somewhat reduced. It is a surprising finding of the present invention that low doses of thyroid hormone compounds are dermatologically effective.

These results are consistent with known results of these drugs in other model systems. For example Vitamin D-3 is not known to affect keratinization of cultured keratinocytes. Betamethasone decreases epidermal collagen. Retinoic acid is known to decrease transglutaminase Ki and keratins 1 and 10 in culture. These results therefore suggest that Triac should have similar properties as these other medically important classes of drugs. In fact a combination of a thyroid hormone with a glucocorticoid should avoid the collagen loss associated with topical steroid application and add an antiinflammatory effect not seen with a thyroid compound.

SUBSTITUTE SHEET (RULE 26)

- 23 -

5 The results of three experiments with Triac at 50 nM dose and retinoic acid at 1 μ Molar dose are shown for comparison in figures 4 and 5. The two hormones appear very similar, but can be differentiated by the lack of inhibition of SCCE by RA in this model, and the modest fall in transcripts for the CRAB PII retinoid binding protein induced by Triac. Both compounds inhibit keratin 1 and more modestly, keratin 10, increase TGF-beta-2, CTGF, collagen and inhibit transglutaminase K.

10 A group of thyroid hormone receptor binding compounds were therefore tested in this model. Eight different compounds which span a range of different structures, including nonhalogenated compounds and compounds containing bromine instead of iodine, all of which bind to the receptor were assayed in the Skin-2 system. One compound, L-T-1, as described in
15 GB7822745, GB859546 and US3198702 as part of a family of molecules which have topical utility, which bind very poorly to the receptor was also tested. The compounds were all tested at concentration ranges above their binding affinity for the receptor except for L-T-1 which binds poorly to the receptor even at the tested ten micromolar concentration. Table 3 displays
20 the results for these compounds along with their K_i (binding affinity) to the human thyroid receptor and the tested concentration of chemical. Affinities for the human thyroid receptor alpha-1 were similar. Again, a reduction in transcripts for keratin 1 (8/8 compounds), keratin 10 (5/8), and transglutaminase K (4/8) was seen, along with increased collagen a-1 (7/8) and collagen 3a (6/8) and CTGF (7/8). For the most part, an inhibition of
25 SCCE was seen, although in some instances a very modest change was displayed by some compounds. The compound (L-T-I), which did not bind to the endogenous receptor, showed no inhibition of keratin 1 or 10, a positive effect on transglutaminase K and SCCE which is opposite to the

SUBSTITUTE SHEET (RULE 26)

- 24 -

thyroid response and retinoic acid response, and only modest effects on collagen.

Certain of the compounds, notably compound number 5 displayed a relative selectively for keratin 1, transglutaminase K and SCCE responses over collagen responses. Therefore it seems likely that some of the compounds will display a relative efficacy more weighted toward regulation of epidermal differentiation than collagen production and potential would healing effects or amelioration of dermal states characterized by collagen deficient skin.

Although the effects of these thyroid compounds as a group reflect specific and reproducible changes in the transcripts of epidermally related genes which affect differentiation, the *in vitro* direction of the response for SCCE, Transglutaminase K and keratin 1 is the opposite to that which might be considered therapeutically useful. Since a similar result is seen for retinoic acid (Koppam *et al*; Griffiths *et al supra*), these two entities are therefore quite similar in their effects. Surprisingly the collagen response to thyroid hormone was the opposite to that reported in the literature (de Ryk *et al supra*). Because of the paradoxically opposite effects of retinoids on skin related proteins and genes when given *in vitro* as compared to *in vivo* testing, and the concomitant medically beneficial usefulness of retinoids. It was considered that thyroid regulation would be subject to the same paradox. therefore Triac was tested on human volunteers.

EXAMPLE 2

HUMAN STUDY: THYROID HORMONE CONTROLS GENE TRANSCRIPTION IN SKIN

Three adult male volunteers ranging in age from 37-46 yrs were treated topically with a cream containing either 200 mg/100 ml or 20 mg/100 ml

SUBSTITUTE SHEET (RULE 26)

- 25 -

5 Triac. The cream was applied in an amount sufficient to just cover an approximately 6 cm² area on the buttocks. A similar sized area on the contralateral side, treated with a dermatologically useful cream, served as control. After application, the areas were covered with Tegaderm (3M) to prevent loss of cream and to enhance penetration. Control and Triac-treated areas were biopsied 96 h following this single treatment. The degree of erythema of each subject was judged on a subjective scale 1 to 4. Epidermis and papillary dermis from control and treated skin were obtained by manually cutting superficially with a razor-blade following 1 % lidoacine anesthesia. Two pieces of tissue measuring 2 x 2 cm and approximately 0.2 mm in depth were obtained for RNA-preparation. The tissue was snap frozen on solid ice (-60°C) and stored at -70°C until used.

15 A large number of transcripts were tested in three male subjects and the results are shown in table 4. The change in transcription of the genes for SCCE, Keratin 1 and 10, and transglutaminase K was now unexpectedly positive, the opposite of what was found in the *in vitro* assay. These changes reflect an increase in the differentiation markers and suggest a change to a more terminally differentiated state. The effect on collagen and CTGF remains the same *in vivo* as *in vitro* when using the Skin-2 model. Thus, at least for gene products which are related to epidermal differentiation the thyroid response *in vitro* is opposite to that *in vivo*, an identical finding as has been seen for the medically important retinoid compounds. Moreover, the unexpected increase in collagen formation suggest utility to help rebuild photodamaged adult human skin (Talwar et al, J. Inv. Derm, 105 p285-290, 1995).

SUBSTITUTE SHEET (RULE 26)

- 26 -

EXAMPLE 3**THYROID HORMONES ARE PHYSIOLOGICALLY ACTIVE WHEN APPLIED TO THE SKIN.**

5 Triac (Tri iodo thyroid acetic acid) or DIMIT (dimethyl isopropyl thyronine) or esters and ethers thereof are mixed in a concentration range of 10 000 000 times K_{diss} to 1000 times K_{diss} , 100 micromolar to 1 nanomolar, in a suitable pharmacological base, such as Johnson and Johnson Purpose™ or Curity™ skin lotion and applied to hairless mice strain SKH/hr 1 for 8 weeks. Punch biopsies are obtained and ultrasound measurements were
10 made of the skin using a 10 MHz B-mode ultrasound (18). As compared to control animals, thyroid hormone treated animals have an increase in the thickness of the epidermal area and a slight decrease in the dermal portion of the skin. An increased cellularity of epidermal cell layers is found, with a decrease in the regularity of the rete pattern.

15

EXAMPLE 4**WOUND HEALING**

Wounds are produced in rats and rabbits as in (19). The tensile strength of the wounds are determined at five, ten and twenty days and collagen
20 formation in the wound determined by SDS-gel electrophoresis (20,22,23,24). Wound healing is also measured by two dimensional A and B mode ultrasound. The wounds to which thyroid hormone is applied have increased tensile strength and close more quickly. Ultrasound measurements disclosed a more rapid granulation base and more rapid
25 wound closure.

EXAMPLE 5**PHOTODAMAGED SKIN**

30 Hairless mice SKH-1 are UV-B irradiated according to the schedule of (22). After 12 weeks of irradiation, significant wrinkling results. The mice

SUBSTITUTE SHEET (RULE 26)

- 27 -

are treated with the thyroid hormone Triac-containing cream for a period of 16 weeks after irradiation. The degree of wrinkling appearing on the irradiated mice is compared to untreated, irradiated animals to which the appropriate pharmaceutical base is not applied. The thyroid hormone containing composition of the invention produces a significant decrease in the wrinkle pattern of the animals and an increase in skin collagen.

EXAMPLE 6

IMPROVEMENT IN THE APPEARANCE OF CELLULITE AND/OR REDUCTION SUBCUTANEOUS FAT DEPOSITS AND DECREASE IN SUB- CUTANEOUS, DERMAL AND SUBDERMAL FAT.

The thyroid compounds reverse T-3, T-3, and Triac were dissolved in 70% isopropanol- water at a concentration of 0.5 to 7 mg/ml⁻¹.

A hydrophillic ointment (USP) or non-USP (Fougera brand) consisting of an oil in water emulsion with suitable fatty acid modifiers in 30 ml to 100 ml amounts was placed in a suitable stirring vessel. The dissolved thyroid compounds were sprayed over the surface of the cream and mixed manually, or with a mechanical stirrer, for several minutes to produce complete mixing. To adjust for batch to batch variations in the ointment base, water or isopropanol in amounts up to 20% of the volume were added to produce a mixture which was both pleasing to touch and was easy to apply to the skin. Other solvents such as isopropanol/water, ethanol or ethanol/water were also tested for dissolution.

The cream was applied daily, twice a day or up to every three days to various parts of the body. Exercise, especially of the tested area, through dancing or mild calisthenics which produced increased warmth and blood flow to the area appeared to accelerate the effects of the cream.

SUBSTITUTE SHEET (RULE 26)

- 28 -

EXAMPLE 6A**RIGHT BUTTOCKS**

Triac, T-3 And Reverse T-3 were applied separately to the right buttock. An observer noted a decrease in the overall volume of the buttocks and a
5 elevation of the gluteal posterior thigh fold by 1/2 to 1cm. Results were noted after 10 days of application. Measurements of hip circumference showed a 0.75 inch increase in circumference after 7 days after stopping the application.

EXAMPLE 6B**RIGHT THIGH**

T-3 and Triac were separately applied to a subject's right thigh for two periods of 3 weeks.

Results

15 The circumference of the right thigh was measured 5 cm beneath gluteal fold decreased, compared with the untreated left thigh as a control, Beginning: Right thigh measured 49 cm; Left thigh measured 47.5 cm After 20 days T₃ treated Right thigh measured 18.75 inches; Left thigh measured 18.5 inches.

20 Triac cream was then applied to Right thigh. After three weeks measurements of both thighs were the same.

There was an one pound decrease in body weight over this period.

EXAMPLE 6C**RIGHT INFRA RENAL AND SUPRA ILLIAC CREST FAT PADS**

Triac cream. Test 1: applied for two weeks to right side.

Results:

Observation shows a decrease in fat pad size. Measurement of skin creases from right to left side showed: R 5.75cm and L 7.5cm. Application
30 stopped for two weeks and restarted with reverse T-3 cream. Effects

SUBSTITUTE SHEET (RULE 26)

- 29 -

appear similar after ten days. Photographs were taken of these areas.
(See Fig. 6)

EXAMPLE 6D

5

**RIGHT SUPRA ILLIAC CREST AND OVER ABDOMINAL RECTUS
MUSCLE**

Triac cream was applied to right supra illiac crest and right abdominal
area.

10

Initial measurements: waist 28 inches, hips measured one inch below
umbillicus, 36 inches

After two weeks: waist 27", hips measured one inch below umbillicus 35.25
inches

After 10 more days: waist 27.5" hips measured one inch below umbillicus
34 inches.

15

There was a body weight loss of approximately two pounds over an eight
week period.

Photographs were taken of these areas as described below. Clothes fitted
appreciably more easily and the appearance of diminished fat easily noted
by other observers.

20

See Figs. 6 and 7.

Fig. 6 shows the results of applying Triac and subsequently T₃ cream daily
to the right side alone. Application of the Triac cream continued for 3.5
weeks and then was stopped for 1- 2 weeks and then T₃ cream was
applied daily for ten days. T₃ cream was applied daily to both sides for 7
days and then to the right side only for a further 3 days.

25

Fig.7 shows the result of applying Triac cream to the right side of a
volunteer on a daily basis for 3 weeks.

30

SUBSTITUTE SHEET (RULE 26)

- 30 -

Fig. 8 shows the effect of applying T₃ cream to the right side of a volunteer for 3 weeks.

5 Thyroid gland size and radial pulse rate were measured bi-monthly. No changes were observed. No hair loss, abdominal distress, cardiac arrhythmia or diarrhoea were observed. No adverse changes to the underlying skin were noted.

10 The composition of the present invention may be conveniently supplied in a unit dose pack comprising a plastic container which may for example be bubble, or blow moulded or injected, together with a tear off plastic or foil top, the pack containing a unit dose of the composition.

15 **EXAMPLE 7**

HUMAN STUDY: TREATMENT OF PSORIASIS

Patients with characterized multilateral psoriasis were subjected to a pharmacological washout period of two weeks followed by treatment of one lesion with an hydrophilic ointment containing 0.04% Triac or vehicle alone
20 an another lesion by application of ointment twice per day. Treatment duration was 8 weeks. Clinical results were measured using a validated five point scale for the severity index of scaling, erythma and infiltration size. All observations were performed by blinded observers at two week intervals. Sixty per cent of treated patients had statistically significant and
25 clinically significant reductions in their severity scores.

SUBSTITUTE SHEET (RULE 26)

REFERENCES

1. Lavin, T.N. Mechanisms of Thyroid Hormone action. In the textbook of Endocrinology (DeGroot, Ed.), 2nd Edition, W. B. Saunders, pub. (1989).
- 5 2. Drozdzm M *et al*. Endokrinologie 1979 Feb; **73**(1) 105-11
3. Murata Y *et al* J Clin Endocrinol Metab 1987 Feb; **64**(2): 334-9
4. Watzke, H., *et al* Thrombosis Research. **46**(2): 347-53, 1987 Apr 15
5. Murata Y *et al* JCEM 1983 Vol. **57** p. 1233-1239
6. Lee J *et al* Endocrinology **130** p 2733-2738, 1992
- 10 7. Ceccarelli, P *et al* JCEM **65** p 242-246, 1987
8. Tomio-Canic M *et al* Journal of Investigative Dermatology **99** p 842-847, 1992
9. Blumenberg M *et al*. J. Invest Dermatol 1992 Jun: **98**(6 Suppl):42S-49S
- 15 10. Ohtsuki M *et al* J Dermatol 1992 Nov **19**(11) p 774-80
11. Holt, P.J.A *et al* British Journal of Dermatology **95** p 513-518, 1976
12. Cronrath CM *et al* Endocrinology, **120**(1) page 43-8, 1987 Jan
13. Towle H. C, Mariash C. N Federation Proceedings **45**(9) p 2406-11, 1986 Aug.
- 20 14. Lemmen C. *et al* Biological Chemistry Hoppe-Seyler **367**(7) p 533-537, 1986
15. Amorosa L. F *et al* Biochim Biophys Acta 1984 Feb 9, **792**(2) p 192-8
16. Armer P *et al* Diabetes **33**(4) p 369-375, 1984
17. Coronary Dru Project, JAMA **220** p 996-1008, 1972
- 25 18. Akesson, A *et al* Acta Radiologica Diagnosis **27** p 91-94, 12986
19. Hunt, T *et al* Annals Surgery **170** p 633-641, 1969
20. Varani, J *et al* J. Invest Dermatol **94** p 717-723, 1990
21. Loireau A *et al* Biochem Pharmacol **35** p 1691-1696, 1986
22. Moloney S. J *et al* Photochem Photobiol **56** p 505-511, 1992

- 32 -

23. Schwartz E *et al* J. Investl. Dermatol **102** p 241-246, 1994
24. Griffiths C. E. M *et al* NEJM **329** p 530-535, 1993
25. Roti, E *et al* Endocrine Reviews **14** p 401-423, 1993
26. Lev-Ran A Perspectives in Biology & Medicine **37** p 486-494, 1994
- 5 27. Apriletti J. *et al* J. Biol. Chem. **263** p 9409-9417, 1988

SUBSTITUTE SHEET (RULE 26)

TABLE 2
COMPARISON OF TRIAC WITH OTHER DERMATOLOGICALLY ACTIVE DRUGS


drug	Genes Tested											
	k1	k10	k16	k19	transgK	scce	tgfbeta-2	IL-6	col 1A-1	col 3A-1	ctgf(pdgf-L)	crabp-II
vit D 1 μ Molar	0	-1	0	0	-1	0	2	-1	2	2	0	-1
Triac 50 nM	-3	-2	-1	-1	-3	-2	2	-0.5	2	2	1	-1
Triac 1 μ M	-2	-2	-0.5	-1	-3	-2	2	-0.5	2	1	0.5	-1
betameth 1 μ M	-3	-0.5	-1	-0.5	-1	-1	0	-2	0.5	-0.5	1	-1
RA 1 μ M	-3	-1	-0.5	-1	-3	0.5	2	-1	2	1	1	1

TABLE 3
TRANSCRIPTIONAL RESPONSES TO THYROID HORMONE RECEPTOR BINDING ENTITIES


		1 μ MOLAR CONCENTRATION									
		Genes tested									
Ki (nM)	compound number	k1	k10	k16	trans gk	scce	col a-1	col a-3gf(pdgf-L)			
0.1	1	-2	-0.5	0	0	0.5	1	2	1		
0.1	2	-1	0	0	0.5	0.5	2	1	1		
10	3	-2	-1	0	1	0	2	0.5	1		
20	4	-2	-0.5	0	0	0	1	0	1		
20000	L-T-1 10 μ M	0	0	0	1	1	0.5	0.5	1		
0.04	Triac 50nM	-2	-2		0	0	2	1	2		
	Triac 1 μ M	-1	-1		-1	0	1	1	2		
8	5	-1	-1		-0.5	0	0	0	1		
0.04	Triac 50nM	-2	0	0	-2	-2	0	0	0		
	Triac 1 μ M	-1	1	0	-0.5	-1	0.5	0.5	1		
8	5	-2	0	-0.5	-2	-2	0	0	0		
75	6	-2	-1	0	-2	-1	1	0.5	1		
0.1	7	-1	1	0.5	-1	-1	1	1	1		
0.08	8	-2	1	0.5	-1	0.5	0.5	1	1		

SUBSTITUTE SHEET (RULE 26)


Number	Name	Conc	Ki (Kd) (Nmol/l)
1	Triiodothyronine	1 μ M	0
2	Tri-form	1 μ M	0
3	Thyroxine	1 μ M	10
4	KB 131-007	1 μ M	20
5	SKF 94-901	1 μ M	8
6	DIMIT	1 μ M	75
7	CIBA 7f-	1 μ M	0
8	KB 131 026	1 μ M	0
	L-T1-	10 μ M	20000
* N-[3,5-Dimethy-4-(4'-hydroxy-3' -isopropylphenoxy)-phenyl]oxamic Acid			
**3-iodo-L-Thronine, (Henning Berlin Germany)			




1) Triiodothyronine




2) Thyroxine




5) SKF 94-901




7) CIBA 7f-




2) Tri-form



4) KB 131-007



6) DIMIT



8) KB 131-026

SUBSTITUTE SHEET (RULE 26)

TABLE 4

Subject		A	A	B	B	C	C	C
Transcript	cycles	C	TR 1	C	TR 1	C	TR 0.1	TR 1
GAPDH	24					ND	ND	ND
cyclophilin	20					ND	ND	ND
Keratin 5	19		+		+			
Keratin 14	19		+		+			
Keratin 1	17		++		+			+
Keratin 10	19		(+)		(+)			
TGase-K	32				(+)		+	
Involucrin	25					ND	ND	ND
RXR θ	27		(+)		(+)	ND	ND	ND
SCCE	25		+		++		+	+
ICAM-1	35	nd	nd	nd	nd	ND	ND	ND
IL-6	25	nd	nd	nd	nd	ND	ND	ND
5 θ -red. I	30				-	ND	ND	ND
5 θ -red. II	35	nd	nd	nd	nd	ND	ND	ND
Col1A1	25		++		++		+	+
Col3A1	22		++		+		+	+
Collase	35	nd	nd	nd	nd	ND	ND	ND
CTGF	30		+		++		-	-
Fibronec	22		+		+			-
CRABP II	25		(-)		-			

nd= not detected, ND= not determined

SUBSTITUTE SHEET (RULE 26)

CLAIMS

5

1. A skin treatment composition for topical application, the composition comprising at least one thyroid hormone compound or thyroid hormone-like compound as herein defined together with a pharmacologically acceptable base.

10

2. A skin treatment composition for topical application, the composition comprising at least one thyroid hormone compound or thyroid hormone-like compound as herein defined together with a pharmacologically acceptable base in which application of the composition to the skin effects an improvement in the skin's condition without resulting in systemic metabolism of the compound.

15

3. A skin treatment composition for topical application, the composition comprising at least one thyroid hormone compound or thyroid hormone-like compound as herein defined together with a pharmacologically acceptable base in which a medically or cosmetically sufficient amount of thyroid hormone compound or thyroid hormone-like compound enters the skin but in which substantially no thyroid hormone compound or thyroid hormone-like compound subsequently has a serum concentration which is physiologically adverse after topical application of the composition.

20

- 38 -

4. A skin treatment composition for topical application, the composition consisting solely of a thyroid hormone compound or thyroid hormone-like compound as herein defined together with a pharmacologically acceptable base composition .

5. A skin treatment composition according to one of claims 1 to 4 in which the thyroid hormone compound is selected from Tri-iodothyronine (T3); D and L tetraiodothyronine - thyroxine (T4); 3,3',5' tri-iodothyronine (reverse T3) ; 3,3'-diiodothyronine ; T3 T4 analogues such as 3,5,3'-Triiodothyroacetic acid ; 3,5,3'-Tetraiodothyroacetic acid ; 3,5,3'- Triiodo-L-thyronine ; 3,5,3'-Triiodo-L-thyronine methyl ester ; 3,5,3'-Triiodo-L-thyronine hydrochloride ; L-thyroxine ; L-thyroxine hydrochloride ; L-T3 ; T4Fo ; Tetrac ; Triac ; Tetraprop ; Triprop ; T4Bu ; T3Bu ; Thyroxamine ; Triiodothyronamine ; L-3'-T1 ; L-3'-T1 ; L-3,5'-T2 ; L-3,3'-T2 ; L-3,3',5'-T3 ; DL-Br2I ; L-Br2iPr ; L-Me2I ; L-Me3 ; L-Me4 ; L- Me2iPr ; DL-IMeI ; L-3,5-Dimethyl-3'-isopropylthyronine (DIMIT) ; DL-BPT4 ; B-triac ; BP-tetrac ; DL-SBT3 ; DL-SBT4 ; DL-MBT3 ; MB-tetrac ; T2 ; T2F ; T2Cl ; T2Br ; T3 ; T2Me ; T2Et ; T2iPr ; T2nPr ; T2sBu ; T2tBu ; T2iBu ; T2Phe ; T2OH ; T2NO2 ; T2F2 ; T2Cl2 ; T4 ; T2Me2 ; 3,5,3',5'-tetraiodo-D-thyronine ; 3,5,3'-Triiodo-D-thyronine ; 3,5-Diiodo-4- hydroxyphenylpropionic acid (DIHPA) ; Aryloxamic acids ; (arylamino) acetic acids ; arylpropionic acids ; arylthioacetic acids ; (aryloxy)acetic acid ; 3,3'-T2 ; 3,5-T2 ; 3'-5'-T2 ; (5-Benzyloxy-2-methoxyphenyl)-(2-methoxypyrimidin-5-yl)-methanol ; Benzyloxy-2- methoxyphenyl)-(6-methylpyridin-3-yl)methanol ; (5-Benzyloxy-2-methoxyphenyl)-(5- bromo-2-methoxypyridin-4-yl)methanol ; (5-benzyloxy-2-methoxyphenyl)-(2,6- difluoropyridin-3-yl)methanol ; (5-Benzyloxy-2-

SUBSTITUTE SHEET (RULE 26)

- 39 -

methoxyphenyl)-(2-methoxypyridin-4-yl)methanol ; 4-Methoxy-3-[(2-methoxypyrimidin-5-yl)methyl]phenol ; 4-Methoxy-3-[(6-methylpyrid-3-yl)methyl]phenol ; 5-Benzyloxy-2-methoxybenzyl Bromide ; (5-Benzyloxy-2-methoxyphenyl)-(6-chloropyridazin-3-yl)-acetonitrile ; 4-Benzyloxy-2-[2-methoxythiazol-5-yl)methyl]anisole ; 6-[(5-Hydroxy-2-methoxyphenyl)methyl]thiazol-2-(3H) ; 3'-Heteroaryl(methyl-4')-methyl-3,5-dinitro-N-trifluoro-acetyl-L-thyronine Ethyl Esters ; 3'-heteroaryl(methyl-3,5-di-iodo-4')-methyl-N-trifluoro-acetyl-L-thyronine Ethyl Esters ; 3'-heteroaryl(methyl analogues of 3,3',5-tri-iodo-L-thyronine (T3) ; 3'-substituted derivatives of the thyroid hormone 3,3',5-triiodo-L-thyronine (T3) ; L-3'-T1 ; L-3,5'-T2 ; L-3,3'-T2 ; L-3,3',5'-T3 ; DL-Br2I ; L-Br2IPr ; L-Me2I ; L-Me3 ; L-Me4 ; L-Me2iPr ; DL-IMeI ; L-3,5-Dimethyl-3'-isopropylthyronine (DIMIT) ; DL-BPT4 ; B-triac ; BP-tetrac ; DL-SBT3 ; DL-SBT4 ; DL-MBT3 ; MB-tetrac ; T2 ; T2F ; T2Cl ; T2Br ; T3 ; T2Me ; T2Et ; T2iPr ; T2nPr ; T2sBu ; T2tBu ; T2iBu ; T2Phe ; T2OH ; T2NO2 ; T2F2 ; T2Cl2 ; T4 ; T2Me2 ; 3,5,3',5'-tetraiodo-D-thyronine ; 3,5,3'-Triiodo-D-thyronine ; 3,5-Diiodo-4-hydroxyphenylpropionic acid (DIHPA) ; Aryloxamic acids ; (arylamino)acetic acids ; arylpropionic acids ; arylthioacetic acids ; (aryloxy)acetic acid ; 3,3'-T2 ; 3,5-T2 ; 3'-5'-T2 ; θ -methyl-3,5,3'-triiodothyroacetic acid, θ -methyl-3,5,3'-triiodothyropropionic acid, and θ -methyl-3,5,3',5'-tetraiodothyropropionic acid ; methylene- and carbonyl-bridged analogs of iodinated thyronines thyroacetic acids ; Iodinated benzofurans ; 3,5-diiodo-4-(2-N,N-diethylaminoethoxy)phenyl-(2-butylbenzofur-3-yl)methanol hydrochloride ; 2-methyl-3-(3,5-diiodo-4-(2-N,N-diethylamino-

SUBSTITUTE SHEET (RULE 26)

- 40 -

ethoxy)-benzoyl)benzofuran hydrochloride ; 2-n-butyl-3-(3,5-diiodo-4-carboxymethoxy-benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4-hydroxy-benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4-carboxymethoxy-benzyl)benzofuran ; [4'-hydroxy-3'-iodo-3,5 diiodo-4-(2-N,N-dimethylamino- ; (ethoxy)benzophenon hydrochloride ; 2-butyl-3-(3-iodo-4-hydroxybenzoyl)benzofuran ; 4',4-dihydroxy 3',5-triiodo-diphenylmethan ; 3,5-diiodo-4-(2-N, N-diethylaminoethoxy)phenyl- ; -(2-butylbenzofur-3-yl)methanol hydrochloride ; 2-methyl-3-(3,5-diiodo-4-(2-N,N-diethylamino-ethoxy)-benzoyl)benzofuran hydrochloride ; 2-n-butyl-3-(3,5-diiodo-4-carboxymethoxy-benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4-hydroxy-benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4-carboxymethoxy-benzyl)benzofuran ; 4'-hydroxy-3'-iodo-3,5 diiodo-4-(2-N,N- dimethylamino-ethoxy)benzophenon hydrochloride ; 2-butyl-3-(3-iodo-4-hydroxybenzoyl)benzofuran ; 4',4-dihydroxy-3',5-triiodo-diphenylmethan ; 3,5-diethyl,3'- isopropyl thyronine (DIET) ; and IpTA2 (3,5 diiodo- 3'-isopropyl thyroacetic acid) and pharmacologically acceptable salts and derivatives thereof.

6. A composition according to any one of claims 1 to 5 comprising a concentration of 5×10^8 times Kd or less of the said at least one thyroid hormone compound or thyroid hormone-like compound.

7. A composition according to any preceding claim in which the said at least one thyroid hormone compound or thyroid hormone-like compound is in chemically pure form.

SUBSTITUTE SHEET (RULE 26)

- 41 -

8. A composition according to any preceding claim in which the pharmacologically acceptable base is selected from oil in water emulsions, sprays, liposomes and solutions.

5

9. A composition according to any preceding claim in which the said at least one thyroid hormone compound is at least partially dissolved in a solvent.

10

10. A composition according to claim 9 in which the solvent is an organic solvent.

11. A composition according to claim 10 in which the organic solvent is selected from alcohol and alcohol and water solutions.

15

12. A composition according to claim 11 in which the organic solvent is selected from isopropanol, isopropanol and water, ethanol, and ethanol and water solutions.

20

13. A composition according to any preceding claim for the treatment of a condition selected from stria, cellulite, roughened skin, actinic skin damage, intrinsically aged skin, photodamaged skin, lichen planus, ichthyosis, acne, psoriasis, wrinkled skin, Dernier's disease, eczema, atopic dermatitis, seborrhoeic dermatitis scleroderma, collagen deficient skin, corticosteroid atrophy, chloracne, pityriasis, and skin scarring.

SUBSTITUTE SHEET (RULE 26)

14. A composition according to any preceding claim comprising a thyroid hormone or a thyroid hormone-like compound together with at least one of a Vitamin D analogue, a glucocorticoid or a retinoic acid receptor binding compound.

5

15. A unit dose package containing a single dose of a composition according to claim any preceding claim.

10

16. A method of modulating the expression of genes in the skin, the method comprising applying a composition comprising at least one thyroid hormone compound or thyroid hormone-like compound as herein defined together with a pharmacologically acceptable base to the skin.

15

17. A method according to claim 16 in which the gene to modulated is selected from genes encoding keratin 1, keratin 10, TGF beta-2, TGF-alpha, TGF beta-1, SCCE, Transglutaminase K, Keratin growth factor (KGF), procollagen 1A1, procollagen 3A-1, keratin 16, connective tissue growth factor CTGF, CRABP-II.

20

18. A method of improving the skin of a subject, the method comprising the steps of:
providing a composition in accordance with any one of claims 1 to 13; and applying the said composition to the skin of the subject.

SUBSTITUTE SHEET (RULE 26)

- 43 -

19. A method according to claim 18 in which the condition of the skin to be improved is selected from stria, cellulite, roughened skin, actinic skin damage, intrinsically aged skin, photodamaged skin, lichen planus, ichthyosis, acne, psoriasis, wrinkled skin, Dernier's disease, eczema, atopic dermatitis, seborrhoeic dermatitis scleroderma, collagen deficient skin, corticosteroid atrophy, chloracne, pityriasis, and skin scarring.

20. A method according to claim 18 or 19 in which the composition is applied from twice a day to every three days.

21. A method of reducing cutaneous or subcutaneous fat deposits in a subject, the method comprising the steps of providing a composition in accordance with any one of claims 1 -14; and applying the said composition to skin of the subject in the vicinity of the deposits to be treated.

22. A method according to claim 21 in which the composition is applied to the skin from between twice a day to every three days.

23. The use of a thyroid hormone or thyroid hormone-like compound in the preparation of a composition for topical application for the treatment of a skin condition.

SUBSTITUTE SHEET (RULE 26)

- 44 -

24. A use according to claim 23 in which the condition is selected from stria, cellulite, roughened skin, actinic skin damage, intrinsically aged skin, photodamaged skin, lichen planus, ichthyosis, acne, psoriasis, wrinkled skin, Dernier's disease, eczema, atopic dermatitis, seborrhoeic dermatitis scleroderma, collagen deficient skin, corticosteroid atrophy, chloracne, pityriasis, and skin scarring.

25. A use according to claim 23-24 in which the thyroid hormone is selected from Tri- iodothyronine (T3); D and L tetraiodothyronine - thyroxine (T4); 3,3',5' tri-iodothyronine (reverse T3) ; 3,3'-diiodothyronine ; T3 T4 analogues such as 3,5,3'-Triiodothyroacetic acid ; 3,5,3'-Tetraiodothyroacetic acid ; 3,5,3'-Triiodo-L-thyronine ; 3,5,3'-Triiodo-L-thyronine methyl ester ; 3,5,3'-Triiodo-L-thyronine hydrochloride ; L-thyroxine ; L-thyroxine hydrochloride ; L-T3 ; T4Fo ; Tetrac ; Triac ; Tetraprop ; Triprop ; T4Bu ; T3Bu ; Thyroxamine ; Triiodothyronamine ; L-3'-T1 ; L-3'-T1 ; L-3,5'-T2 ; L-3,3'-T2 ; L-3,3',5'-T3 ; DL- Br2I ; L-Br2iPr ; L-Me2I ; L-Me3 ; L-Me4 ; L-Me2iPr ; DL-IMeI ; l-3,5-Dimethyl- 3'-isopropylthyronine (DIMIT) ; DL-BPT4 ; B-triac ; BP-tetrac ; DL-SBT3 ; DL- SBT4 ; DL- MBT3 ; MB-tetrac ; T2 ; T2F ; T2Cl ; T2Br ; T3 ; T2Me ; T2Et ; T2iPr ; T2nPr ; T2sBu ; T2tBu ; T2iBu ; T2Phe ; T2OH ; T2NO2 ; T2F2 ; T2Cl2 ; T4 ; T2Me2 ; 3,5,3',5'-tetraiodo-D- thyronine ; 3,5,3'-Triiodo-D-thyronine ; 3,5-Diiodo-4-hydroxyphenylpropionic acid (DIHPA) ; Aryloxamic acids ; (arylamino) acetic acids ; arylpropionic acids ; arylthioacetic acids ; (aryloxy)acetic acid ; 3,3'-T2 ; 3,5-T2 ; 3'-5'-T2 ; (5-Benzyloxy-2-methoxyphenyl)-(2- methoxypyrimidin-5-yl)- methanol ;

SUBSTITUTE SHEET (RULE 26)

Benzyloxy-2-methoxyphenyl)-(6-methylpyridin-3-yl)methanol ;

(5-Benzyloxy-2-methoxyphenyl)-(5-bromo-2-methoxypyridin-4-yl)methanol ; (5-benzyloxy-2-methoxyphenyl)-(2,6-difluoropyridin-3-yl)methanol ; (5-Benzyloxy-2-methoxyphenyl)-(2-methoxypyridin-4-yl)methanol ;

5 4-Methoxy-3-[(2-methoxypyrimidin-5-yl)methyl]phenol ;

4-Methoxy-3-[(6-methylpyrid-3-yl)methyl]phenol ; 5-Benzyloxy-2-methoxybenzyl Bromide ; (5-Benzyloxy-2-methoxyphenyl)-(6-chloropyridazin-3-yl)-acetonitrile ;

4-Benzyloxy-2-[2-methoxythiazol-5-yl)methyl]anisole ; 6-[(5-Hydroxy-2-methoxyphenyl)methyl]thiazol-2-(3H) ; 3'-Heteroaryl-methyl-4'-methyl-3,5-dinitro-

10 N-trifluoro-acetyl-L-thyronine Ethyl Esters ; 3'-heteroaryl-methyl-3,5-di-iodo-4'-methyl-N-trifluoro-acetyl-L-thyronine Ethyl Esters ; 3'-heteroaryl-methyl analogues of 3,3',5-tri-iodo-L-thyronine (T3) ; 3'-substituted derivatives of the thyroid hormone 3,3',5-triiodo-L-thyronine (T3) ; L-3'-T1 ; L-3,5'-T2 ; L-3,3'-T2 ; L-

3,3',5'-T3 ; DL-Br2I ; L-Br2IPr ; L-Me2I ; L-Me3 ; L-Me4 ; L-Me2iPr ; DL-IMeI ;

15 L-3,5-Dimethyl-3'-isopropylthyronine (DIMIT) ; DL-BPT4 ; B-triac ; BP-tetrac ;

DL-SBT3 ; DL-SBT4 ; DL-MBT3 ; MB-tetrac ; T2 ; T2F ; T2Cl ; T2Br ; T3 ; T2Me ;

T2Et ; T2iPr ; T2nPr ; T2sBu ; T2tBu ; T2iBu ; T2Phe ; T2OH ; T2NO2 ; T2F2 ;

T2Cl2 ; T4 ; T2Me2 ; 3,5,3',5'-tetraiodo-D-thyronine ; 3,5,3'-Triiodo-D-thyronine ;

3,5-Diiodo-4-hydroxyphenylpropionic acid (DIHPA) ; Aryloxamic acids ;

20 (arylamino)acetic acids ; arylpropionic acids ; arylthioacetic acids ; (aryloxy)acetic

acid ; 3,3'-T2 ; 3,5-T2 ; 3'-5'-T2 ; θ -methyl-3,5,3'-triiodothyroacetic acid, θ -

methyl-3,5,3'-triiodothyropropionic acid, and θ -methyl-3,5,3',5'-

tetraiodothyropropionic acid ; methylene- and carbonyl-bridged analogs of

SUBSTITUTE SHEET (RULE 26)

iodinated thyronines thyroacetic acids ; Iodinated benzofurans ;

3,5-diiodo-4-(2-N,N- diethylaminoethoxy)phenyl-(2-butylbenzofur-3-yl)methanol

hydrochloride ; 2- methyl-3-(3,5- diiodo-4-(2-N,N-diethylamino-

ethoxy)-benzoyl)benzofuran hydrochloride ; 2-n-butyl-3-

5 (3,5-diiodo-4-carboxymethoxy-benzoyl)benzofuran ; 2-

methyl-3-(3,5-diiodo-4-hydroxy- benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4-

carboxymethoxy-benzyl)benzofuran; ; [4'- hydroxy-3'-iodo-3,5 diiodo-4-(2-N,N-

dimethylamino- ; ethoxy)benzophenon hydrochloride ; 2-butyl-3-(3-iodo-4-

hydroxybenzoyl)benzofuran ; 4',4-dihydroxy 3'3,5-triiodo- diphenylmethan ; 3,5-

10 diiodo-4-(2-N, N-diethylaminoethoxy)phenyl- ; -(2-butylbenzofur-3- yl)methanol

hydrochloride ; 2-methyl-3-(3,5-diiodo-4-(2-N,N-diethylamino-ethoxy)-

benzoyl)benzofuran hydrochloride ; 2-n-butyl-3-(3,5-diiodo-4-carboxymethoxy-

benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4-hydroxy-benzoyl)benzofuran ; 2-

methyl-3- (3,5-diiodo-4-carboxymethoxy-benzyl)benzofuran ; 4'hydroxy-3'-iodo-3,5

15 diiodo-4-(2-N,N- dimethylamino-ethoxy)benzophenon hydrochloride ; 2-butyl-3-(3-

iodo-4- hydroxybenzoyl)benzofuran ; 4',4-dihydroxy-3'3,5-triiodo-diphenylmethan ;

3,5-diethyl,3'- isopropyl thyronine (DIET) ; and IpTA2 (3,5 diiodo- 3'isopropyl

thyroacetic acid) and pharmacologically acceptable salts and derivatives thereof.

20 26. The use of a thyroid hormone or thyroid hormone-like compound in the preparation of a composition for topical application for the reduction of cutaneous or subcutaneous fat deposits.

27. The use according to claim 26 in which the fat deposits cause cellulite.

28. A use according to claim 26 or 27 in which the thyroid hormone is selected from Tri- iodothyronine (T3); D and L tetraiodothyronine - thyroxine (T4); 3,3',5' tri-
5 iodothyronine (reverse T3) ; 3,3'-diiodothyronine ; T3 T4 analogues such as
3,5,3'- Triiodothyroacetic acid ; 3,5,3'-Tetraiodothyroacetic acid ; 3,5,3'-Triiodo-L-
thyronine ; 3,5,3'-Triiodo-L-thyronine methyl ester ; 3,5,3'-Triiodo-L-thyronine
hydrochloride ; L-thyroxine ; L-thyroxine hydrochloride ; L-T3 ; T4Fo ; Tetrac ; Triac
; Tetraprop ; Triprop ; T4Bu ; T3Bu ; Thyroxamine ; Triiodothyronamine ; L- 3'-T1 ;
10 L-3'-T1 ; L-3,5'-T2 ; L-3,3'-T2 ; L-3,3',5'-T3 ; DL-Br2I ; L-Br2iPr ; L-Me2I ; L-Me3 ;
L-Me4 ; L-Me2iPr ; DL-IMeI ; l-3,5-Dimethyl-3'- isopropylthyronine (DIMIT) ;
DL-BPT4 ; B-triac ; BP-tetrac ; DL-SBT3 ; DL-SBT4 ; DL- MBT3 ; MB- tetrac ; T2 ;
T2F ; T2Cl ; T2Br ; T3 ; T2Me ; T2Et ; T2iPr ; T2nPr ; T2sBu ; T2tBu ; T2iBu ;
T2Phe ; T2OH ; T2NO2 ; T2F2 ; T2Cl2 ; T4 ; T2Me2 ; 3,5,3',5'-tetraiodo-D-
15 thyronine ; 3,5,3'-Triiodo-D-thyronine ; 3,5-Diiodo-4-hydroxyphenylpropionic acid
(DIHPA) ; Aryloxamic acids ; (arylamino) acetic acids ; arylpropionic acids ;
arylthioacetic acids ; (aryloxy)acetic acid ; 3,3'-T2 ; 3,5-T2 ; 3'-5'-T2 ; (5-
Benzyloxy-2-methoxyphenyl)-(2- methoxypyrimidin-5-yl)-methanol ; Benzyloxy-2-
methoxyphenyl)-(6-methylpyridin-3- yl)methanol ; (5-Benzyloxy-2-methoxyphenyl)-
20 (5-bromo-2-methoxypyridin-4-yl)methanol ; (5-benzyloxy-2-methoxyphenyl)-(2,6-
difluoropyridin-3-yl)methanol ; (5-Benzyloxy-2- methoxyphenyl)-(2-methoxypyridin-
4-yl)methanol ; 4-Methoxy-3-[(2-methoxypyrimidin-5- yl)methyl]phenol ; 4-
Methoxy-3-[(6-methylpyrid-3-yl)methyl]phenol ; 5-Benzyloxy-2- methoxybenzyl

SUBSTITUTE SHEET (RULE 26)

- 48 -

Bromide ; (5-Benzyloxy-2-methoxyphenyl)-(6-chloropyridazin-3-yl)- acetonitrile ; 4-Benzyloxy-2-[2-methoxythiazol-5-yl)methyl]anisole ; 6-[(5-Hydroxy-2-methoxyphenyl)methyl]thiazol-2-(3H) ; 3'-Heteroarylmethyl-4'-)-methyl-3,5-dinitro-N- trifluoro-acetyl-L-thyronine Ethyl Esters ; 3'-heteroarylmethyl-3,5-di-iodo-4')-methyl-N- trifluoro-acetyl-L-thyronine Ethyl Esters ; 3'-heteroarylmethyl analogues of 3,3',5-tri-iodo-L- thyronine (T3) ; 3'-substituted derivatives of the thyroid hormone 3,3',5-triiodo-L-thyronine (T3) ; L-3'-T1 ; L-3,5'-T2 ; L-3,3'-T2 ; L-3,3',5'-T3 ; DL-Br2I ; L-Br2IPr ; L-Me2I ; L-Me3 ; L-Me4 ; L-Me2iPr ; DL-IMeI ; L-3,5-Dimethyl-3'-isopropylthyronine (DIMIT) ; DL-BPT4 ; B-triac ; BP-tetrac ; DL-SBT3 ; DL-SBT4 ; DL-MBT3 ; MB-tetrac ; T2 ; T2F ; T2Cl ; T2Br ; T3 ; T2Me ; T2Et ; T2iPr ; T2nPr ; T2sBu ; T2tBu ; T2iBu ; T2Phe ; T2OH ; T2NO2 ; T2F2 ; T2Cl2 ; T4 ; T2Me2 ; 3,5,3',5'-tetraiodo-D-thyronine ; 3,5,3'-Triiodo-D-thyronine ; 3,5- Diiodo-4-hydroxyphenylpropionic acid (DIHPA) ; Aryloxamic acids ; (arylamino)acetic acids ; arylpropionic acids ; arylthioacetic acids ; (aryloxy)acetic acid ; 3,3'-T2 ; 3,5-T2 ; 3'-5'-T2 ; θ -methyl-3,5,3'-triiodothyroacetic acid, θ -methyl-3,5,3'-triiodothyropropionic acid, and θ - methyl-3,5,3',5'-tetraiodothyropropionic acid ; methylene- and carbonyl-bridged analogs of iodinated thyronines thyroacetic acids ; Iodinated benzofurans ; 3,5-diiodo-4-(2-N,N- diethylaminoethoxy)phenyl-(2-butylbenzofur-3-yl)methanol hydrochloride ; 2- methyl-3-(3,5- diiodo-4-(2-N,N-diethylamino- ; ethoxy)-benzoyl)benzofuran hydrochloride ; 2-n-butyl-3-(3,5-diiodo-4-carboxymethoxy-benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4-hydroxy- benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4-

SUBSTITUTE SHEET (RULE 26)

- 49 -

carboxymethoxy-benzyl)benzofuran; ; [4'- hydroxy-3'-iodo-3,5 diiodo-4-(2-N,N-
dimethylamino- ; ethoxy)benzophenon hydrochloride ; 2-butyl-3-(3-iodo-4-
hydroxybenzoyl)benzofuran ; 4',4-dihydroxy 3'3,5-triiodo- diphenylmethan ; 3,5-
diiodo-4-(2-N, N-diethylaminoethoxy)phenyl- ; -(2-butylbenzofur-3- yl)methanol
5 hydrochloride ; 2-methyl-3-(3,5-diiodo-4-(2-N,N-diethylamino-ethoxy)-
benzoyl)benzofuran hydrochloride ; 2-n-butyl-3-(3,5-diiodo-4-carboxymethoxy-
benzoyl)benzofuran ; 2-methyl-3-(3,5-diiodo-4-hydroxy-benzoyl)benzofuran ; 2-
methyl-3- (3,5-diiodo-4-carboxymethoxy-benzyl)benzofuran ; 4'hydroxy-3'-iodo-3,5
10 diiodo-4-(2-N,N- dimethylamino-ethoxy)benzophenon hydrochloride ; 2-butyl-3-(3-
iodo-4- hydroxybenzoyl)benzofuran ; 3,5-diethyl,3'-isopropyl thyronine (DIET) ;
4',4-dihydroxy- 3'3,5-triiodo-diphenylmethan ; and IpTA2 (3,5 diiodo- 3'isopropyl
thyroacetic acid) and pharmacologically acceptable salts and derivatives thereof.

29. A composition according to any one of claims 1 to 14 comprising less than
15 or equal to about 50mg/100ml of thyroid hormone compound.

30. A composition according to claim 29 comprising less than or equal to about
20mg/100ml of thyroid hormone compound.

SUBSTITUTE SHEET (RULE 26)

FIG. 1





FIG. 3



06/05/95

FIG. 4

RA 1 uM	k1	k10	k16	k19	transK	soce	il-6	tgfbeta-2	col a-1	col a-3	ctgf(pdgf-L)	fibronectin	crabp-II
study 2	-3	-1	-0.5	-1	-3	-0.5	-1	2	2	1	1	-0.5	1
study 3.1	-3	-1	0	1	-1	2	-1	2	2	2	2	2	1
study 3.2b	-3	-2			-2	0	-1		-0.5	-1	0.5	-1	0

RA 1uM





FIG. 5



6/8

FIG. 6





FIG. 6A



SUBSTITUTE SHEET (RULE 26)

7/8

FIG. 7





FIG. 7A






FIG. 8




FIG. 8A

SUBSTITUTE SHEET (RULE 26)

This Page Blank (uspto)

This Page Blank (uspto)

INTERNATIONAL SEARCH REPORT

International Application No.

US 96/09975

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K7/48 A61K31/195 A61K31/00 A61K38/22

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	STN, File Supplier, Karlsruhe, DE, XP002020415 File Embase, AN: 84027313 see the abstract ---	1-13, 15, 18-20, 23-25, 29, 30
X	STN, File Supplier, Karlsruhe, DE, XP002020416 File Embase, AN: 82189935 see the abstract ---	1-13, 15, 18-20, 23-25, 29, 30

	-/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

18 September 1997

Date of mailing of the international search report

30.09.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Fischer, J.P.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/09975

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	STN, File Supplier, Karlsruhe, DE, XP002020417 File Embase, AN: 81038096 see the abstract ---	1-13,15, 18-20, 23-25, 29,30
X	STN, File Supplier, Karlsruhe, DE, XP002020418 File Embase, AN: 74156248 see the abstract ---	1-13,15, 18-20, 23-25, 29,30
X	GB 859 546 A (HELLBAUM) 25 January 1961 cited in the application see the whole document ---	1-13,15, 18-20, 23-25, 29,30
X	GB 782 745 A (HELLBAUM) 11 September 1957 cited in the application see the whole document ---	1-13,15, 18-20, 23-25, 29,30
X	DATABASE WPI Week 8205 Derwent Publications Ltd., London, GB; AN 82-004847 XP002020419 & R0 76 691 A (INTR. FARMEC. COSMETI.) cited in the application see abstract ---	1-13,15, 18-20, 23-25, 29,30
X	FR 6 656 M (GLASS) 27 January 1969 see the whole document ---	1-13,15, 18-20, 23-25, 29,30
X	FR 2 357 246 A (MARTINEZ) 3 February 1978 see the whole document ---	1-15, 18-30
X	BE 515 812 A (MARECHAL) 26 May 1953 see the whole document ---	1-13,15, 18-30
X	FR 2 153 202 A (SOCIETE ANONYME POUR L'INDUSTRIE CHIMIQUE) 4 May 1973 cited in the application see the whole document ---	1-13,15, 18-30
	-/--	

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 96/09975

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CH 642 851 A (BEREMA) 15 May 1984 cited in the application see the whole document ---	1-13, 15, 18-30
X	GB 1 354 263 A (LABORATOIRE THERANOL) 5 June 1974 cited in the application see the whole document ---	1-13, 15, 18-30
X	FR 2 139 748 A (PRUGNAUD) 12 January 1973 see the whole document ---	1-13, 15, 18-30
X	EP 0 060 776 A (SOMACHIM) 22 September 1982 cited in the application see the whole document ---	1-13, 15, 18-30
X	FR 2 354 101 A (BEREMA) 6 January 1978 cited in the application see the whole document ---	1-13, 15, 18-30
A	DE RYCKER ET AL.: "Effects of 3,5,3'-triiodothyronine on collagen synthesis by cultured human skin fibroblasts" FEBS LETTERS, vol. 174, no. 1, August 1984, ELSEVIER SCIENCE PUBLISHERS, pages 34-37, XP002041073 cited in the application see the whole document ---	16, 17
A	STN, File Supplier, Karlsruhe, DE, File XP002040739 Chemical Abstracts, vol 122, AN=102081 see the abstract ---	16, 17
A	STN, File Supplier, Karlsruhe, DE, File XP002040740 Chemical Abstracts, vol 122, AN=53295 see the abstract ---	16, 17
A	STN, File Supplier, Karlsruhe, DE, File XP002040741 Chemical Abstracts, vol 116, AN=232324 see the abstract ---	16, 17
A	STN, File Supplier, Karlsruhe, DE, File XP002040742 Chemical Abstracts, vol 114, AN=179422 see the abstract ---	16, 17

-/--

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 96/09975

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>STN, File Supplier, Karlsruhe, DE, File XP002040743 Chemical Abstracts, vol 111, AN=4612 see the abstract -----</p>	16,17

INTERNATIONAL SEARCH REPORT

Int. application No

PCT/US 96/ 09975

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons.

1. ☒ Claims Nos.: 1-30 partially
because they relate to subject matter not required to be searched by this Authority, namely:

See annex
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6 4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See annex

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA210

Subjects:

1. Claims 1-15, 18-30 (all partially): Method, use, composition for topical treatment of the skin, comprising a thyroid-hormone (-like) compound selected from thyroid hormone, and thyroxine or thyronine compounds.
2. Claims 1-15, 18-30 (all partially): Method, use, composition for topical treatment of the skin, comprising further thyroid-hormone (-like) compounds.
3. Claims 16-17: Method of modulating the expression of genes in the skin.

Obscurities:

The expression "as herein defined" violates Rule 6.2(a) PCT, and consequently has been neglected in defining the searcheable subject matters of the claims.

The definition "thyroid hormone compound or thyroid hormone-like compound" does not represent a definition in structural terms of chemical compounds. As a consequence a complete search is virtually impossible for the subject matter of such claims. The same applies to the definitions given in claim 14.

The subject matter of claims 2-3 is characterised by the effect to be achieved. A complete search is impossible for such subject matters.

The unit "Kd" used in claim 6 does not represent a parameter usual in the field of the application. As a consequence a complete search for the subject matter of this claim is virtually impossible. In view of the large number of compounds, which are defined in the claims, the search had to be restricted for economic reasons. The search was limited to the compounds specified in subject 1. of the non-unity objection, and to the general idea underlying the application. Even so, the search could only be performed in general terms, for reasons of economy.

The attention of the Applicant was drawn to the fact that further objections as to lack of unity of inventions might be raised if the Applicant wished to have an International Search Report for the second group of inventions. The extensive list of compounds, often identified by means of acronyms, would require extensive additional search efforts in order to identify the structural classes to which they belong. Moreover, the attention of the Applicant was drawn to the PCT Search Guidelines, Chapter VIII, 2.1. Accordingly, also a restriction of the International Search may be anticipated for reasons of economy (see PCT Search Guidelines, Chapter III, 3.6). Should the Applicant wish to have an International Search Report for the second group of inventions, the Applicant was asked for clarification as to the structural formulas of each compound identified by means of acronyms in the claims. The Applicant should for each group within the second group of inventions define the special technical feature, i.e. the significant structural element shared by the compounds of each such group. Upon payment of the required search fee(s), the ISA would judge unity of invention of such further different invention(s), which the Applicant wishes the ISA to search.

It did take till 11/8/97 before the Applicant provided the requested clarification. The Applicant did not comply with the request to define the special technical feature for each group within the second group of inventions. Accordingly the search for the second subject was restricted for reasons of economy, and was limited to phenylformic acid derivatives. In view of the significant delay and the failure to define a special technical feature *at present* no further lack of unity objections are being raised for the second subject.

Incomplete search:

Claims searcheable completely: none
Claims searcheable incompletely: 1-30
Claims not searcheable: none

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 96/09975

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 859546 A		NONE	
GB 782745 A		NONE	
FR 6656 M	27-01-69	NONE	
FR 2357246 A	03-02-78	NONE	
BE 515812 A		NONE	
FR 2153202 A	04-05-73	DE 2239136 A	29-03-73
CH 642851 A	15-05-84	NONE	
GB 1354263 A	05-06-74	FR 2139748 A	12-01-73
		BE 784267 A	01-12-72
		CA 982477 A	27-01-76
		CH 572744 A	27-02-76
		DE 2226927 A	18-01-73
FR 2139748 A	12-01-73	BE 784267 A	01-12-72
		CA 982477 A	27-01-76
		CH 572744 A	27-02-76
		DE 2226927 A	18-01-73
		GB 1354263 A	05-06-74
EP 60776 A	22-09-82	FR 2501505 A	17-09-82
		CH 652925 A	13-12-85
FR 2354101 A	06-01-78	CH 622703 A	30-04-81

This Page Blank (uspto)

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

This Page Blank (uspto)